

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 February 2003 (13.02.2003)

PCT

(10) International Publication Number
WO 03/012049 A2

B2

- (51) International Patent Classification⁷: C12N (74) Agent: LANDRUM, Charles, P.; Fulbright & Jaworski L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX 78701 (US).
- (21) International Application Number: PCT/US02/24177
- (22) International Filing Date: 31 July 2002 (31.07.2002) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/308,929 31 July 2001 (31.07.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/308,929 (CON)
Filed on 31 July 2001 (31.07.2001)
- (71) Applicant (*for all designated States except US*): UNIVERSITY OF CHICAGO [US/US]; 5640 South Ellis Avenue, Chicago, IL 60637 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MUNGER, Joshua [—/US]; - (US). ROIZMAN, Bernard [US/US]; 910 East 58th Street, Chicago, IL 60637 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/012049 A2

(54) Title: METHODS AND COMPOSITION CONCERNING HERPES VIRUS U_s3 AND BAD-INVOLVED APOPTOSIS

(57) Abstract: The present invention concerns methods of compositions for inhibiting or inducing apoptosis in a cell. The methods and compositions concern either the herpesviral protein U_s3, the cellular pro-apoptotic polypeptide BAD, or modulators thereof to modulate apoptosis in a cell.

METHODS AND COMPOSITION CONCERNING HERPESVIRUS U_s3.
AND BAD-INVOLVED APOPTOSIS

BACKGROUND OF THE INVENTION

This application claims the priority of U.S. Provisional Application Ser. No. 60/308,929, filed July 31, 2001, the entire disclosure of which is specifically incorporated
5 herein by reference.

The government may own rights in this application by virtue of federal funding under grant numbers AI124009 from the National Institute of Allergy and Infectious Disease and CA47451, CA87761, CA83939, CA71933, and CA78766 from the National Cancer Institute.

10

I. Field of the Invention

The present invention relates to the fields of virology and cell biology generally, and more specifically, it addresses mechanisms for growth control in eukaryotic cells. In particular, there are provided methods and compositions involving the inhibition of the
15 pro-apoptotic protein BAD by U_s3.

II. Related Art

The control of host cell gene expression, and often the control of genes involved in DNA replication, are integral parts of the life cycle of a virus. However, recent
20 evidence suggests that most eukaryotic cells respond to viral disruption of normal cellular physiology by undergoing programmed cell death, also known as "apoptosis" (White, 1993). To counteract apoptosis, many viruses have evolved mechanisms to block host cell death (Clem and Miller, 1994; White and Gooding, 1994). In several cases, viral genomes have been found to contain genes whose products interact with proteins that
25 play a central role in regulating cell survival.

Studies have shown that the interaction of herpes simplex virus 1 (HSV-1) with cells results in programmed cell death and that the virus has evolved mechanisms that block apoptosis whether it is induced by viral gene products or by exogenous agents. Specifically, wild-type HSV does not induce apoptosis, and infection with wild-type virus

blocks apoptosis induced by osmotic or thermal shock or by Fas ligand (Koyama *et al.*, 1997; Sieg *et al.*, 1996; Galvan *et al.*, 1998; Leopardi *et al.*, 1996; Galvan *et al.*, 1999; Aubert *et al.*, 1999; Jerome *et al.*, 1999). A number of HSV-1 mutants have been reported to induce apoptosis. These include mutants lacking the infected cell protein numbers 4
5 (ICP4) or 27 (ICP27) (Leopardi *et al.*, 1996; DeLuca *et al.*, 1985; Auber *et al.*, 1999), two regulatory proteins expressed immediately after infection, a mutant lacking glycoprotein D (Zhou *et al.*, 2000), and a mutant carrying a temperature sensitive mutation that blocks the release of viral DNA from capsids at nuclear pores in cells infected and maintained at the nonpermissive temperatures (Galvan *et al.*, 1998; Baeterson *et al.*, 1983). Detailed analyses
10 of the mutant d120, from which both copies of the gene encoding ICP4 had been deleted, revealed that the virus induces apoptosis in all of the cell lines tested, but that the mechanisms by which the virus induces apoptosis is cell-type dependent (Galvan *et al.*, 1999). In HEp-2 cells, the d120 mutant caused the translocation of cytochrome C from mitochondria, activation of caspase 3 and fragmentation of cellular DNA (Galvan *et al.*,
15 1999; Galvan *et al.*, 2000). Apoptosis was blocked in a HEp-2-derived cell line that overexpressed Bcl-2 (Galvan *et al.*, 2000).

Earlier studies have also reported that d120 rescueants in which the deleted gene encoding ICP4 was repaired continued to induce apoptosis, but that DNA fragments sharing the U_s3 gene blocked apoptosis (Leopardi *et al.*, 1997). Other laboratories have since
20 confirmed that the U_s3 protein kinase contributes to HSV-mediated protection from a variety of exogenous apoptotic inducers (Jerome *et al.*, 1999; Asano *et al.*, 1999; Asano *et al.*, 2000; Hata *et al.*, 1999). In a recent study, the inventors have shown that the U_s3 protein kinase blocked d120 induced apoptosis at a premitochondria stage, and that activation of caspase 3 could be blocked by the U_s3 protein kinase expressed as late as 6 to 9 hrs after
25 infection of HEp-2 cells with the d120 mutant (Munger *et al.*, 2001).

Programmed cell death is triggered by several factors and may take various forms. For example, the synthesis of double-stranded RNA activates kinases which phosphorylate the α subunit of eIF-2 and completely turn off protein synthesis (Sarre, 1989). Ultimately, activation of metabolic pathways causes a pattern of morphological, biochemical, and

molecular changes which result in cell death without spillage of cellular constituents which would result in an inflammatory response detrimental to the host (Wyllie *et al.*, 1980.).

Apoptotic cell death is commonly observed during embryogenesis and organ involution and in the natural death of terminally differentiated cells at the end of their life span. Most viruses which induce either the shut-off of protein synthesis or apoptosis also have evolved mechanisms which block host responses and enable them to replicate in their hosts (Shen and Shenk, 1995). Among the best-known examples of viral gene products which block apoptosis are the adenovirus E1B M₁19,000 protein (Rao, *et al.*, 1992.), vaccinia CrmA protein (Ray, *et al.*), simian virus 40 (SV40) T antigen (McCarthy, *et al.*, 1994), human papillomavirus No. 16 (HPV 16) E6 protein (Pan and Griep, 1994), Epstein-Barr virus BHRF1 protein (Henderson, *et al.*, 1993) and human cytomegalovirus IE1 and IE2 gene products (Zhu, *et al.*, 1995). Herpes simplex virus 1 (HSV-1) encodes a protein, γ_1 34.5, which blocks the phosphorylation of eIF-2 α (Chou and Roizman, 1992).

The utility of proteins that are capable of inhibiting apoptosis are manifold. First, such proteins, or their corresponding genes, may be used to immortalize cell lines that otherwise would perish during culture. This makes possible not only the study of these cells, but also presents the option of growing these cells in large numbers in order to isolate protein species therefrom. Second, the identification of inhibitors of apoptosis and their function permits the possible intervention, in a clinical setting, when these proteins are interfering with normal programmed cell death, or apoptosis. This may be accomplished by providing an inhibitor or an antisense nucleic acid that interferes with the expression of a protein that interferes with apoptosis.

Furthermore, the identification of proteins that promote apoptosis is also beneficial. Cells that are diseased or infected, either *in vitro* or *in vivo*, can be induced to undergo apoptosis. A therapeutic development may be achieved either by inducing such a cell *in vivo* to undergo apoptosis or by studying such a cell that can be induced to undergo apoptosis *in vitro*. Cells *in vitro* can be used to screen for apoptosis inhibitors or inducers. Apoptosis has clinical relevance. Cells that are diseased or infected can be targeted for apoptosis as a therapeutic treatment. For example, the death of cancer,

tumor, or other hyperproliferative cells can be beneficial, as could the induced cell death of cells infected with pathogens or cells involved in autoimmune conditions. Furthermore, inhibition of apoptosis has clinical significance too. Because apoptosis has been implicated in atrophy following stroke and heart attack, prevention of apoptosis with respect to those particular conditions could be desirable. Other conditions or diseases involving apoptosis include neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, and cerebellar degeneration, and myelodysplastic syndromes such as aplastic anemia and ischemic injury mentioned above. Thus, both inhibitors and inducers of apoptosis continue to be pursued for scientific and, ultimately, medical purposes.

Thus, the identification of proteins having these activities and uses provide important new tools for those working in this arena.

SUMMARY OF THE INVENTION

The present invention takes advantage of the observation that herpesviral protein U_s3 inhibits apoptosis in a cell by inhibiting the pro-apoptotic protein BAD. Thus, the present invention concerns methods and compositions involving the modulation of BAD activity so as to effect induction or inhibition of apoptosis. The methods and compositions relate to a variety of compounds, including U_s3 peptides, polypeptides, and nucleic acids; BAD peptides, polypeptides, and nucleic acids; modulators of U_s3 or BAD activity; and, modulators of apoptosis. The methods employ compounds that induce apoptosis such as BAD peptides and polypeptides, inhibitors of U_s3, including inhibitors that block or impede U_s3 from inhibiting BAD polypeptide—such as BAD peptides or polypeptides that compete with endogenous BAD polypeptide—and modulators of BAD polypeptide that improve or make available the activity of endogenous BAD polypeptide, such as phosphatases. Methods of the invention also involve compounds that inhibit apoptosis. Such compounds include U_s3 peptides and polypeptides; inhibitors of BAD polypeptide, such as kinases, 14-3-3 proteins that sequester BAD, and other modulators that alter its pro-apoptotic activities.

In some embodiments, the present invention involves methods for inducing apoptosis in a cell. The cell may or may not be infected with a virus, though in some cases the cell is infected with a herpesvirus, such as herpes simplex virus. It is contemplated that the cell may be infected with any herpesvirus. Human cells may be infected with herpes simplex virus (HSV) type 1, HSV-2, varicella zoster virus, cytomegalovirus (CMV), Epstein-Barr virus, human herpesvirus (HHV) 6, HHV 7, or HHV 8. It is contemplated that methods and examples discussed with respect to one herpesvirus, such as HSV-1, may be applied with respect to other herpesviruses to the extent there is homology among family members. Such methods involve administering to a cell a composition comprising an agent or compound that modulates BAD activity. BAD is a polypeptide of multiple isoforms, which have pro-apoptotic activity.

In any methods of the invention, the term "BAD polypeptide" refers to any BAD polypeptide isoform unless otherwise specified. Human BAD peptides and polypeptides are contemplated for use in the present invention. Also contemplated for use is any BAD peptide or polypeptide from a mammal, such as murine BAD. It is contemplated that murine BAD is interchangeable with human BAD for many embodiments of the invention. The human BAD cDNA sequence is provided as SEQ ID NO:1 and the corresponding amino acid sequence is provided in SEQ ID NO:2. The murine BAD cDNA sequence is provided as SEQ ID NO:3, and the polypeptide sequence is provided as SEQ ID NO:4. In some embodiments of the invention, an agent that inhibits a herpesviral U_s3 polypeptide from modulating BAD activity is administered to the cell, in some cases, in an amount effective to inhibit U_s3 modulation of BAD. A herpesviral U_s3 refers to a U_s3 or homologous protein or peptide from herpes simplex virus (HSV) type 1 (SEQ ID NO:6), HSV-2 (SEQ ID NO:7), varicella zoster virus (SEQ ID NO:8), bovine herpesvirus 1 (SEQ ID NO:9), equine herpesvirus 1 (SEQ ID NO:10), equine herpesvirus 4 (SEQ ID NO:11), galid herpesvirus 1 (SEQ ID NO:12), galid herpesvirus 2 (SEQ ID NO:13), galid herpesvirus 3 (SEQ ID NO:14), cercopithecine herpesvirus 7 (SEQ ID NO:15), cercopithecine herpesvirus 9 (SEQ ID NO:16), simian herpesvirus B (SEQ ID NO:17), infectious laryngotracheitis virus (SEQ ID NO:18), canine herpesvirus (SEQ ID NO:19), or suid virus 1 (SEQ ID NO:20). The other human herpesviruses may also be

employed in methods of the invention; they include: cytomegalovirus (CMV), Epstein-Barr virus, human herpesvirus (HHV) 6, HHV 7, or HHV 8. As used herein, "modulation" refers to an alteration of some characteristic of a protein or molecule, such as its activity. In some embodiments, activity is reduced or decreased or inhibited. In other embodiments, modulation of activity constitutes increasing, raising, promoting, or reducing activity. In the context of the present invention, an agent that inhibits a U_s3 polypeptide is one that prevents the U_s3 polypeptide from inhibiting BAD activity level, including the ability of U_s3 to reduce the protein levels of BAD and to phosphorylate BAD at particular residues.

In some embodiments of the invention, an agent that inhibits BAD modulation by U_s3 is a BAD peptide. The BAD peptide, in certain embodiments, may contain one or more amino acid residues that may be phosphorylated. Natural amino acids that may be phosphorylated include serine, threonine, and tyrosine. However, any non-natural amino acid that can be phosphorylated is also contemplated as part of the invention. Amino acids, in the context of particular amino acid sequences, that can be phosphorylated by U_s3 are specifically contemplated. The BAD peptide may comprise a sequence of between 4 to 100 contiguous amino acids from SEQ ID NO:2, which is the amino acid sequence for human BAD. In still further embodiments, the peptide may include a sequence that includes ser136, ser155, or ser112, or a combination thereof. Such peptides with additional BAD amino acid sequence are also contemplated. Peptides comprising a sequence of at least 15, 20, 25, 40, 50, 60, 70, 80, 90, or more contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4. In additional embodiments, peptides may have more than one amino acid that can be phosphorylated.

The invention also includes compositions in which two, three, four, five, or more different BAD peptide sequences are provided. The additional peptide sequences may comprise a sequence of between 4 to 100 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4 and may have characteristics as described above. For example, the second peptide may include an amino acid that can be phosphorylated, such as one that can be phosphorylated by HSV U_s3.

To deliver a composition that contains peptides to a cell, the composition may also comprise one or more lipid molecules, a number of which are disclosed in further detail in this application. Lipid compositions may also be used in the context of the present invention to introduce a nucleic acid into a cell, or other therapeutic agents of the invention.

In some embodiments, an agent that inhibits modulation of BAD by U_s3 is a polypeptide, instead of a peptide. In some embodiments, the polypeptide can bind to BAD that may or may not be phosphorylated. In some cases, the polypeptide binds a BAD polypeptide, and such binding involves or affects an amino acid residue that can be phosphorylated, particularly one that can be phosphorylated by U_s3. In some cases, the binding may affect the ability of U_s3 to inhibit BAD, but it may not affect the pro-apoptotic activity of BAD. Under these circumstances, the agent would prevent or interfere with U_s3 so that BAD could induce apoptosis in the cell. The BAD polypeptide may have the amino acid sequence identified in SEQ ID NO:2 or SEQ ID NO:4. In some embodiments, the agent binds to, masks, or hides an amino acid residue(s) that is involved in U_s3 inhibition of BAD. In some embodiments, the amino acid residue is one that may be post-translationally modified, such as by phosphorylation, by U_s3 or other kinases. Such residues include ser136, ser155, or ser112. It is also contemplated that multiple amino acid residues may be involved, including a combination of these residues. Thus, ser136 and ser155 may be included on particular peptides or polypeptides for use as inhibitors of U_s3.

In some cases, polypeptides of the invention may be antibodies, such as a monoclonal antibody, polyclonal antibody, single chain antibody, a humanized antibody, or a bi-specific antibody.

In additional embodiments, a polypeptide may be employed not to bind BAD but to compete with it. In those cases, methods involve administering to the cell a BAD polypeptide. As discussed above, a BAD polypeptide may comprise at least 100 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4.

It is further contemplated that, while peptides and polypeptides may be employed in methods of the invention, they may be first provided as a nucleic acid that is transcribed and translated into the desired proteinaceous compound. The nucleic acid may be an expression construct. In some embodiments an expression construct is a viral
5 vector, such as an adenovirus, adeno-associated virus, herpesvirus, lentivirus, retrovirus, vaccinia virus, or other viruses vectors employed with respect to gene transfer.

In some embodiments, particularly those involving therapeutic or preventative therapies, methods concerning infected cells may also include administering to the cells an antiviral agent. Antiviral agents against herpesvirus infection are specifically
10 included, such as famcyclovir, valacyclovir, or acyclovir. Antiviral agents may be administered before, during, or after other therapeutic compositions—those modulating apoptosis—are provided to cells. Therapeutic methods of the invention are specifically contemplated to be of use on patients, particularly human patients.

Methods for treating a patient infected with herpes simplex virus are part of the
15 present invention. Methods including administering to the patient an effective amount of a composition that includes a peptide comprising a sequence comprising between 4 to 100 amino acids of SEQ ID NO:2 or SEQ ID NO:4. Peptide compositions discussed above are contemplated for use with any treatment methods disclosed herein, including methods for treating patients infected with viruses such as herpesviruses. Also included
20 in such methods are other modulators of apoptosis, such as modulators of BAD or U_s3.

Other methods of the invention, which have therapeutic and research uses, involve methods for blocking BAD-induced apoptosis of a cell. In some embodiments, such methods involve providing a U_s3 polypeptide to a cell suspected of undergoing BAD-induced apoptosis. The phrase “BAD-induced apoptosis” refers to apoptosis induced by
25 or involving BAD. Of course, one way of identifying BAD-induced apoptosis is to determine whether BAD is expressed in such a cell. An “effective amount” of a U_s3 polypeptide may be provided to the cell so as to prevent the cell from undergoing apoptosis. It is contemplated that any herpesviral U_s3 may be implemented in methods of the invention. Specifically contemplated are U_s3 polypeptide sequences comprising all or

part of SEQ ID NO:6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20. As discussed above and in further detail elsewhere, the U₃ polypeptide may be provided to a cell by introducing into the cell an expression construct that includes a nucleic acid sequence encoding all or part of a U₃ polypeptide or peptide. The expression construct may
5 contain a nucleic acid sequence of SEQ ID NO: 5. Any nucleic acid sequence may be under the transcriptional control of a promoter active in eukaryotic cells. In some embodiments, the promoter is a tetracycline controlled promoter. Expression constructs may also include a selectable marker.

Screening methods are also provided by the invention. Embodiments discussed
10 with respect to therapeutic methods may be implemented with respect to screening methods as well, and *vice versa*.

In some embodiments, screening methods can be used to identify a therapeutic agent to modulate apoptosis comprising a) contacting a BAD peptide or polypeptide with a candidate compound; and b) assaying the compound for an ability to modulate the
15 activity of the BAD peptide or polypeptide. As discussed earlier, a modulator of activity is one that may affect activity, directly or indirectly, by *inter alia* reducing, inhibiting, retarding, promoting, inducing or increasing it. While the BAD polypeptide or peptide may have multiple activities, many of the embodiments of the invention concern its apoptosis ability, that is, the ability of BAD to promote apoptosis in a cell. A compound
20 that increases or promotes the activity, directly or indirectly, of the BAD peptide or polypeptide capable of inducing apoptosis is a possible therapeutic agent to promote apoptosis, if an increase in apoptosis activity is detected. A compound that reduces the activity, directly or indirectly, of the BAD peptide or polypeptide capable of inducing
25 apoptosis, is a possible therapeutic agent to inhibit apoptosis if a reduction in apoptosis activity is detected. Screening methods of the invention may be performed *in vitro*, in cells, or in organisms. Factors contributing to a reduction in activity include, but are not limited to, reduction in BAD transcript level, reduction in BAD peptide/polypeptide level, sequestering of BAD transcripts, peptides, or polypeptides, increase in kinase activity, increase in post-translational modification of BAD peptides/polypeptides,

decrease in phosphatase activity on BAD peptides/polypeptides, binding to the BAD peptide or polypeptide so as to reduce any activity of BAD, such as its ability to bind Bcl-X_L. Factors contributing to an increase or promotion in activity include, but are not limited to, an increase in BAD transcript or peptide/polypeptide level, localization of
5 BAD-encoding nucleic acids or BAD peptides/polypeptides, inhibition of BAD inhibitors such as kinases, increase in phosphatase activity on BAD peptides/polypeptides, and binding to proteins or polypeptides that bind and sequester BAD peptides/polypeptides, such as 14-3-3 proteins. Comparisons of these factors between BAD peptides/polypeptides exposed to a candidate compound and those not exposed to the
10 candidate compound can be done to determine the effect of the candidate compound on a particular characteristic or activity of BAD. In some embodiments, a BAD peptide or polypeptide may be contacted with a U₅3 under conditions that allow U₅3 to inhibit BAD-induced apoptosis. The contact may occur before or after the BAD peptide/polypeptide is incubated with the candidate compound. The effect of the candidate compound on BAD
15 with respect to U₅3 inhibition of BAD may be evaluated to identify a compound that relieves U₅3 inhibition or reduces the inhibition in any way. Such a compound could be used to promote apoptosis.

Characteristics of apoptosis can be assayed or evaluated in methods of the invention. Assays may involve measuring or observing cell shrinkage, nuclear chromatin
20 condensation and margination, or DNA fragmentation. Alternatively, caspase or procaspases may be evaluated to qualify or quantify apoptosis. The cleavage of a procaspase, its activity based on the amount of its substrate is used or the amount of a product it makes based on the substrate conversion, or the amount of cytochrome c released from the mitochondria may be evaluated. Automation can be done with
25 procaspase cleavage or substrate cleavage.

In some embodiments of the screening methods, also included is a step concerning assaying the ability of the BAD peptide or polypeptide to promote apoptosis after contacting the BAD peptide or polypeptide with the candidate compound. While in other embodiments a BAD peptide or polypeptide activity is evaluated based on amount

of BAD-encoding nucleic acids or BAD peptide or polypeptide. In still further embodiments, BAD activity may be evaluated by assaying for post-translation modification of BAD. This may involve identifying whether BAD is modified at all, to what extent it is modified, or at which location(s) it is modified, such as at any of the phosphorylated residues of BAD discussed throughout this application. Alternatively, BAD peptide or polypeptide activity may be evaluated based on the ability to specifically bind a substrate or binding protein, such as Bcl-X_L or 14-3-3. Other methods of the invention concern identifying binding sites on BAD. Such methods may involve mutating BAD, by implementing deletions or substitutions of amino acids, and assaying for binding activity or by using peptides of BAD, assaying the peptides for binding activity, and mapping the sites. Any of the proteinaceous compounds that binds to BAD may be employed to map the binding or active sites of BAD.

BAD peptides or polypeptides for use with methods of the invention are disclosed above. In some embodiments, BAD peptides are employed, while in other embodiments, BAD polypeptides are used.

Candidate compounds that may be tested in screening methods of the invention include peptides, polypeptides—including antibodies—small molecules, and peptide mimetics. Candidate compounds may also be comprised in combinatorial or small molecule libraries. They also may be contained in expression libraries or implemented using high throughput screening methods known to those of ordinary skill in the art. Bioinformatics, computer modeling, or DNA-chip technology may also be employed in methods of the invention.

Apoptosis modulators identified by screening methods of the invention are contemplated as part of the present invention. Such methods include a) contacting a BAD peptide or polypeptide with a candidate compound; and b) assaying the compound for an ability to modulate the activity of the BAD peptide or polypeptide, wherein the compound modulates the activity of the BAD peptide or polypeptide. In further embodiments, the process further includes c) incubating the BAD peptide or polypeptide with a U₅3 polypeptide; and d) comparing the BAD peptide or polypeptide after being

contacted with the candidate compound to a second BAD peptide or polypeptide not contacted with the candidate compound. Apoptosis modulators may be apoptosis inhibitors or apoptosis inducers, as the invention provides materials to identify either or both.

5

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the
10 detailed description of specific embodiments presented herein.

FIG. 1: Diagrammatic representation of the HSV-1 genome showing the location of the $\alpha 4$ and U_L29 genes encoding ICP4 and ICP8, respectively. The reiterated sequences (open rectangles) flanking the unique short (U_S) and unique long (U_L) sequences (thin lines) and the location and direction of genes are as shown. Because the $\alpha 4$ gene maps within
15 inverted repeats flanking the U_L , it is present in two copies per genome. The hatched lines within the rectangles indicates the position of the sequences deleted from the d120 mutant (DeLuca *et al.*, 1985).

FIG. 2. BHK-C13 cells were infected at a multiplicity of 10 pfu/cell with the indicated viruses. At 13 hr post-infection cells were incubated in phosphate-free medium
20 for 1 hr and then labeled with ^{32}Pi for 4 hr. Cell lysates were electrophoretically separated in SDS polyacrylamide gels and electrically transferred onto nitrocellulose filters. Filters were exposed to film or probed with a U_L34 antibody.

FIG. 3. The effect of baculovirus-mediated gene expression on DEVDase activity in cells. Replicate 25 cm² flask cultures of HEp-2 cells were either mock infected
25 or infected with 10 or 20 PFU of Bac-WT or Bac- U_S3 or 0.5, 2.5, 5.0 PFU of Bac-BAD per cell. The cells were harvested at 18 hrs after Bac-BAD infection and assayed for DEVDase activity colorimetrically at 405 nm as described in Example 6. The results are expressed as fold increase in activity over that of mock-infected cells.

FIG. 4. The effect of U₃ protein kinase on DEVDase activity induced by BAD. Replicate HEP-2 cell cultures were exposed to 5 PFU of Bac-BAD per cell 6.5 hrs after infection of the cells with 20 PFU of either Bac-WT or Bac-U₃ per cell. The cells were harvested and processed as described in the legend to FIG. 3. The results are expressed as fold increase in DEVDase activity over that of mock-infected cells.

DETAILED DESCRIPTION OF THE INVENTION

The identification of novel proteins having apoptotic activities and uses will provide important new tools to develop therapeutic and preventative compounds and methods of HSV infection, as well as other diseases and conditions in which apoptosis can or may be involved or implemented to effect beneficial treatment. The present invention provides methods for the use of U₃ gene and its gene product as inhibitors of apoptosis, as well as methods concerning the induction and inhibition of apoptosis through the BAD polypeptide.

The herpes simplex virus 1 (HSV-1) mutant lacking the major regulatory gene designated $\alpha 4$ induces apoptosis, whereas in cells infected with wild-type virus do not exhibit apoptosis (Leopardi and Roizman, 1996). It has been reported that wild-type virus blocked apoptosis induced by thermal shock. Recent studies by Koyama and Miwa (1997), and also in the inventors' laboratory, demonstrated that the virus also blocks the induction of apoptosis by osmotic shock. These studies suggested that a functional $\alpha 4$ gene was necessary to block apoptosis but did not address the question of sufficiency. This led to several studies that included the rescue of the deleted $\alpha 4$ genes in the mutant virus.

A mutant lacking the $\alpha 4$ gene, HSV-1(KOS)d120, was discovered, due to lack of complementation of the $\alpha 4$ gene, to have a secondary mutation in the gene U₃, encoding a protein kinase. Thus, a functional U₃ is required in order to block apoptosis. This important finding was exploited to identify the mechanism behind the inhibition of apoptosis, as well as provide methods concerning the induction of apoptosis, as described herein below. Further, this invention allows for the provision of methods for the use of

agents that inhibit U_s3 function and expression in order to induce apoptosis in HSV-infected cells, and for the identification of agents that inhibit the apoptosis-inhibiting function of ICP4. These and other related aspects of the present invention are described in further detail herein below. U.S. Patent Application Serial Nos. 08/843,659 and 5 09/837,861 discuss some of the observations on which the present application is based; these applications are specifically incorporated by reference herein.

Furthermore, the present invention involves the observation that U_s3 from a herpesvirus prevents apoptosis by modulating the pro-apoptotic protein BAD. Methods for inducing apoptosis by administering BAD or for inducing apoptosis in a cell inhibited 10 from undergoing apoptosis by U_s3 are also provided. Screens for identifying BAD modulators are also described.

I. HERPESVIRUSES

Herpesviruses constitute a family (Herpesviridae) of DNA viruses with genomes 15 between 120 and 235 kilobases. They have linear, double-stranded DNA and an icosahedral shape and are enveloped. Human herpesviruses (HHV) include Herpes Simplex Virus types 1 and 2 (HHV-1 and HHV-2; commonly known as HSV-1 and HSV-2); Varicella zoster (known as VZV or HHV-3), which causes chicken pox; Epstein Bar virus (known as EBV or HHV-4); human cytomegalovirus (known as HCMV or 20 HHV-5); human herpesvirus 6 (HHV-6); human herpesvirus 7 (HHV-7); and Kaposi's sarcoma herpesvirus or human herpesvirus 8 (KSHV or HHV-8). They are classified into one of three classes—alpha, beta, and gamma—based upon of tissue tropism, pathogenicity, and behavior.

Alpha herpesviruses are typically fast replicating; HSV-1 and -2, and Varicella 25 zoster virus are α herpesviruses. Beta herpesviruses are slow replicaters and they include cytomegalovirus and human herpesvirus-6 and -7. Gamma herpesviruses poorly replicate and readily transform cells. Epstein-Barr Virus, which transforms B-cells and causes infectious mononucleosis, and the human herpesvirus-8 are gamma herpesviruses. While there are significant differences among the herpesvirus family members, there is notable

homology among the protein sequences of cognate polypeptides. The U_s3 gene and encoded U_s3 polypeptide represents such a polypeptide that has considerable homology and identity among the human herpesviruses. Thus, methods of the present invention are directed to herpesviruses and, in some embodiments, more specifically to individual

5 herpesviruses. It is contemplated that methods and compositions with respect to the U_s3 from HSV-1 may be implemented with respect to other herpesvirus U_s3 genes and polypeptides. The U_s3 gene and polypeptide sequences for the following herpesvirus members are provided herein. HSV-1 gene and polypeptide sequences are provided as SEQ ID NO:5 and 6, respectively. The polypeptide sequences of other U_s3 polypeptides

10 include: HSV-2 (SEQ ID NO:7), varicella zoster virus (SEQ ID NO:8), bovine herpesvirus 1 (SEQ ID NO:9), equine herpesvirus 1 (SEQ ID NO:10), equine herpesvirus 4 (SEQ ID NO:11), galid herpesvirus 1 (SEQ ID NO:12), galid herpesvirus 2 (SEQ ID NO:13), galid herpesvirus 3 (SEQ ID NO:14), cercopithecine herpesvirus 7 (SEQ ID NO:15), cercopithecine herpesvirus 9 (SEQ ID NO:16), simian herpesvirus B (SEQ ID

15 NO:17), infectious laryngotracheitis virus (SEQ ID NO:18), canine herpesvirus (SEQ ID NO:19), or suid virus 1 (SEQ ID NO:20).

A. Herpes Simplex Viruses

Herpes simplex viruses, designated with subtypes 1 and 2, are enveloped viruses that are among the most common infectious agents encountered by humans, infecting

20 millions of human subjects worldwide. These viruses cause a broad spectrum of disease which ranges from relatively insignificant to severe and life-threatening. The clinical outcome of herpes infections is dependent upon early diagnosis and prompt initiation of antiviral therapy. Despite some successful efforts in treating HSV infections, dermal and epidermal lesion often recur, and HSV infections of neonates and infections of the brain

25 are associated with high morbidity and mortality.

The large, complex, double-stranded DNA genome encodes dozens of different gene products, some of which derive from spliced transcripts. In addition to virion and envelope structural components, the virus encodes numerous other proteins including a

protease, a ribonucleotides reductase, a DNA polymerase, a ssDNA binding protein, a helicase/primase, a DNA dependent ATPase, a dUTPase and others.

HSV genes form several groups whose expression is coordinately regulated and sequentially ordered in a cascade fashion (Honess and Roizman, 1974; Honess and Roizman 1975; Roizman and Sears, 1996). The expression of α genes, the first set of genes to be expressed after infection, is enhanced by the virion protein number 16, or α -transinducing factor (Post *et al.*, 1981; Batterson and Roizman, 1983; Campbell, *et al.*, 1984). The expression of β genes requires functional α gene products, most notably ICP4, which is encoded by the $\alpha 4$ gene (DeLuca *et al.*, 1985). γ genes, a heterogeneous group of genes encoding largely virion structural proteins, require the onset of viral DNA synthesis for optimal expression (Holland *et al.*, 1980).

In line with the complexity of the genome, the life cycle of HSV is quite involved. In addition to the lytic cycle, which results in synthesis of virus particles and, eventually, cell death, the virus has the capability to enter a latent state in which the genome is maintained in neural ganglia until some as of yet undefined signal triggers a recurrence of the lytic cycle.

HSV-1 replication, defined by accumulation of infectious virus, lasts approximately 18-24 hrs although viral protein synthesis can last much longer. The replication of HSV is accompanied by the development of cytopathic effects. In cells overexpressing Bcl-2, the development of cytopathic effects is delayed without significant effect on viral replication (Galvan *et al.*, 2000). These results suggest that cytopathic effects at the end of the replicative cycle reflect injuries to the cell resulting from pro-apoptotic events. These pro-apoptotic events most likely are not specifically targeted by the virus to be blocked inasmuch as they are not detrimental to viral replication as they occur very late during infection. Alternatively, some pro-apoptotic events may benefit viral replication. If such were the case, the virus would dictate the cellular apoptotic environment by blocking apoptotic events that are detrimental to viral replication and by allowing apoptotic events that benefit viral replication. The available data suggest that the virus has evolved a number of inducers of apoptosis and very likely, each is blocked by specific gene products. A

number of different HSV-1 gene products have been reported to inhibit apoptosis; among them U_S3, gD and gJ (Leopardi *et al.*, 1996; Jerome *et al.*, 1999; Zhou *et al.*, 2000). It must be stressed, however, that in the normal course of wild-type virus replication, *i.e.*, at 18-24 hrs, late apoptotic manifestations such as caspase 3 activation and DNA fragmentation are not detected and as noted in the introduction, wild-type virus protects cells from these apoptotic manifestations induced by exogenous agents.

HSV-1 encodes two well characterized protein kinases. The U_L13 protein kinase has been shown to mediate the phosphorylation of a large number of viral and cellular proteins. In contrast, the U_S3 protein kinase appears to have a narrow, less defined range of substrates. Its functions in the course of viral infection has always been somewhat of a puzzle: although a virus deleted for the U_S3 ORF is growth impaired in mice (Purves *et al.*, 1987), the gene is not essential for viral replication in tissue culture although the cytopathic effects of the deletion mutant are very different from those of wild-type virus. By light microscopy, the cells have a crenated appearance but exhibit no evidence of classical apoptosis resulting in activation of caspases or degradation of cellular DNA.

1. The U_S3 Polypeptide

HSV encodes two protein kinases expressed by the genes U_S3 and U_L13, respectively (reviewed in Roizman and Sears, 1996). Whereas U_L13 is packaged in the virion, U_S3 is not. Not all substrates of the U_S3 are known (Purves *et al.*, 1986; 1987; Leader *et al.*, 1991). The major substrate of U_S3 protein kinase is an intrinsic membrane protein exposed on the surface of infected cells and encoded by the U_L34 gene (Purves *et al.*, 1991; 1992). The U_L34 is phosphorylated by more than one kinase (Purves 1991, 1992). In the absence of U_S3 protein kinase, the U_L34 protein has an apparent M_r of 33,000 and associates with several cellular phosphoproteins, whereas in wild-type infected cells U_L34 has an apparent M_r of 30,000 and does not exhibit an association with the host proteins (Purves *et al.*, 1992).

The U_S3 protein kinase phosphorylates threonine/serine in the consensus sequence RRR-R/X-S/T-R/Y (SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25)

(Purves *et al.*, 1986; Leader *et al.*, 1991). In the case of U_L34, this was verified by mutagenesis of the threonine codon in the sequence encoding RRRRTRRSRE (SEQ ID NO:21) (Purves *et al.*, 1991; 1992). The apparent M_r of the mutant U_L34 protein was 33,000, that is, corresponding to the apparent M_r of the U_L34 protein in cells infected with a virus lacking the U_S3 gene.

U_S3 blocks apoptosis by phosphorylating one or more proteins; BAD polypeptide is one such protein. As stated above, for ICP4 to be functional it needs to be phosphorylated, this leads the inventors to believe that one of the substrates of U_S3 protein kinase is ICP4 itself, among other, as yet unidentified, phosphoproteins.

The involvement of U_S3 protein kinase in the blocking of apoptosis induced by infection, thermal or osmotic shocks suggests that HSV differs from other viruses in the mechanism by which it blocks the apoptosis as a result to a host response to infection. Thus, U_S3 may be used to control or modulate apoptosis independent of viral infection.

Accordingly, the present invention takes advantage of the mechanism by which the protein kinase U_S3 is able to inhibit apoptosis by modifying the pro-apoptotic protein BAD, either by reducing its expression level or availability or its phosphorylation. Apoptosis, or programmed cell death, is characterized by certain cellular events, including nuclear condensation, DNA fragmentation, cytoplasmic membrane blebbing and, ultimately, irreversible cell death. Apoptosis is an energy-dependent event. For the purposes of this application, apoptosis will be defined as inducing one or more of these events. Thus, use of the term "U_S3" in this application encompasses polypeptides having all or part of the U_S3 polypeptide sequence and the anti-apoptosis function of U_S3. These need not be wild-type U_S3.

This functional attribute is manifested, for example, in U_S3's ability to protect cells from apoptosis triggered by modification of the BAD polypeptide. The term "modification" with respect to BAD refers to any alteration, direct or indirect, on BAD activity or function, including alterations on BAD transcript or BAD polypeptide such as their expression levels, in transcript or polypeptide stability or half-life, in transcript or polypeptide cellular localization, in transcript or polypeptide availability, in post-

translational additions to amino acid residues (including phosphorylation) on the polypeptide, or on the availability or accessibility to a BAD active site or binding site. This observation permits utilization of U₃ or ICP4 alone or in combination with each other, in a number of ways that could not have been predicted from the prior art. For example, according to the present invention, the production of HSV vectors or recombinant proteins from HSV vectors can be enhanced by increasing the apoptosis inhibiting function of U₃ or ICP4 or both. When cells are infected with HSV, premature cell death can limit the titer of virus produced or the amount of recombinant protein synthesized. Similarly, U₃ and ICP4 may prolong the life of the cells expressing human or animal genes introduced into cells by viral vectors in order to correct a genetic defect. If the cell can be sustained longer, the titer of the virus stocks and the amount of protein should increase.

2. The BAD Pro-Apoptotic Polypeptide

Members of the Bcl-2 family of proteins regulate the execution of programmed cell death. The members of this family can be functionally separated into apoptotic antagonists, including Bcl-2, Bcl-X_L and Bcl-w, and apoptotic agonists, such as BAD, BID, and BAX. These key apoptotic regulators mediate their pro- or anti-apoptotic signals through their relative abundance, subcellular localization and posttranslational modifications.

As used herein, the term "apoptosis" refers to the physiological process known as programmed cell death. This process is a morphologically and biochemically distinct form of cell death that regulates cell turnover under normal physiological conditions. The morphological features include an orchestrated sequence of changes that include cell shrinkage, chromatin condensation, nuclear segmentation and eventual cellular disintegration into discrete membrane-bound apoptotic bodies. The biochemical features include, for example, internucleosomal cleavage of cellular DNA and the activation of ICE/Ced-3 family of proteases. The term "apoptosis" is used here synonymously with the phrase "programmed cell death." These terms are intended to be consistent with their use as they are known and used by those skilled in the art.

Pro- and anti-apoptotic family members are capable of dimerizing through the three Bcl-2 homology domains (BH1, BH2, and BH3) apparently titrating out each other's function (Oltvai *et al.*, 1993; Chittenden *et al.*, 1995; Yin *et al.*, 1994). Specifically, BH1, BH2 and BH3 domains form a hydrophobic cleft to which the BH3 domain can bind
5 (Sattler *et al.*, 1997). Some pro-apoptotic Bcl-2 family members, such as BAD, contain only the BH3 domain which is essential for binding to anti-apoptotic family members, such as Bcl-2 and Bcl-X_L and for their pro-apoptotic function (Chittenden *et al.*, 1995).

Cell survival signals block BAD from inducing apoptosis by phosphorylation (Franke *et al.*, 1997). Some of these signals activate phosphatidylinositol (PI) 3-kinase
10 with subsequent activation of Akt, which phosphorylates BAD at serine 136 (del Peso *et al.*, 1997; Scheid *et al.*, 1998). Survival signals also promote the activation of RSK and PKA which have both been shown to phosphorylate BAD at ser112 (Tan *et al.*, 1999; Harada *et al.*, 1999). Phosphorylation of BAD at ser112 and ser136 has been demonstrated to abrogate its pro-apoptotic activity by promoting its association with 14-
15 3-3 proteins which sequester phosphorylated BAD, thereby preventing its localization to the mitochondria and association with Bcl-X_L (Harada *et al.*, 1999; Pastorino *et al.*, 1998; Zha *et al.*, 1996; Hsu *et al.*, 1997). Additionally, phosphorylation of BAD at serine 155 disrupts its interaction with Bcl-X_L (Zhou *et al.*, 2000; Tan *et al.*, 2000; Datta *et al.*, 2000). Conversely, activation of BAD appears to be carried out by phosphatases. Thus two
20 different phosphatases, calcineurin and PP1 α dephosphorylate BAD at serine 112 and 136, thereby releasing BAD from 14-3-3- proteins, stimulating its binding to Bcl-2/ Bcl-X_L, and ultimately leading to cytochrome c release, caspase activation and apoptosis (Salomoni *et al.*, 2000; Wang *et al.*, 1999). Recently it has been reported that death receptor engagement induces the caspase mediated cleavage of BAD, yielding an M,
25 15,000 truncated protein that is a more potent inducer of apoptosis than the full length BAD (Condreay *et al.*, 1999). The human BAD cDNA and protein sequences are provided as SEQ ID NO:1 and 2, respectively, while the murine cDNA and protein sequences are provided as SEQ ID NO:3 and SEQ ID NO:4, respectively. Information about BAD can be found in U.S. Patent 5,965,703, which is specifically incorporated by

reference. The sequence for the murine BAD cDNA and protein sequences are readily available to those of ordinary skill in the art.

II. PROTEINACEOUS COMPOSITIONS

5 In certain embodiments, the present invention concerns compositions comprising at least one proteinaceous molecule. The proteinaceous molecule may be a modulator of apoptosis through U_s3 or BAD or it may be used as a candidate substance to be screened as a modulator of BAD activity or of U_s3 activity. The proteinaceous molecule may also be used, for example, in a pharmaceutical composition for the delivery of a therapeutic
10 agent or as part of a screening assay to identify apoptosis modulators. As used herein, a "proteinaceous molecule," "proteinaceous composition," "proteinaceous compound," "proteinaceous chain" or "proteinaceous material" generally refers, but is not limited to, a protein of greater than about 200 amino acids or the full length endogenous sequence translated from a gene; a polypeptide of greater than about 100 amino acids; and/or a
15 peptide of from about 3 to about 100 amino acids. All the "proteinaceous" terms described above may be used interchangeably herein.

In certain embodiments, the size of the at least one proteinaceous molecule may comprise, but is not limited to, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
20 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68,
69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210,
220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600,
625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100,
25 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 or greater amino molecule residues, and any range derivable therein. Furthermore, such proteinaceous molecules may include 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,

78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 or more contiguous amino acid residues from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, or SEQ ID NO:25.

As used herein, an "amino molecule" refers to any amino acid, amino acid derivative or amino acid mimic as would be known to one of ordinary skill in the art. In certain embodiments, the residues of the proteinaceous molecule are sequential, without any non-amino molecule interrupting the sequence of amino molecule residues. In other embodiments, the sequence may comprise one or more non-amino molecule moieties. In particular embodiments, the sequence of residues of the proteinaceous molecule may be interrupted by one or more non-amino molecule moieties.

Accordingly, the term "proteinaceous composition" encompasses amino molecule sequences comprising at least one of the 20 common amino acids in naturally synthesized proteins, or at least one modified or unusual amino acid, including but not limited to those shown on Table 1 below.

TABLE 1			
Modified and Unusual Amino Acids			
Abbr.	Amino Acid	Abbr.	Amino Acid
Aad	2-Aminoadipic acid	EtAsn	N-Ethylasparagine
Baad	3- Aminoadipic acid	Hyl	Hydroxylysine
Bala	β -alanine, β -Amino-propionic acid	AHyl	allo-Hydroxylysine
Abu	2-Aminobutyric acid	3Hyp	3-Hydroxyproline

TABLE 1			
Modified and Unusual Amino Acids			
Abbr.	Amino Acid	Abbr.	Amino Acid
4Abu	4- Aminobutyric acid, piperidinic acid	4Hyp	4-Hydroxyproline
Acp	6-Aminocaproic acid	Ide	Isodesmosine
Ahe	2-Aminoheptanoic acid	Alle	allo-Isoleucine
Aib	2-Aminoisobutyric acid	MeGly	N-Methylglycine, sarcosine
Baib	3-Aminoisobutyric acid	Melle	N-Methylisoleucine
Apm	2-Aminopimelic acid	MeLys	6-N-Methyllysine
Dbu	2,4-Diaminobutyric acid	MeVal	N-Methylvaline
Des	Desmosine	Nva	Norvaline
Dpm	2,2'-Diaminopimelic acid	Nle	Norleucine
Dpr	2,3-Diaminopropionic acid	Orn	Ornithine
EtGly	N-Ethylglycine		

In certain embodiments the proteinaceous composition comprises at least one protein, polypeptide or peptide. In further embodiments the proteinaceous composition comprises a biocompatible protein, polypeptide or peptide. As used herein, the term

5 "biocompatible" refers to a substance which produces no significant untoward effects when applied to, or administered to, a given organism according to the methods and amounts described herein. Organisms include, but are not limited to, Such untoward or undesirable effects are those such as significant toxicity or adverse immunological reactions. In preferred embodiments, biocompatible protein, polypeptide or peptide

10 containing compositions will generally be mammalian proteins or peptides or synthetic proteins or peptides each essentially free from toxins, pathogens and harmful immunogens.

Proteinaceous compositions may be made by any technique known to those of skill in the art, including the expression of proteins, polypeptides or peptides through

standard molecular biological techniques, the isolation of proteinaceous compounds from natural sources, or the chemical synthesis of proteinaceous materials. The nucleotide and protein, polypeptide and peptide sequences for various genes have been previously disclosed, and may be found at computerized databases known to those of ordinary skill
5 in the art. One such database is the National Center for Biotechnology Information's Genbank and GenPept databases (<http://www.ncbi.nlm.nih.gov/>). The coding regions for these known genes may be amplified and/or expressed using the techniques disclosed herein or as would be known to those of ordinary skill in the art. Alternatively, various commercial preparations of proteins, polypeptides and peptides are known to those of
10 skill in the art.

In certain embodiments a proteinaceous compound may be purified. Generally, "purified" will refer to a specific protein, polypeptide, or peptide composition that has been subjected to fractionation to remove various other proteins, polypeptides, or peptides, and which composition substantially retains its activity, as may be assessed, for
15 example, by the protein assays, as would be known to one of ordinary skill in the art for the specific or desired protein, polypeptide or peptide.

It is contemplated that virtually any protein, polypeptide or peptide containing component may be used in the compositions and methods disclosed herein. However, it is preferred that the proteinaceous material is biocompatible. In certain embodiments, it
20 is envisioned that the formation of a more viscous composition will be advantageous in that it will allow the composition to be more precisely or easily applied to the tissue and to be maintained in contact with the tissue throughout the procedure. In such cases, the use of a peptide composition, or more preferably, a polypeptide or protein composition, is contemplated. Ranges of viscosity include, but are not limited to, about 40 to about 100
25 poise. In certain aspects, a viscosity of about 80 to about 100 poise is preferred.

Proteins and peptides suitable for use in this invention may be autologous proteins or peptides, although the invention is clearly not limited to the use of such autologous proteins. As used herein, the term "autologous protein, polypeptide or peptide" refers to a protein, polypeptide or peptide which is derived or obtained from an organism.

Organisms that may be used include, but are not limited to, a bovine, a reptilian, an amphibian, a piscine, a rodent, an avian, a canine, a feline, a fungal, a plant, or a prokaryotic organism, with a selected animal or human subject being preferred. The "autologous protein, polypeptide or peptide" may then be used as a component of a composition intended for application to the selected animal or human subject. In certain aspects, the autologous proteins or peptides are prepared, for example from whole plasma of the selected donor. The plasma is placed in tubes and placed in a freezer at about -80°C for at least about 12 hours and then centrifuged at about 12,000 times g for about 15 minutes to obtain the precipitate. The precipitate, such as fibrinogen may be stored for up to about one year (Oz, 1990).

A. Antibodies

In certain embodiments, the proteinaceous composition may comprise at least one antibody. Antibodies can be used in the context of the present invention as an apoptosis modulator or in screening assays to identify apoptosis modulators. Furthermore, they may be employed to determine whether a cell is infected with a herpesvirus or whether the cell expresses a particular protein, in order to understand the mechanism by which apoptosis is inhibited in herpesvirus-infected cells or to gain in understanding about how to inhibit or induce apoptosis more generally.

As used herein, the term "antibody" is intended to refer broadly to any immunologic binding agent such as IgG, IgM, IgA, IgD and IgE. Generally, IgG and/or IgM are preferred because they are the most common antibodies in the physiological situation and because they are most easily made in a laboratory setting. The term "antibody" is used to refer to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab', Fab, F(ab')₂, single domain antibodies (DABs), Fv, scFv (single chain Fv), and the like. The techniques for preparing and using various antibody-based constructs and fragments, as well as means for preparing and characterizing antibodies, are well known in the art (See, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference).

In certain embodiments, the present invention involves antibodies. For example, all or part of a monoclonal, single chain, or humanized antibody may be employed as an apoptosis modulator, for example, an antibody against BAD to either inhibit U₅₃ from acting on it so as to effect apoptosis or to prevent BAD from promoting apoptosis.

5 Alternatively, other aspects of the invention involve detecting a particular antigen or antigenic region for use in screening methods of the present invention. As detailed above, in addition to antibodies generated against full length proteins, antibodies also may be generated in response to smaller constructs comprising epitopic core regions, including wild-type and mutant epitopes. An epitope is an antigenic determinant. An

10 antigen is any substance that is specifically recognized by an antibody or T-cell receptor. An immunogen is an antigen that induces a specific immune response.

Monoclonal antibodies (mAbs) are recognized to have certain advantages, *e.g.*, reproducibility and large-scale production, and their use is generally preferred. The invention thus provides monoclonal antibodies of the human, murine, monkey, rat,

15 hamster, rabbit and even chicken origin.

The methods for generating monoclonal antibodies (mAbs) generally begin along the same lines as those for preparing polyclonal antibodies. Briefly, a polyclonal antibody may be prepared by immunizing an animal with an immunogenic polypeptide composition in accordance with the present invention and collecting antisera from that

20 immunized animal. Alternatively, in some embodiments of the present invention, serum is collected from persons who may have been exposed to a particular antigen. Exposure to a particular antigen may occur in a work environment, such that those persons have been occupationally exposed to a particular antigen and have developed polyclonal antibodies to a peptide, polypeptide, or protein. In some embodiments of the invention

25 polyclonal serum from occupationally exposed persons is used to identify antigenic regions in the gelonin toxin through the use of immunodetection methods.

A wide range of animal species can be used for the production of antisera. Typically the animal used for production of antisera is a rabbit, a mouse, a rat, a hamster,

a guinea pig or a goat. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

As is well known in the art, a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by
5 coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin also can be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester,
10 carbodiimide and bis-biazotized benzidine.

As also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Suitable molecule adjuvants include all acceptable immunostimulatory compounds, such as cytokines, toxins or synthetic compositions.

15 Adjuvants that may be used include IL-1, IL-2, IL-4, IL-7, IL-12, γ -interferon, GMCSF, BCG, aluminum hydroxide, MDP compounds, such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A, and monophosphoryl lipid A (MPL). RIBI, which contains three components extracted from bacteria, MPL, trehalose dimycolate (TDM) and cell wall skeleton (CWS) in a 2% squalene/Tween 80 emulsion also is contemplated.
20 MHC antigens may even be used. Exemplary adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

In addition to adjuvants, it may be desirable to coadminister biologic response
25 modifiers (BRM), which have been shown to upregulate T cell immunity or downregulate suppressor cell activity. Such BRMs include, but are not limited to, Cimetidine (CIM; 1200 mg/d) (Smith/Kline, PA); low-dose Cyclophosphamide (CYP; 300 mg/m²) (Johnson/ Mead, NJ), cytokines such as γ -interferon, IL-2, or IL-12 or genes encoding proteins involved in immune helper functions, such as B-7.

The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The
5 production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization.

A second, booster injection also may be given. The process of boosting and titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated
10 and stored, and/or the animal can be used to generate mAbs.

mAbs may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference. Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, a purified or partially purified polypeptide, peptide or domain, be it a
15 wild-type or mutant composition. The immunizing composition is administered in a manner effective to stimulate antibody producing cells.

mAbs may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography. Fragments of the monoclonal antibodies of the invention can be obtained from the monoclonal
20 antibodies so produced by methods which include digestion with enzymes, such as pepsin or papain, and/or by cleavage of disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer.

It also is contemplated that a molecular cloning approach may be used to generate
25 mAbs. For this, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning using cells expressing the antigen and control cells. The advantages of this approach over conventional hybridoma techniques are that approximately 10^4 times as many antibodies can be produced and screened in a

single round, and that new specificities are generated by H and L chain combination which further increases the chance of finding appropriate antibodies.

Humanized monoclonal antibodies are antibodies of animal origin that have been modified using genetic engineering techniques to replace constant region and/or variable region framework sequences with human sequences, while retaining the original antigen specificity. Such antibodies are commonly derived from rodent antibodies with specificity against human antigens. Such antibodies are generally useful for *in vivo* therapeutic applications. This strategy reduces the host response to the foreign antibody and allows selection of the human effector functions.

“Humanized” antibodies are also contemplated, as are chimeric antibodies from mouse, rat, or other species, bearing human constant and/or variable region domains, bispecific antibodies, recombinant and engineered antibodies and fragments thereof. The techniques for producing humanized immunoglobulins are well known to those of skill in the art. For example U.S. Patent 5,693,762 discloses methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's). When combined into an intact antibody, the humanized immunoglobulins are substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope. Examples of other teachings in this area include U.S. Patents 6,054,297; 5,861,155; and 6,020,192, all specifically incorporated by reference. Methods for the development of antibodies that are “custom-tailored” to the patient's disease are likewise known and such custom-tailored antibodies are also contemplated.

In yet another embodiment, a single-chain antibody may be employed as an apoptosis modulator. Methods for the production of single-chain antibodies are well known to those of skill in the art. The skilled artisan is referred to U.S. Patent 5,359,046, (incorporated herein by reference) for such methods. A single chain antibody is created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule.

Single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is tethered to the N-terminus of the other *via* a 15 to 25 amino acid peptide or linker, have been developed without significantly disrupting antigen binding or specificity of the binding (Bedzyk *et al.*, 1990; Chaudhary *et al.*, 1990). These Fvs lack
5 the constant regions (Fc) present in the heavy and light chains of the native antibody. Immunotoxins employing single-chain antibodies are described in U.S. Patent 6,099,842, specifically incorporated by reference.

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one
10 of the binding specificities is for a chimeric polypeptide, the other one is for any other antigen, and preferably for another receptor or receptor subunit. For example, bispecific antibodies specifically binding a chimeric polypeptide and neurotrophic factor, or two different chimeric polypeptides are within the scope of the present invention.

Traditionally, the recombinant production of bispecific antibodies is based on the
15 coexpression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (Millstein and Cuello (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule, which is usually
20 done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker *et al.* (1991).

According to a different and more preferred approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an
25 immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH₂ and CH₃ regions. It is preferred to have the first heavy chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are

cotransfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance. In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in copending application U.S. serial No. 07/931,811, filed Aug. 17, 1992. For further details of generating bispecific antibodies see, for example, Suresh *et al.* (1986).

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent 4,676,980, along with a number of cross-linking techniques.

A large number of assays involving antibodies are well known to those of skill in the art, including immunodetection such as immunohistochemistry, ELISA, Western blotting, FACS analysis, radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, and bioluminescent assay. The steps of various useful immunodetection methods have been described in the scientific literature,

such as, *e.g.*, Doolittle MH and Ben-Zeev O, 1999; Gulbis B and Galand P, 1993; De Jager R *et al.*, 1993; and Nakamura *et al.*, 1987, each incorporated herein by reference.

B. Isolating Proteinaceous Compounds

5 U₅3, BAD, or ICP4 may be obtained according to various standard methodologies that are known to those of skill in the art. For example, antibodies specific for U₅3 or ICP4 may be used in immunoaffinity protocols to isolate the respective polypeptide from infected cells, in particular, from infected cell lysates. Antibodies are advantageously bound to supports, such as columns or beads, and the immobilized antibodies can be used
10 to pull the U₅3 or IPC4 target out of the cell lysate.

Alternatively, expression vectors, rather than viral infections, may be used to generate the polypeptide of interest. A wide variety of expression vectors may be used, including viral vectors. The structure and use of these vectors is discussed further, below. Such vectors may significantly increase the amount of U₅3, BAD, and/or ICP4 protein in
15 the cells, and may permit less selective purification methods such as size fractionation (chromatography, centrifugation), ion exchange or affinity chromatograph, and even gel purification. Alternatively, the expression vector may be provided directly to target cells, again as discussed further, below.

U₅3, according to the present invention, may advantageously be cleaved into
20 fragments for use in further structural or functional analysis, or in the generation of reagents such as U₅3-related polypeptides and U₅3-specific antibodies. This can be accomplished by treating purified or unpurified U₅3 with a peptidase such as endoproteinase glu-C (Boehringer, Indianapolis, IN). Treatment with CNBr is another method by which U₅3 fragments may be produced from natural U₅3. Recombinant techniques also can be used to
25 produce specific fragments of U₅3. It may be that the phosphorylating and apoptosis-inhibiting functions of U₅3 reside in distinct domains of the protein. If such is the case, the ability to make domain-specific reagents now has significance. For example, the ability to provide an apoptosis-inhibiting U₅3 fragment that does not phosphorylate viral genes may

prove to be effective in extending the life of neurons expressing compensatory or therapeutic genes from a viral vector.

Likewise ICP4 or BAD may advantageously be cleaved into fragments for use in further structural or functional analysis, or in the generation of reagents such as ICP4- or BAD-related polypeptides and ICP4- or BAD-specific antibodies. Because the transactivating and apoptosis-inhibiting functions of ICP4 appear to reside in distinct domains, the ability to make domain-specific reagents now has significance. For example, the ability to provide an apoptosis-inhibiting ICP4 fragment that does not transactivate viral genes may prove to be effective in extending the life of neurons expressing compensatory or therapeutic genes from a viral vector. Similarly, BAD has been identified as possessing a "death domain," which is a region of the polypeptide necessary for BAD pro-apoptotic activity. This region may be separated from the remainder of the BAD polypeptide and used as a modulator of apoptosis or as an agent in a screening method to identify BAD modulators.

It is expected that changes may be made in the sequence of U_s3, BAD, or ICP4 while retaining a molecule having the structure and function of the natural U_s3, BAD, or ICP4, respectively. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive capacity with structures such as, for example, substrate-binding regions. These changes are termed "conservative" in the sense that they preserve the structural and, presumably, required functional qualities of the starting molecule. The importance of U_s3 variants is highlighted by the observation, discussed in the examples, that mutants lacking the α 4 gene also have an additional mutation in the U_s3 gene making it non-functional in apoptosis. The mutation in U_s3 was silent and would not have affected the studies carried out by DeLuca *et al.* (1985) since viral gene expression, including that of U_s3, requires a functional α 4 gene and apoptosis is a very late event. Even if a rescue had been done, it would not have detected the mutation in U_s3 unless the infected cell were probed for the U_s3 function.

C. Variants

The importance of ICP4 variants is highlighted by the observation that temperature sensitive (*ts*) mutants of ICP4 exist that are impaired in their ability to transactivate viral genes at elevated temperatures (above about 39°C), but retain the apoptosis inhibiting function associated with this polypeptide. Further exploration of this dichotomy should reveal significant information on the regions in which these functions lie. It has been shown that the transactivation domain of ICP4 lies between about residues 100 and 200, the DNA-binding domains lies between about residues 300 and 500, the nuclear localization domain lies between about residues 700 and 750 and the transactivation domain lies between about residues 750 and 1298.

Conservative amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as equivalent.

In making such changes, the hydropathic index of amino acids also may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, 1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making

changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the polypeptide created is intended for use in immunological embodiments, as in the present case. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *i.e.*, with a biological property of the protein.

As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

Numerous scientific publications have been devoted to the prediction of secondary structure, and to the identification of epitopes, from analyses of amino acid sequences (Chou & Fasman, 1974a,b; 1978a,b; 1979). Any of these may be used, if desired, to supplement the teachings of Hopp in U.S. Patent 4,554,101. Moreover, computer programs are currently available to assist with predicting antigenic portions and epitopic core regions of proteins. Examples include those programs based upon the Jameson-Wolf analysis (Jameson & Wolf, 1988; Wolf *et al.*, 1988), the program PepPlot® (Brutlag *et al.*, 1990; Weinberger *et al.*, 1985), and other new programs for protein tertiary structure prediction (Fetrow & Bryant, 1993).

Two designations for amino acids are used interchangeably throughout this application, as is common practice in the art. Alanine = Ala (A); Arginine = Arg (R); Aspartate = Asp (D); Asparagine = Asn (N); Cysteine = Cys (C); Glutamate = Glu (E); Glutamine = Gln (Q); Glycine = Gly (G); Histidine = His (H); Isoleucine = Ile (I); Leucine = Leu (L); Lysine = Lys (K); Methionine = Met (M); Phenylalanine = Phe (F); Proline = Pro (P); Serine = Ser (S); Threonine = Thr (T); Tryptophan = Trp (W); Tyrosine = Tyr (Y); Valine = Val (V).

D. Peptides

The present invention encompasses modulators of apoptosis, including proteinaceous compounds that inhibit, induce, or promote apoptosis in a cell, including peptides, as well as fusion proteins, for use in various embodiments of the present invention. The peptides of the invention can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, (1984); Tam *et al.*, (1983); Merrifield, (1986); and Barany and Merrifield (1979), each incorporated herein by reference. Short peptide sequences, or libraries of overlapping peptides, usually from about 6 up to about 35 to 50 amino acids, which correspond to the selected regions described herein, can be readily synthesized and then screened in screening assays designed to identify reactive peptides. Peptides with at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or up to about 100 amino acid residues are contemplated by the present invention. Peptides comprising 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 and 100 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID

NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25 are specifically contemplated as part of the invention.

The compositions of the invention may include a peptide comprising an apoptosis modulator that has been modified to enhance its activity or to render it biologically
5 protected. Biologically protected peptides have certain advantages over unprotected peptides when administered to human subjects and, as disclosed in U.S. patent 5,028,592, incorporated herein by reference, protected peptides often exhibit increased pharmacological activity.

Compositions for use in the present invention may also comprise peptides that
10 include all L-amino acids, all D-amino acids, or a mixture thereof. The use of D-amino acids may confer additional resistance to proteases naturally found within the human body and are less immunogenic and can therefore be expected to have longer biological half lives.

In addition to the peptidyl compounds described herein, the inventors also
15 contemplate that other sterically similar compounds may be formulated to mimic the key portions of the peptide structure, called peptidomimetics. Mimetics are peptide-containing molecules which mimic elements of protein secondary structure. See, for example, Johnson *et al.* (1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as
20 to facilitate molecular interactions, such as those of receptor and ligand.

Successful applications of the peptide mimetic concept have thus far focused on mimetics of β -turns within proteins. Likely β -turn structures within U₃, BAD, and ICP4 can be predicted by computer-based algorithms as discussed above. Once the component amino acids of the turn are determined, mimetics can be constructed to achieve a similar
25 spatial orientation of the essential elements of the amino acid side chains, as discussed in Johnson *et al.*, *supra*.

III. NUCLEIC ACID COMPOSITIONS

Also contemplated by the present invention are nucleic acids encoding U_s3, BAD, and ICP4, and fragments thereof. The cDNA sequence for human BAD is provided as SEQ ID NO:1, while the murine sequence is provided as SEQ ID NO:3. The gene for HSV-1 U_s3 is given in SEQ ID NO:5. The gene for ICP4 is known as α 4. The full length genomic sequence of HSV is known and can be found in Genbank (Accession No. x14112) and is specifically incorporated by reference herein; ICP4 is encoded by identical diploid genes inverted relative to each other, their coding sequences are located from nucleotide 131,128 to 127,232 and 147,104 to 151,000. The U_s3 protein coding sequence is from nucleotide 135,222 to 136,667.

Certain embodiments of the present invention involve the synthesis and/or mutation of at least one isolated nucleic acid molecule, such as recombinant expression vectors encoding all or part of the amino acid sequences, such as those shown in SEQ ID NO: 2, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22, or one or more modulators of apoptosis. Embodiments of the invention also involve the creation and use of recombinant host cells through the application of DNA recombinant technology, that express one or more U_s3 and/or BAD peptides or polypeptides. In certain aspects, a nucleic acid encoding a U_s3 and/or BAD peptides or polypeptides or a modulator of apoptosis comprises a wild-type or a mutant nucleic acid. The nucleic acid compositions can, for example, be used in an assay for modulators of apoptosis or for modulators of BAD activity.

Because of the degeneracy of the genetic code, many other nucleic acids also may encode a given U_s3, BAD, or a given ICP4. For example, four different three-base codons encode the amino acids alanine, glycine, proline, threonine and valine, while six different codons encode arginine, leucine and serine. Only methionine and tryptophan are encoded by a single codon. A table of amino acids and the corresponding codons is presented herein for use in such embodiments.

In order to generate any nucleic acid encoding U_s3, BAD, or ICP4, one need only refer to the preceding codon table. Substitution of the natural codon with any codon

encoding the same amino acid will result in a distinct nucleic acid that encodes U₃, BAD, or ICP4 or a variant thereof. As a practical matter, this can be accomplished by site-directed mutagenesis of an existing U₃, BAD, or α 4 gene or *de novo* chemical synthesis of one or more nucleic acids.

5

TABLE 2

Amino Acids			Codons						
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

The preceding observations regarding codon selection, site-directed mutagenesis and chemical synthesis apply with equal force to the discussion of substitutional mutants in the section of peptides. Normally, substitutional mutants are generated by site-directed changes in the nucleic acid designed to alter one or more codons of the coding sequence.

5 The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (*i.e.*, a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (*e.g.*, an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (*e.g.*, an A, a G, an uracil "U" or a C). The term
10 "nucleic acid" encompass the terms "oligonucleotide" and "polynucleotide," each as a subgenus of the term "nucleic acid." The term "oligonucleotide" refers to a molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length.

These definitions generally refer to a single-stranded molecule, but in specific
15 embodiments will also encompass an additional strand that is partially, substantially or fully complementary to the single-stranded molecule. Thus, a nucleic acid may encompass a double-stranded molecule or a triple-stranded molecule that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a molecule. As used herein, a single stranded nucleic acid may be denoted by the prefix
20 "ss," a double stranded nucleic acid by the prefix "ds," and a triple stranded nucleic acid by the prefix "ts."

A. Nucleobases

As used herein a "nucleobase" refers to a heterocyclic base, such as for example a naturally occurring nucleobase (*i.e.*, an A, T, G, C or U) found in at least one naturally
25 occurring nucleic acid (*i.e.*, DNA and RNA), and naturally or non-naturally occurring derivative(s) and analogs of such a nucleobase. A nucleobase generally can form one or more hydrogen bonds ("anneal" or "hybridize") with at least one naturally occurring nucleobase in manner that may substitute for naturally occurring nucleobase pairing (*e.g.*, the hydrogen bonding between A and T, G and C, and A and U).

"Purine" and/or "pyrimidine" nucleobase(s) encompass naturally occurring purine and/or pyrimidine nucleobases and also derivative(s) and analog(s) thereof, including but not limited to, those a purine or pyrimidine substituted by one or more of an alkyl, carboxyalkyl, amino, hydroxyl, halogen (*i.e.*, fluoro, chloro, bromo, or iodo), thiol or alkylthiol moiety. Preferred alkyl (*e.g.*, alkyl, carboxyalkyl, *etc.*) moieties comprise of 5 from about 1, about 2, about 3, about 4, about 5, to about 6 carbon atoms. Other non-limiting examples of a purine or pyrimidine include a deazapurine, a 2,6-diaminopurine, a 5-fluorouracil, a xanthine, a hypoxanthine, a 8-bromoguanine, a 8-chloroguanine, a bromothymine, a 8-aminoguanine, a 8-hydroxyguanine, a 8-methylguanine, a 8-10 thioguanine, an azaguanine, a 2-aminopurine, a 5-ethylcytosine, a 5-methylcytosine, a 5-bromouracil, a 5-ethyluracil, a 5-iodouracil, a 5-chlorouracil, a 5-propyluracil, a thiouracil, a 2-methyladenine, a methylthioadenine, a N,N-dimethyladenine, an azaadenines, a 8-bromoadenine, a 8-hydroxyadenine, a 6-hydroxyaminopurine, a 6-thiopurine, a 4-(6-aminoethyl/cytosine), and the like. A table non-limiting, purine and 15 pyrimidine derivatives and analogs is also provided herein below.

A nucleobase may be comprised in a nucleoside or nucleotide, using any chemical or natural synthesis method described herein or known to one of ordinary skill in the art.

TABLE 3-Purine and Pyrimidine Derivatives or Analogs

<u>Abbr.</u>	<u>Modified base description</u>	<u>Abbr.</u>	<u>Modified base description</u>
ac4c	4-acetylcytidine	Mam5s2u	5-methoxyaminomethyl-2-thiouridine
Chm5u	5-(carboxyhydroxymethyl) uridine	Man q	Beta,D-mannosylqueosine
Cm	2'-O-methylcytidine	Mcm5s2u	5-methoxycarbonylmethyl-2-thiouridine
Cmm5s2u	5-carboxymethylamino-methyl-2-thiouridine	Mcm5u	5-methoxycarbonylmethyluridine
Cmm5u	5-carboxymethylaminomethyluridine	Mo5u	5-methoxyuridine
D	Dihydrouridine	Ms2i6a	2-methylthio-N6-isopentenyladenosine
Fm	2'-O-methylpseudouridine	Ms2i6a	N-((9-beta-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine
Gal q	Beta,D-galactosylqueosine	Mi6a	N-((9-beta-D-ribofuranosylpurine-6-yl)N-methylcarbamoyl)threonine
Gm	2'-O-methylguanosine	Mv	Uridine-5-oxyacetic acid methyl ester
I	Inosine	o5u	Uridine-5-oxyacetic acid (v)
I6a	N6-isopentenyladenosine	Osyw	Wybutoxosine
mla	1-methyladenosine	P	Pseudouridine
mlf	1-methylpseudouridine	Q	Queosine

25184298.1

TABLE 3-Purine and Pyrimidine Derivatives or Analogs.

<u>Abbr.</u>	<u>Modified base description</u>	<u>Abbr.</u>	<u>Modified base description</u>
m1g	1-methylguanosine	s2c	2-thiocytidine
m1l	1-methylinosine	s2t	5-methyl-2-thiouridine
m22g	2,2-dimethylguanosine	s2u	2-thiouridine
m2a	2-methyladenosine	s4u	4-thiouridine
m2g	2-methylguanosine	T	5-methyluridine
m3c	3-methylcytidine	t6a	N-((9-beta-D-ribofuranosylpurine-6-yl)carbamoyl)threonine
m5c	5-methylcytidine	Tm	2'-O-methyl-5-methyluridine
m6a	N6-methyladenosine	Um	2'-O-methyluridine
m7g	7-methylguanosine	Yw	Wybutosine
Mam5u	5-methylaminomethyluridine	X	3-(3-amino-3-carboxypropyl)uridine, (acp3)u

B. Nucleosides

As used herein, a "nucleoside" refers to an individual chemical unit comprising a nucleobase covalently attached to a nucleobase linker moiety. A non-limiting example of a "nucleobase linker moiety" is a sugar comprising 5-carbon atoms (*i.e.*, a "5-carbon sugar"), including but not limited to a deoxyribose, a ribose, an arabinose, or a derivative or an analog of a 5-carbon sugar. Non-limiting examples of a derivative or an analog of a 5-carbon sugar include a 2'-fluoro-2'-deoxyribose or a carbocyclic sugar where a carbon is substituted for an oxygen atom in the sugar ring.

Different types of covalent attachment(s) of a nucleobase to a nucleobase linker moiety are known in the art. By way of non-limiting example, a nucleoside comprising a purine (*i.e.*, A or G) or a 7-deazapurine nucleobase typically covalently attaches the 9 position of a purine or a 7-deazapurine to the 1'-position of a 5-carbon sugar. In another non-limiting example, a nucleoside comprising a pyrimidine nucleobase (*i.e.*, C, T or U) typically covalently attaches a 1 position of a pyrimidine to a 1'-position of a 5-carbon sugar (Kornberg and Baker, 1992).

C. Nucleotides

As used herein, a "nucleotide" refers to a nucleoside further comprising a "backbone moiety". A backbone moiety generally covalently attaches a nucleotide to another molecule comprising a nucleotide, or to another nucleotide to form a nucleic acid. The "backbone moiety" in naturally occurring nucleotides typically comprises a phosphorus moiety, which is covalently attached to a 5-carbon sugar. The attachment of the backbone moiety typically occurs at either the 3'- or 5'-position of the 5-carbon sugar. However, other types of attachments are known in the art, particularly when a nucleotide comprises derivatives or analogs of a naturally occurring 5-carbon sugar or phosphorus moiety.

D. Nucleic Acid Analogs

A nucleic acid may comprise, or be composed entirely of, a derivative or analog of a nucleobase, a nucleobase linker moiety and/or backbone moiety that may be present in a naturally occurring nucleic acid. As used herein a "derivative" refers to a chemically

modified or altered form of a naturally occurring molecule, while the terms "mimic" or "analog" refer to a molecule that may or may not structurally resemble a naturally occurring molecule or moiety, but possesses similar functions. As used herein, a "moiety" generally refers to a smaller chemical or molecular component of a larger chemical or molecular structure. Nucleobase, nucleoside and nucleotide analogs or derivatives are well known in the art, and have been described (see for example, Scheit, 1980, incorporated herein by reference).

Additional non-limiting examples of nucleosides, nucleotides or nucleic acids comprising 5-carbon sugar and/or backbone moiety derivatives or analogs, include those in U.S. Patent No. 5,681,947 which describes oligonucleotides comprising purine derivatives that form triple helices with and/or prevent expression of dsDNA; U.S. Patents 5,652,099 and 5,763,167 which describe nucleic acids incorporating fluorescent analogs of nucleosides found in DNA or RNA, particularly for use as fluorescent nucleic acids probes; U.S. Patent 5,614,617 which describes oligonucleotide analogs with substitutions on pyrimidine rings that possess enhanced nuclease stability; U.S. Patents 5,670,663, 5,872,232 and 5,859,221 which describe oligonucleotide analogs with modified 5-carbon sugars (*i.e.*, modified 2'-deoxyfuranosyl moieties) used in nucleic acid detection; U.S. Patent 5,446,137 which describes oligonucleotides comprising at least one 5-carbon sugar moiety substituted at the 4' position with a substituent other than hydrogen that can be used in hybridization assays; U.S. Patent 5,886,165 which describes oligonucleotides with both deoxyribonucleotides with 3'-5' internucleotide linkages and ribonucleotides with 2'-5' internucleotide linkages; U.S. Patent 5,714,606 which describes a modified internucleotide linkage wherein a 3'-position oxygen of the internucleotide linkage is replaced by a carbon to enhance the nuclease resistance of nucleic acids; U.S. Patent 5,672,697 which describes oligonucleotides containing one or more 5' methylene phosphonate internucleotide linkages that enhance nuclease resistance; U.S. Patents 5,466,786 and 5,792,847 which describe the linkage of a substituent moiety which may comprise a drug or label to the 2' carbon of an oligonucleotide to provide enhanced nuclease stability and ability to deliver drugs or detection moieties; U.S. Patent 5,223,618 which describes oligonucleotide analogs with a 2 or 3 carbon backbone linkage attaching

the 4' position and 3' position of adjacent 5-carbon sugar moiety to enhanced cellular uptake, resistance to nucleases and hybridization to target RNA; U.S. Patent 5,470,967 which describes oligonucleotides comprising at least one sulfamate or sulfamide internucleotide linkage that are useful as nucleic acid hybridization probe; U.S. Patents 5,378,825, 5,777,092, 5,623,070, 5,610,289 and 5,602,240 which describe oligonucleotides with three or four atom linker moiety replacing phosphodiester backbone moiety used for improved nuclease resistance, cellular uptake and regulating RNA expression; U.S. Patent 5,858,988 which describes hydrophobic carrier agent attached to the 2'-O position of oligonucleotides to enhanced their membrane permeability and stability; U.S. Patent 5,214,136 which describes oligonucleotides conjugated to anthraquinone at the 5' terminus that possess enhanced hybridization to DNA or RNA; enhanced stability to nucleases; U.S. Patent 5,700,922 which describes PNA-DNA-PNA chimeras wherein the DNA comprises 2'-deoxy-erythro-pentofuranosyl nucleotides for enhanced nuclease resistance, binding affinity, and ability to activate RNase H; and U.S. Patent 5,708,154 which describes RNA linked to a DNA to form a DNA-RNA hybrid.

In a non-limiting example, one or more nucleic acid analogs may be prepared containing about 3, about 5, about 8, about 10 to about 14, or about 15, about 20, about 30, about 40, about 50, about 100, about 200, about 500, about 1,000, about 2,000, about 3,000, about 5,000, about 10,000, about 15,000, about 20,000, about 30,000, about 50,000, about 100,000, about 250,000, about 500,000, about 750,000, to about 1,000,000 nucleotides in length, as well as constructs of greater size, up to and including chromosomal sizes (including all intermediate lengths and intermediate ranges). Such analogs may be implemented with respect to SEQ ID NOS:1, 3, or 5, as provided herein.

E. Polyether and Peptide Nucleic Acids

In certain embodiments, it is contemplated that a nucleic acid comprising a derivative or analog of a nucleoside or nucleotide may be used in the methods and compositions of the invention. A non-limiting example is a "polyether nucleic acid", described in U.S. Patent Serial No. 5,908,845, incorporated herein by reference. In a

polyether nucleic acid, one or more nucleobases are linked to chiral carbon atoms in a polyether backbone.

Another non-limiting example is a "peptide nucleic acid", also known as a "PNA", "peptide-based nucleic acid analog" or "PENAM", described in U.S. Patent Serial Nos. 5,786,461, 5,891,625, 5,773,571, 5,766,855, 5,736,336, 5,719,262, 5,714,331, 5,539,082, and WO 92/20702, each of which is incorporated herein by reference. Peptide nucleic acids generally have enhanced sequence specificity, binding properties, and resistance to enzymatic degradation in comparison to molecules such as DNA and RNA (Egholm *et al.*, 1993; PCT/EP/01219). A peptide nucleic acid generally comprises one or more nucleotides or nucleosides that comprise a nucleobase moiety, a nucleobase linker moiety that is not a 5-carbon sugar, and/or a backbone moiety that is not a phosphate backbone moiety. Examples of nucleobase linker moieties described for PNAs include aza nitrogen atoms, amido and/or ureido tethers (see for example, U.S. Patent No. 5,539,082). Examples of backbone moieties described for PNAs include an aminoethylglycine, polyamide, polyethyl, polythioamide, polysulfonamide or polysulfonamide backbone moiety.

In certain embodiments, a nucleic acid analogue such as a peptide nucleic acid may be used to inhibit nucleic acid amplification, such as in PCR, to reduce false positives and discriminate between single base mutants, as described in U.S. Patent Serial No. 5,891,625. Other modifications and uses of nucleic acid analogs are known in the art, and are encompassed by the nucleic acid encoding for apoptosis modulators. In a non-limiting example, U.S. Patent 5,786,461 describes PNAs with amino acid side chains attached to the PNA backbone to enhance solubility of the molecule. In another example, the cellular uptake property of PNAs is increased by attachment of a lipophilic group. U.S. application Ser. No. 117,363 describes several alkylamino moieties used to enhance cellular uptake of a PNA. Another example is described in U.S. Patent Nos. 5,766,855, 5,719,262, 5,714,331 and 5,736,336, which describe PNAs comprising naturally and non-naturally occurring nucleobases and alkylamine side chains that provide improvements in

sequence specificity, solubility and/or binding affinity relative to a naturally occurring nucleic acid.

F. Antisense and Ribozymes

The invention also concerns modulators of apoptosis including molecules that
5 directly affect BAD or U₃ transcripts encoding promoters and inhibitors, respectively, of
apoptosis. Antisense and ribozyme molecules target a particular sequence to achieve a
reduction or elimination of a particular polypeptide, such as apoptosis modulators. Thus,
it is contemplated that nucleic acid molecules that are identical or complementary to all or
part of SEQ ID NO:1, 3, and 5 are included as part of the invention. For example, an
10 antisense molecule complementary to the transcript of a BAD-encoding nucleic acid may
be used in the context of the present invention to inhibit apoptosis. Similarly, an
antisense molecule complementary to the transcript of a U₃-encoding nucleic acid may
be used in the context of the present invention to relieve apoptosis inhibition and promote
apoptosis of a cell.

15 a. Antisense Molecules

Antisense methodology takes advantage of the fact that nucleic acids tend to pair
with "complementary" sequences. By complementary, it is meant that polynucleotides
are those which are capable of base-pairing according to the standard Watson-Crick
complementarily rules. That is, the larger purines will base pair with the smaller
20 pyrimidines to form combinations of guanine paired with cytosine (G:C) and adenine
paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U)
in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine,
6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere
with pairing.

25 Targeting double-stranded (ds) DNA with polynucleotides leads to triple-helix
formation; targeting RNA will lead to double-helix formation. Antisense
polynucleotides, when introduced into a target cell, specifically bind to their target
polynucleotide and interfere with transcription, RNA processing, transport, translation
and/or stability. Antisense RNA constructs, or DNA encoding such antisense RNAs, may

be employed to inhibit gene transcription or translation or both within a host cell, either *in vitro* or *in vivo*, such as within a host animal, including a human subject.

Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. It is contemplated that the most effective antisense constructs may include regions complementary to intron/exon splice junctions. Thus, antisense constructs with complementarity to regions within 50-200 bases of an intron-exon splice junction may be used. It has been observed that some exon sequences can be included in the construct without seriously affecting the target selectivity thereof. The amount of exonic material included will vary depending on the particular exon and intron sequences used. One can readily test whether too much exon DNA is included simply by testing the constructs *in vitro* to determine whether normal cellular function is affected or whether the expression of related genes having complementary sequences is affected.

As stated above, "complementary" or "antisense" means polynucleotide sequences that are substantially complementary over their entire length and have very few base mismatches. For example, sequences of fifteen bases in length may be termed complementary when they have complementary nucleotides at thirteen or fourteen positions. Naturally, sequences which are completely complementary will be sequences which are entirely complementary throughout their entire length and have no base mismatches. Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region (e.g., ribozyme) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.

It may be advantageous to combine portions of genomic DNA with cDNA or synthetic sequences to generate specific constructs. For example, where an intron is desired in the ultimate construct, a genomic clone will need to be used. The cDNA or a synthesized polynucleotide may provide more convenient restriction sites for the

remaining portion of the construct and, therefore, would be used for the rest of the sequence.

b. Ribozymes

The use of apoptosis modulator-specific ribozymes is claimed in the present application. The following information is provided in order to compliment the earlier
5 section and to assist those of skill in the art in this endeavor.

Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, 1987; Gerlach *et al.*, 1987; Forster and Symons, 1987). For example, a
10 large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, 1981; Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992). This specificity has been attributed to the requirement that the substrate bind *via* specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme
15 prior to chemical reaction.

Ribozyme catalysis has primarily been observed as part of sequence specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cech *et al.*, 1981). For example, U.S. Patent 5,354,855 reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that
20 of the DNA restriction enzymes. Thus, sequence-specific ribozyme-mediated inhibition of gene expression may be particularly suited to therapeutic applications (Scanlon *et al.*, 1991; Sarver *et al.*, 1990; Sioud *et al.*, 1992). Recently, it was reported that ribozymes elicited genetic changes in some cell lines to which they were applied; the altered genes included the oncogenes *H-ras*, *c-fos* and genes of HIV. Most of this work involved the
25 modification of a target mRNA, based on a specific mutant codon that is cleaved by a specific ribozyme. In light of the information included herein and the knowledge of one of ordinary skill in the art, the preparation and use of additional ribozymes that are specifically targeted to a given gene will now be straightforward.

Several different ribozyme motifs have been described with RNA cleavage activity (reviewed in Symons, 1992). Examples that would be expected to function equivalently for the down regulation of apoptosis modulators include sequences from the Group I self splicing introns including tobacco ringspot virus (Prody *et al.*, 1986),
5 avocado sunblotch viroid (Palukaitis *et al.*, 1979; Symons, 1981), and Lucerne transient streak virus (Forster and Symons, 1987). Sequences from these and related viruses are referred to as hammerhead ribozymes based on a predicted folded secondary structure.

Other suitable ribozymes include sequences from RNase P with RNA cleavage activity (Yuan *et al.*, 1992; Yuan and Altman, 1994), hairpin ribozyme structures (Berzal-
10 Herranz *et al.*, 1992; Chowrira *et al.*, 1993) and hepatitis δ virus based ribozymes (Perrotta and Been, 1992). The general design and optimization of ribozyme directed RNA cleavage activity has been discussed in detail (Haseloff and Gerlach, 1988; Symons, 1992; Chowrira, *et al.*, 1994; and Thompson, *et al.*, 1995).

The other variable on ribozyme design is the selection of a cleavage site on a
15 given target RNA. Ribozymes are targeted to a given sequence by virtue of annealing to a site by complimentary base pair interactions. Two stretches of homology are required for this targeting. These stretches of homologous sequences flank the catalytic ribozyme structure defined above. Each stretch of homologous sequence can vary in length from 7 to 15 nucleotides. The only requirement for defining the homologous sequences is that,
20 on the target RNA, they are separated by a specific sequence which is the cleavage site. For hammerhead ribozymes, the cleavage site is a dinucleotide sequence on the target RNA, uracil (U) followed by either an adenine, cytosine or uracil (A,C or U; Perriman, *et al.*, 1992; Thompson, *et al.*, 1995). The frequency of this dinucleotide occurring in any given RNA is statistically 3 out of 16. Therefore, for a given target messenger RNA of
25 1000 bases, 187 dinucleotide cleavage sites are statistically possible.

Designing and testing ribozymes for efficient cleavage of a target RNA is a process well known to those skilled in the art. Examples of scientific methods for designing and testing ribozymes are described by Chowrira *et al.* (1994) and Lieber and Strauss (1995), each incorporated by reference. The identification of operative and

preferred sequences for use in apoptosis modulator-targeted ribozymes is simply a matter of preparing and testing a given sequence, and is a routinely practiced "screening" method known to those of skill in the art.

G. Preparation of Nucleic Acids

5 A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production or biological production. Non-limiting examples of a synthetic nucleic acid (*e.g.*, a synthetic oligonucleotide), include a nucleic acid made by *in vitro* chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such
10 as described in EP 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, 1986 and U.S. Patent Serial No. 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents. 4,659,774,
15 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCRTM (see for example, U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference), or
20 the synthesis of an oligonucleotide described in U.S. Patent No. 5,645,897, incorporated herein by reference. A non-limiting example of a biologically produced nucleic acid includes a recombinant nucleic acid produced (*i.e.*, replicated) in a living cell, such as a recombinant DNA vector replicated in bacteria (see for example, Sambrook *et al.* 1989 and 2001, incorporated herein by reference).

25 H. Purification of Nucleic Acids

A nucleic acid may be purified on polyacrylamide gels, cesium chloride centrifugation gradients, or by any other means known to one of ordinary skill in the art (see for example, Sambrook *et al.*, 1989, incorporated herein by reference).

In certain aspect, the present invention concerns a nucleic acid that is an isolated nucleic acid. As used herein, the term "isolated nucleic acid" refers to a nucleic acid molecule (e.g., an RNA or DNA molecule) that has been isolated free of, or is otherwise free of, the bulk of the total genomic and transcribed nucleic acids of one or more cells.

- 5 In certain embodiments, "isolated nucleic acid" refers to a nucleic acid that has been isolated free of, or is otherwise free of, bulk of cellular components or *in vitro* reaction components such as for example, macromolecules such as lipids or proteins, small biological molecules, and the like.

I. Nucleic Acid Segments

- 10 In certain embodiments, the nucleic acid is a nucleic acid segment. As used herein, the term "nucleic acid segment," are fragments of a nucleic acid, such as for non-limiting example, those that encode only part of a U_s3 or BAD peptide or polypeptide sequence. Thus, a "nucleic acid segment" may comprise any part of a gene sequence, of from about 10 nucleotides to the full length of the U_s3 or BAD peptide- or polypeptide-
15 encoding region.

Various nucleic acid segments may be designed based on a particular nucleic acid sequence, and may be of any length. By assigning numeric values to a sequence, for example, the first residue is 1, the second residue is 2, *etc.*, an algorithm defining all nucleic acid segments can be created:

$$20 \qquad n \text{ to } n + y$$

- where *n* is an integer from 1 to the last number of the sequence and *y* is the length of the nucleic acid segment minus one, where *n* + *y* does not exceed the last number of the sequence. Thus, for a 10-mer, the nucleic acid segments correspond to bases 1 to 10, 2 to 11, 3 to 12 ... and so on. For a 15-mer, the nucleic acid segments correspond to bases 1 to 15, 2 to 16, 3 to 17 ... and so on. For a 20-mer, the nucleic segments correspond to bases 1
25 to 20, 2 to 21, 3 to 22 ... and so on. In certain embodiments, the nucleic acid segment may be a probe or primer. As used herein, a "probe" generally refers to a nucleic acid used in a detection method or composition. As used herein, a "primer" generally refers to a nucleic acid used in an extension or amplification method or composition.

In a non-limiting example, nucleic acid segments may contain up to 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, or 5000 nucleotides. Contiguous nucleic acids segments of SEQ ID NO: 1, 3, or 5 may be used in the present invention. Nucleic acid segments may also contain up to 10,000, 20,000, 30,000, 50,000, 100,000, 250,000, 500,000, 750,000, to 1,000,000 nucleotides in length, as well as constructs of greater size, up to and including chromosomal sizes are contemplated for use in the present invention. Furthermore, nucleic acids, including expression constructs, may comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, or 5000 contiguous nucleic acid residues or nucleotides from SEQ ID NO: 1, 3, or 5.

J. Nucleic Acid Complements

The present invention also encompasses a nucleic acid that is complementary to the nucleic acid encoding for BAD or a herpesvirus U_S3 polypeptide. In particular embodiments the invention encompasses a nucleic acid or a nucleic acid segment complementary to the sequence set forth in SEQ ID NO: 1, 3, or 5. A nucleic acid is "complement(s)" or is "complementary" to another nucleic acid when it is capable of base-pairing with another nucleic acid according to the standard Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. As used herein "another nucleic acid" may refer to a separate molecule or a spatial separated sequence of the same molecule.

As used herein, the term "complementary" or "complement(s)" also refers to a nucleic acid comprising a sequence of consecutive nucleobases or semiconsecutive nucleobases (e.g., one or more nucleobase moieties are not present in the molecule) capable of hybridizing to another nucleic acid strand or duplex even if less than all the nucleobases do not base pair with a counterpart nucleobase. In certain embodiments, a "complementary" nucleic acid comprises a sequence in which about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 77%, about

78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, to about 100%, and any range derivable therein, of the nucleobase sequence is capable of base-pairing with a single or double stranded nucleic acid molecule during hybridization. In certain embodiments, the term "complementary" refers to a nucleic acid that may hybridize to another nucleic acid strand or duplex in stringent conditions, as would be understood by one of ordinary skill in the art.

In certain embodiments, a "partly complementary" nucleic acid comprises a sequence that may hybridize in low stringency conditions to a single or double stranded nucleic acid, or contains a sequence in which less than about 70% of the nucleobase sequence is capable of base-pairing with a single or double stranded nucleic acid molecule during hybridization.

K. Hybridization

As used herein, "hybridization", "hybridizes" or "capable of hybridizing" is understood to mean the forming of a double or triple stranded molecule or a molecule with partial double or triple stranded nature. The term "anneal" as used herein is synonymous with "hybridize." The term "hybridization", "hybridize(s)" or "capable of hybridizing" encompasses the terms "stringent condition(s)" or "high stringency" and the terms "low stringency" or "low stringency condition(s)."

As used herein "stringent condition(s)" or "high stringency" are those conditions that allow hybridization between or within one or more nucleic acid strand(s) containing complementary sequence(s), but precludes hybridization of random sequences. Stringent conditions tolerate little, if any, mismatch between a nucleic acid and a target strand. Such conditions are well known to those of ordinary skill in the art, and are preferred for applications requiring high selectivity. Non-limiting applications include isolating a nucleic acid, such as a gene or a nucleic acid segment thereof, or detecting at least one specific mRNA transcript or a nucleic acid segment thereof, and the like.

Stringent conditions may comprise low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.15 M NaCl at temperatures of about 50°C to about 70°C. It is understood that the temperature and ionic strength of a desired stringency are determined in part by the length of the particular nucleic acid(s), the length
5 and nucleobase content of the target sequence(s), the charge composition of the nucleic acid(s), and to the presence or concentration of formamide, tetramethylammonium chloride or other solvent(s) in a hybridization mixture.

It is also understood that these ranges, compositions and conditions for hybridization are mentioned by way of non-limiting examples only, and that the desired
10 stringency for a particular hybridization reaction is often determined empirically by comparison to one or more positive or negative controls. Depending on the application envisioned it is preferred to employ varying conditions of hybridization to achieve varying degrees of selectivity of a nucleic acid towards a target sequence. In a non-limiting example, identification or isolation of a related target nucleic acid that does not hybridize
15 to a nucleic acid under stringent conditions may be achieved by hybridization at low temperature and/or high ionic strength. Such conditions are termed "low stringency" or "low stringency conditions", and non-limiting examples of low stringency include hybridization performed at about 0.15 M to about 0.9 M NaCl at a temperature range of about 20°C to about 50°C. Of course, it is within the skill of one in the art to further
20 modify the low or high stringency conditions to suite a particular application.

As used herein "wild-type" refers to the naturally occurring sequence of a nucleic acid at a genetic locus in the genome of an organism, or a sequence transcribed or translated from such a nucleic acid. Thus, the term "wild-type" also may refer to an amino acid sequence encoded by a nucleic acid. As a genetic locus may have more than
25 one sequence or alleles in a population of individuals, the term "wild-type" encompasses all such naturally occurring allele(s). As used herein the term "polymorphic" means that variation exists (*i.e.*, two or more alleles exist) at a genetic locus in the individuals of a population. As used herein "mutant" refers to a change in the sequence of a nucleic acid or its encoded protein, polypeptide or peptide that is the result of the hand of man.

The present invention also concerns the isolation or creation of a recombinant construct or a recombinant host cell through the application of recombinant nucleic acid technology known to those of skill in the art or as described herein. A recombinant construct or host cell may express an U₃, BAD, or apoptosis modulator protein, peptide or peptide, or at least one biologically functional equivalent thereof. The recombinant host cell may be a prokaryotic cell. In a more preferred embodiment, the recombinant host cell is a eukaryotic cell. As used herein, the term "engineered" or "recombinant" cell is intended to refer to a cell into which a recombinant gene, such as a gene encoding an U₃, BAD, or apoptosis modulator, has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced gene. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinantly introduced genes will either be in the form of a cDNA gene (*i.e.*, they will not contain introns), a copy of a genomic gene, or will include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene.

In certain embodiments, a "gene" refers to a nucleic acid that is transcribed. In certain aspects, the gene includes regulatory sequences involved in transcription, or message production or composition. In particular embodiments, the gene comprises transcribed sequences that encode for a protein, polypeptide or peptide. As will be understood by those in the art, this function term "gene" includes both genomic sequences, RNA or cDNA sequences or smaller engineered nucleic acid segments, including nucleic acid segments of a non-transcribed part of a gene, including but not limited to the non-transcribed promoter or enhancer regions of a gene. Smaller engineered gene nucleic acid segments may express, or may be adapted to express using nucleic acid manipulation technology, proteins, polypeptides, domains, peptides, fusion proteins, mutants and/or such like. The term "cDNA" refers to that portion of a gene that is transcribed.

The nucleic acid(s) of the present invention, regardless of the length of the sequence itself, may be combined with other nucleic acid sequences, including but not

limited to, promoters, enhancers, polyadenylation signals, restriction enzyme sites, multiple cloning sites, coding segments, and the like, to create one or more nucleic acid construct(s). As used herein, a "nucleic acid construct" is a nucleic acid engineered or altered by the hand of man, and generally comprises one or more nucleic acid sequences organized by the hand of man.

In a non-limiting example, one or more nucleic acid constructs may be prepared containing about 3, about 5, about 8, about 10 to about 14, or about 15, about 20, about 30, about 40, about 50, about 100, about 200, about 500, about 1,000, about 2,000, about 3,000, about 5,000, about 10,000, about 15,000, about 20,000, about 30,000, about 50,000, about 100,000, about 250,000, about 500,000, about 750,000, to about 1,000,000 nucleotides in length, as well as constructs of greater size, up to and including chromosomal sizes (including all intermediate lengths and intermediate ranges), given the advent of nucleic acids constructs such as a yeast artificial chromosome are known to those of ordinary skill in the art. It will be readily understood that "intermediate lengths" and "intermediate ranges", as used herein, means any length or range including or between the quoted values (*i.e.*, all integers including and between such values). Non-limiting examples of intermediate lengths include about 11, about 12, about 13, about 16, about 17, about 18, about 19, *etc.*; about 21, about 22, about 23, *etc.*; about 31, about 32, *etc.*; about 51, about 52, about 53, *etc.*; about 101, about 102, about 103, *etc.*; about 151, about 152, about 153, *etc.*; about 1,001, about 1002, *etc.*; about 50,001, about 50,002, *etc.*; about 750,001, about 750,002, *etc.*; about 1,000,001, about 1,000,002, *etc.* Non-limiting examples of intermediate ranges include about 3 to about 32, about 150 to about 500,001, about 3,032 to about 7,145, about 5,000 to about 15,000, about 20,007 to about 1,000,003, *etc.* Such constructs may be implemented and used with respect to SEQ ID NO: 1, 3, or 5.

The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine and serine, and also refers to codons that encode biologically equivalent amino acids. For optimization of expression of genes in human cells, the codons are shown in Table 4 in preference of use

from left to right. Thus, the most preferred codon for alanine is thus "GCC", and the least is "GCG". Codon usage for various organisms and organelles can be found at the website <http://www.kazusa.or.jp/codon/>, incorporated herein by reference, allowing one of skill in the art to optimize codon usage for expression in various organisms using the disclosures herein. Thus, it is contemplated that codon usage may be optimized for other animals, as well as other organisms such as a prokaryote (e.g., an eubacteria, an archaea), an eukaryote (e.g., a protist, a plant, a fungi, an animal), a virus and the like, as well as organelles that contain nucleic acids, such as mitochondria, chloroplasts and the like, based on the preferred codon usage as would be known to those of ordinary skill in the art.

It will also be understood that amino acid sequences or nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, or various combinations thereof, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein, polypeptide or peptide activity where expression of a proteinaceous composition is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' and/or 3' portions of the coding region or may include various internal sequences, *i.e.*, introns, which are known to occur within genes.

The nucleic acids of the present invention encompass biologically functional equivalent U₅3, BAD, or apoptosis modulator proteins, polypeptides, or peptides. Such sequences may arise as a consequence of codon redundancy or functional equivalency that are known to occur naturally within nucleic acid sequences or the proteins, polypeptides or peptides thus encoded. Alternatively, functionally equivalent proteins, polypeptides or peptides may be created via the application of recombinant DNA technology, in which changes in the protein, polypeptide or peptide structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man may be introduced, for example, through the application of site-directed mutagenesis techniques as discussed herein below, *e.g.*, to

introduce improvements or alterations to the antigenicity of the protein, polypeptide or peptide, or to test mutants in order to examine U_s3, BAD, or apoptosis modulator protein, polypeptide or peptide activity at the molecular level.

Fusion proteins, polypeptides or peptides may be prepared, *e.g.*, where the coding regions are aligned within the same expression unit with other proteins, polypeptides or peptides having desired functions. Non-limiting examples of such desired functions of expression sequences include purification or immunodetection purposes for the added expression sequences, *e.g.*, proteinaceous compositions that may be purified by affinity chromatography or the enzyme labeling of coding regions, respectively.

As used herein an "organism" may be a prokaryote, eukaryote, virus and the like. As used herein the term "sequence" encompasses both the terms "nucleic acid" and "proteinaceous composition." As used herein, the term "proteinaceous composition" encompasses the terms "protein", "polypeptide" and "peptide." As used herein "artificial sequence" refers to a sequence of a nucleic acid not derived from sequence naturally occurring at a genetic locus, as well as the sequence of any proteins, polypeptides or peptides encoded by such a nucleic acid. A "synthetic sequence", refers to a nucleic acid or proteinaceous composition produced by chemical synthesis *in vitro*, rather than enzymatic production *in vitro* (*i.e.*, an "enzymatically produced" sequence) or biological production *in vivo* (*i.e.*, a "biologically produced" sequence).

L. Vectors and Expression Constructs

The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous," which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (*e.g.*, YACs). One of skill in the art would be well equipped to construct a vector through

standard recombinant techniques (see, for example, Sambrook *et al.*, 1988 and Ausubel *et al.*, 1994, both incorporated herein by reference).

The term "expression vector" refers to any type of genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operable linked coding sequence in a particular host cell. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described *infra*.

In order to express an U₃ peptide or polypeptide, or an antisense U₃ transcript, it is necessary to provide an U₃ gene in an expression vehicle. Similarly to express a BAD peptide or polypeptide, or an antisense BAD transcript, it is necessary to provide a BAD cDNA in an expression vehicle. The appropriate nucleic acid can be inserted into an expression vector by standard subcloning techniques. For example, an *E. coli* or baculovirus expression vector is used to produce recombinant polypeptide *in vitro*. The manipulation of these vectors is well known in the art. In one embodiment, the protein is expressed as a fusion protein with β -gal, allowing rapid affinity purification of the protein. Examples of such fusion protein expression systems are the glutathione S-transferase system (Pharmacia, Piscataway, NJ), the maltose binding protein system (NEB, Beverly, MA), the FLAG system (IBI, New Haven, CT), and the 6xHis system (Qiagen, Chatsworth, CA).

Some of these fusion systems produce recombinant protein bearing only a small number of additional amino acids, which are unlikely to affect the functional capacity of the recombinant protein. For example, both the FLAG system and the 6xHis system add only short sequences, both of which are known to be poorly antigenic and which do not adversely affect folding of the protein to its native conformation. Other fusion systems produce proteins where it is desirable to excise the fusion partner from the desired

protein. In another embodiment, the fusion partner is linked to the recombinant protein by a peptide sequence containing a specific recognition sequence for a protease. Examples of suitable sequences are those recognized by the Tobacco Etch Virus protease (Life Technologies, Gaithersburg, MD) or Factor Xa (New England Biolabs, Beverly, MA).

Recombinant bacterial cells, for example *E. coli*, are grown in any of a number of suitable media, for example LB, and the expression of the recombinant polypeptide induced by adding IPTG to the media or switching incubation to a higher temperature. After culturing the bacteria for a further period of between 2 and 24 hours, the cells are collected by centrifugation and washed to remove residual media. The bacterial cells are then lysed, for example, by disruption in a cell homogenizer and centrifuged to separate the dense inclusion bodies and cell membranes from the soluble cell components. This centrifugation can be performed under conditions whereby the dense inclusion bodies are selectively enriched by incorporation of sugars such as sucrose into the buffer and centrifugation at a selective speed.

If the recombinant protein is expressed in the inclusion bodies, as is the case in many instances, these can be washed in any of several solutions to remove some of the contaminating host proteins, then solubilized in solutions containing high concentrations of urea (e.g. 8M) or chaotropic agents such as guanidine hydrochloride in the presence of reducing agents such as β -mercaptoethanol or DTT (dithiothreitol).

Under some circumstances, it may be advantageous to incubate the polypeptide for several hours under conditions suitable for the protein to undergo a refolding process into a conformation which more closely resembles that of the native protein. Such conditions generally include low protein concentrations less than 500 μ g/ml, low levels of reducing agent, concentrations of urea less than 2 M and often the presence of reagents such as a mixture of reduced and oxidized glutathione which facilitate the interchange of disulphide bonds within the protein molecule.

The refolding process can be monitored, for example, by SDS-PAGE or with antibodies which are specific for the native molecule (which can be obtained from

animals vaccinated with the native molecule isolated from parasites). Following refolding, the protein can then be purified further and separated from the refolding mixture by chromatography on any of several supports including ion exchange resins, gel permeation resins or on a variety of affinity columns.

5 In yet another embodiment, the expression system used is one driven by the baculovirus polyhedron promoter. The gene encoding the protein can be manipulated by standard techniques in order to facilitate cloning into the baculovirus vector. A preferred baculovirus vector is the pBlueBac vector (Invitrogen, Sorrento, CA). The vector carrying the gene of interest is transfected into *Spodoptera frugiperda* (Sf9) cells by
10 standard protocols, and the cells are cultured and processed to produce the recombinant protein. Mammalian cells exposed to baculoviruses become infected and may express the foreign gene only. This way one can transduce all cells and express the gene in dose dependent manner.

There also are a variety of eukaryotic vectors that provide a suitable vehicle in
15 which recombinant polypeptide can be produced. HSV itself has been used in tissue culture to express a large number of exogenous genes as well as for high level expression of its endogenous genes. For example, the chicken ovalbumin gene has been expressed from HSV using an α promoter. Herz and Roizman (1983). The *lacZ* gene also has been expressed under a variety of HSV promoters.

20 Throughout this application, the term "expression construct" is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. Thus, in certain embodiments, expression includes both transcription of a gene and translation of a RNA
25 into a gene product. In other embodiments, expression only includes transcription of the nucleic acid, for example, to generate antisense constructs.

In preferred embodiments, the nucleic acid is under transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific

transcription of a gene. The phrase "under transcriptional control" means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.

The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

The particular promoter that is employed to control the expression of a nucleic acid is not believed to be critical, so long as it is capable of expressing the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable

of being expressed in a human cell. Generally speaking, such a promoter might include either a human or viral promoter. Preferred promoters include those derived from HSV, including the U_s3, or the α 4 promoter. Another preferred embodiment is the tetracycline controlled promoter.

5 In various other embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of transgenes. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a transgene is contemplated as well, provided that the levels of
10 expression are sufficient for a given purpose. Tables 4 and 5 list several elements/promoters which may be employed, in the context of the present invention, to regulate the expression of a transgene. This list is not exhaustive of all the possible elements involved but, merely, to be exemplary thereof.

Enhancers were originally detected as genetic elements that increased
15 transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

20 The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities.
25 Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.

Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of a transgene. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells

can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

TABLE 4

PROMOTER
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ α and DQ β
β -Interferon
Interleukin-2
Interleukin-2 Receptor
MHC Class II 5
MHC Class II HLA-DR α
β -Actin
Muscle Creatine Kinase
Prealbumin (Transthyretin)
Elastase I
Metallothionein
Collagenase
Albumin Gene
α -Fetoprotein
τ -Globin
β -Globin
c-fos
c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM)

PROMOTER
α_1 -Antitrypsin
H2B (TH2B) Histone
Mouse or Type I Collagen
Glucose-Regulated Proteins (GRP94 and GRP78)
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
Polyoma
Retroviruses
Papilloma Virus
Hepatitis B Virus
Human Immunodeficiency Virus
Cytomegalovirus
Gibbon Ape Leukemia Virus

TABLE 5

Element	Inducer
MT II	Phorbol Ester (TPA) Heavy metals
MMTV (mouse mammary tumor virus)	Glucocorticoids
β -Interferon	poly(rI)X poly(rc)
Adenovirus 5 E2	Ela
c-jun	Phorbol Ester (TPA), H ₂ O ₂

Collagenase	Phorbol Ester (TPA)
Stromelysin	Phorbol Ester (TPA), IL-1
SV40	Phorbol Ester (TPA)
Murine MX Gene	Interferon, Newcastle Disease Virus
GRP78 Gene	A23187
α -2-Macroglobulin	IL-6
Vimentin	Serum
MHC Class I Gene H-2kB	Interferon
HSP70	Ela, SV40 Large T Antigen
Proliferin	Phorbol Ester-TPA
Tumor Necrosis Factor	FMA
Thyroid Stimulating Hormone α Gene	Thyroid Hormone

Use of the baculovirus system will involve high level expression from the powerful polyhedron promoter.

One will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation signal and the bovine growth hormone polyadenylation signal, convenient and known to function well in various target cells. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be

"in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements (Bittner *et al.*, 1987).

5 In various embodiments of the invention, the expression construct may comprise a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis and to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells (Ridgeway, 1988; Nicolas and
10 Rubenstein, 1988; Baichwal and Sugden, 1986; Temin, 1986). The first viruses used as vectors were DNA viruses including the papovaviruses (simian virus 40, bovine papilloma virus, and polyoma) (Ridgeway, 1988; Baichwal and Sugden, 1986) and adenoviruses (Ridgeway, 1988; Baichwal and Sugden, 1986) and adeno-associated viruses. Retroviruses also are attractive gene transfer vehicles (Nicolas and Rubenstein,
15 1988; Temin, 1986) as are vaccinia virus (Ridgeway, 1988) and adeno-associated virus (Ridgeway, 1988). Such vectors may be used to (i) transform cell lines *in vitro* for the purpose of expressing proteins of interest or (ii) to transform cells *in vitro* or *in vivo* to provide therapeutic polypeptides in a gene therapy scenario.

In a preferred embodiment, the vector is HSV. Because HSV is neurotropic, it
20 has generated considerable interest in treating nervous system disorders. Moreover, the ability of HSV to establish latent infections in non-dividing neuronal cells without integrating into the host cell chromosome or otherwise altering the host cell's metabolism, along with the existence of a promoter that is active during latency. And though much attention has focused on the neurotropic applications of HSV, this vector
25 also can be exploited for other tissues.

Another factor that makes HSV an attractive vector is the size and organization of the genome. Because HSV is large, incorporation of multiple genes or expression cassettes is less problematic than in other smaller viral systems. In addition, the availability of different viral control sequences with varying performance (temporal,

strength, *etc.*) makes it possible to control expression to a greater extent than in other systems. It also is an advantage that the virus has relatively few spliced messages, further easing genetic manipulations.

HSV also is relatively easy to manipulate and can be grown to high titers. Thus, delivery is less of a problem, both in terms of volumes needed to attain sufficient MOI and in a lessened need for repeat dosings. For a review of HSV as a gene therapy vector, see Glorioso *et al.* (1995).

1. Viral Vectors

Viral vectors are a kind of expression construct that utilizes viral sequences to introduce nucleic acid and possibly proteins into a cell. The ability of certain viruses to infect cells or enter cells *via* receptor-mediated endocytosis, and to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign nucleic acids into cells (*e.g.*, mammalian cells). Vector components of the present invention may be a viral vector that encode one or more candidate substance or other components such as, for example, an immunomodulator or adjuvant for the candidate substance. Non-limiting examples of virus vectors that may be used to deliver a nucleic acid of the present invention are described below.

a. Adenoviral Vectors

A particular method for delivery of the nucleic acid involves the use of an adenovirus expression vector. Although adenovirus vectors are known to have a low capacity for integration into genomic DNA, this feature is counterbalanced by the high efficiency of gene transfer afforded by these vectors. "Adenovirus expression vector" is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to ultimately express a tissue or cell-specific construct that has been cloned therein. Knowledge of the genetic organization of adenovirus, a 36 kb, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992).

b. AAV Vectors

The nucleic acid may be introduced into the cell using adenovirus assisted transfection. Increased transfection efficiencies have been reported in cell systems using adenovirus coupled systems (Kelleher and Vos, 1994; Cotten *et al.*, 1992; Curiel, 1994).
5 Adeno-associated virus (AAV) is an attractive vector system for use in the candidate substances of the present invention as it has a high frequency of integration and it can infect nondividing cells, thus making it useful for delivery of genes into mammalian cells, for example, in tissue culture (Muzyczka, 1992) or *in vivo*. AAV has a broad host range for infectivity (Tratschin *et al.*, 1984; Laughlin *et al.*, 1986; Lebkowski *et al.*, 1988;
10 McLaughlin *et al.*, 1988). Details concerning the generation and use of rAAV vectors are described in U.S. Patents 5,139,941 and 4,797,368, each incorporated herein by reference.

c. Retroviral Vectors

Retroviruses have promise as an antigen delivery vectors in vaccines of the candidate substances due to their ability to integrate their genes into the host genome,
15 transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and of being packaged in special cell-lines (Miller, 1992).

In order to construct a vaccine retroviral vector, a nucleic acid (*e.g.*, one encoding an U₃, BAD, or apoptosis modulator or therapeutic agent antigen of interest) is inserted into the viral genome in the place of certain viral sequences to produce a virus that is
20 replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into a special cell line (*e.g.*, by calcium phosphate precipitation for example), the packaging sequence allows the RNA
25 transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a

broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind *et al.*, 1975).

Lentiviruses are complex retroviruses, which, in addition to the common retroviral genes *gag*, *pol*, and *env*, contain other genes with regulatory or structural function. Lentiviral vectors are well known in the art (see, for example, Naldini *et al.*, 1996; Zufferey *et al.*, 1997; Blomer *et al.*, 1997; U.S. Patents 6,013,516 and 5,994,136). Some examples of lentivirus include the Human Immunodeficiency Viruses: HIV-1, HIV-2 and the Simian Immunodeficiency Virus: SIV. Lentiviral vectors have been generated by multiply attenuating the HIV virulence genes, for example, the genes *env*, *vif*, *vpr*, *vpu* and *nef* are deleted making the vector biologically safe.

Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for both *in vivo* and *ex vivo* gene transfer and expression of nucleic acid sequences. For example, recombinant lentivirus capable of infecting a non-dividing cell wherein a suitable host cell is transfected with two or more vectors carrying the packaging functions, namely *gag*, *pol* and *env*, as well as *rev* and *tat* is described in U.S. Patent 5,994,136, incorporated herein by reference. One may target the recombinant virus by linkage of the envelope protein with an antibody or a particular ligand for targeting to a receptor of a particular cell-type. By inserting a sequence (including a regulatory region) of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target-specific.

d. Other Viral Vectors

Other viral vectors may be employed as vaccine constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988), sindbis virus, cytomegalovirus and herpes simplex virus may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988; Horwich *et al.*, 1990).

e. Delivery Using Modified Viruses

A nucleic acid to be delivered may be housed within an infective virus that has been engineered to express a specific binding ligand. The virus particle will thus bind specifically to the cognate receptors of the target cell and deliver the contents to the cell.

- 5 A novel approach designed to allow specific targeting of retrovirus vectors was developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope. This modification can permit the specific infection of hepatocytes *via* sialoglycoprotein receptors.

- Another approach to targeting of recombinant retroviruses was designed in which
10 biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled *via* the biotin components by using streptavidin (Roux *et al.*, 1989). Using antibodies against major histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).
15

2. Vector Delivery and Cell Transformation

- Suitable methods for nucleic acid delivery for transformation of an organelle, a cell, a tissue or an organism for use with the current invention are believed to include virtually any method by which a nucleic acid (*e.g.*, DNA) can be introduced into an
20 organelle, a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by *ex vivo* transfection (Wilson *et al.*, 1989, Nabel *et al.*, 1989), by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including
25 microinjection (Harlan and Weintraub, 1985; U.S. Patent 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent 5,384,253, incorporated herein by reference; Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE-dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading

(Fechheimer *et al.*, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991) and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988); by microprojectile bombardment (WO 94/09699 and WO 95/06128; U.S. Patents 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein
5 by reference); by agitation with silicon carbide fibers (Kaepler *et al.*, 1990; U.S. Patents 5,302,523 and 5,464,765, each incorporated herein by reference); by *Agrobacterium*-mediated transformation (U.S. Patents 5,591,616 and 5,563,055, each incorporated herein by reference); by PEG-mediated transformation of protoplasts
10 (Omirulleh *et al.*, 1993; U.S. Patents 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition-mediated DNA uptake (Potrykus *et al.*, 1985), and any combination of such methods. Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

15 3. Host Cells

As used herein, the terms "cell," "cell line," and "cell culture" may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. In the context of expressing a heterologous nucleic
20 acid sequence, "host cell" refers to a prokaryotic or eukaryotic cell, and it includes any transformable organism that is capable of replicating a vector and/or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors. A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A
25 transformed cell includes the primary subject cell and its progeny. As used herein, the terms "engineered" and "recombinant" cells or host cells are intended to refer to a cell into which an exogenous nucleic acid sequence, such as, for example, a vector, has been introduced. Therefore, recombinant cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced nucleic acid.

In certain embodiments, it is contemplated that RNAs or proteinaceous sequences may be co-expressed with other selected RNAs or proteinaceous sequences in the same host cell. Co-expression may be achieved by co-transfecting the host cell with two or more distinct recombinant vectors. Alternatively, a single recombinant vector may be constructed to include multiple distinct coding regions for RNAs, which could then be expressed in host cells transfected with the single vector.

In certain embodiments, the host cell or tissue may be comprised in at least one organism. In certain embodiments, the organism may be, but is not limited to, a prokaryote (e.g., a eubacteria, an archaea) or an eukaryote, as would be understood by one of ordinary skill in the art (see, for example, webpage <http://phylogeny.arizona.edu/tree/phylogeny.html>).

Numerous cell lines and cultures are available for use as a host cell, and they can be obtained through the American Type Culture Collection (ATCC), which is an organization that serves as an archive for living cultures and genetic materials (www.atcc.org). An appropriate host can be determined by one of skill in the art based on the vector backbone and the desired result. A plasmid or cosmid, for example, can be introduced into a prokaryote host cell for replication of many vectors. Cell types available for vector replication and/or expression include, but are not limited to, bacteria, such as *E. coli* (e.g., *E. coli* strain RR1, *E. coli* LE392, *E. coli* B, *E. coli* X 1776 (ATCC No. 31537) as well as *E. coli* W3110 (F-, lambda-, prototrophic, ATCC No. 273325), DH5 α , JM109, and KC8, bacilli such as *Bacillus subtilis*; and other enterobacteriaceae such as *Salmonella typhimurium*, *Serratia marcescens*, various *Pseudomonas* specie, as well as a number of commercially available bacterial hosts such as SURE[®] Competent Cells and SOLOPACK[™] Gold Cells (STRATAGENE[®], La Jolla). In certain embodiments, bacterial cells such as *E. coli* LE392 are particularly contemplated as host cells for phage viruses.

Examples of eukaryotic host cells for replication and/or expression of a vector include, but are not limited to, HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Many host cells from various cell types and organisms are available and would be known

to one of skill in the art. Similarly, a viral vector may be used in conjunction with either a eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector.

Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further understand the conditions under which to incubate all of the above described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.

It is an aspect of the present invention that the nucleic acid compositions described herein may be used in conjunction with a host cell. For example, a host cell may be transfected using all or part of SEQ ID NO: 1 or any of SEQ ID NOS; 3 or 5.

4. Expression Systems

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patents. 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC[®] 2.0 from INVITROGEN[®] and BACPACK[™] BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH[®].

Other examples of expression systems include STRATAGENE[®]'s COMPLETE CONTROL[™] Inducible Mammalian Expression System, which involves a synthetic ecdysone-inducible receptor, or its pET Expression System, an *E. coli* expression system. Another example of an inducible expression system is available from INVITROGEN[®],

which carries the T-REX™ (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. INVITROGEN® also provides a yeast expression system called the *Pichia methanolica* Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast *Pichia methanolica*. One of skill in the art would know how to
5 express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

It is contemplated that the proteins, polypeptides or peptides produced by the methods of the invention may be "overexpressed," i.e., expressed in increased levels
10 relative to its natural expression in cells. Such overexpression may be assessed by a variety of methods, including radio-labeling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or western blotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot. A specific increase in the level of the recombinant
15 protein, polypeptide or peptide in comparison to the level in natural cells is indicative of overexpression, as is a relative abundance of the specific protein, polypeptides or peptides in relation to the other proteins produced by the host cell, e.g., visible on a gel.

In some embodiments, the expressed proteinaceous sequence forms an inclusion body in the host cell, the host cells are lysed, for example, by disruption in a cell
20 homogenizer, washed and/or centrifuged to separate the dense inclusion bodies and cell membranes from the soluble cell components. This centrifugation can be performed under conditions whereby the dense inclusion bodies are selectively enriched by incorporation of sugars, such as sucrose, into the buffer and centrifugation at a selective speed. Inclusion bodies may be solubilized in solutions containing high concentrations of
25 urea (e.g., 8M) or chaotropic agents such as guanidine hydrochloride in the presence of reducing agents, such as β -mercaptoethanol or DTT (dithiothreitol), and refolded into a more desirable conformation, as would be known to one of ordinary skill in the art.

The nucleotide and protein, polypeptide and peptide sequences for various genes have been previously disclosed, and may be found at computerized databases known to

those of ordinary skill in the art. One such database is the National Center for Biotechnology Information's Genbank and GenPept databases (www.ncbi.nlm.nih.gov/). The coding regions for these known genes may be amplified and/or expressed using the techniques disclosed herein or by any technique that would be known to those of ordinary skill in the art. Additionally, peptide sequences may be synthesized by methods known to those of ordinary skill in the art, such as peptide synthesis using automated peptide synthesis machines, such as those available from Applied Biosystems (Foster City, CA).

IV. METHODS OF MODULATING APOPTOSIS AND METHODS FOR SCREENING FOR MODULATORS OF U_s3, BAD ACTIVITY, AND APOPTOSIS

In one embodiment of the present invention, there are provided methods of screening compounds for activity against U_s3's anti-apoptotic activity. These screening methods will determine the cell pathology of target cells that express U_s3, both in the presence and absence of the test compound. In another embodiment, the present invention, provides methods of screening compounds for activity against ICP4's anti-apoptotic activity. At least three different assays may be employed, as discussed below.

First, one may look at DNA fragmentation using a separative method, *e.g.*, chromatography or electrophoresis, to size fractionate the sample. As described in greater detail in the examples, an exemplary assay involves the isolation of DNA from cells, followed by agarose gel electrophoresis and staining with ethidium bromide. DNA fragmentation, characteristic of apoptosis, will be visualized as "ladders" containing a wide range of fragment sizes.

Second, one may employ terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labeling (TUNEL) assays to measure the integrity of DNA (Gorczyca, 1993). This assay measures the fragmentation of DNA by monitoring the incorporation of labeled UTP into broken DNA strands by the enzyme terminal transferase. The incorporation can be monitored by electrospectroscopy or by cell sorting methodologies (*e.g.*, FACS)

Third, one may examine cells using standard light or electron microscopy to assess the presence or absence of the cytopathologies characteristic of apoptosis. Those of skill in the art, applying standard methods of microscopy, will be able to assess cytopathology.

5 In each of these assays, a cell will be employed as the target for induction and inhibition of apoptosis. In one embodiment, the cell will be infected with HSV that expresses its own U_s3 protein. In a second embodiment, the cell will carry the U_s3 gene linked to a viral promoter. Infection with the appropriate virus will result in stimulation of the U_s3 gene and expression of U_s3. In these first two embodiments, the infection
10 should induce apoptosis in the cell, and the expression of U_s3 should limit this effect. In a third embodiment, the cell will contain, as part of its own genetic material, an inducible version of the U_s3 gene (*i.e.*, U_s3 linked to an inducible promoter). In this situation, it will be necessary to induce apoptosis via some other mechanism, such as hypothermia, osmotic shock or ICP4 expression, and express U_s3 by inducing the promoter. The
15 present invention may further employ ICP4 alone or in combination with U_s3 in any of the embodiments described above.

The cell is contacted with a candidate inhibitor substance in order to assess its effect on U_s3 activity. The substance may be contacted with the cell prior to, at the same time, or after the provision of U_s3. In some cases, the candidate inhibitor substance may
20 be contacted with the cell directly. In other situations, depending on the nature and putative mechanism of action, the candidate inhibitor substance may be reformulated to provide improved uptake. For example, where antisense oligonucleotides are provided, these may advantageously be formulated in liposomes or as virally-encapsulated expression vehicles. Where polypeptides are to be tested, it may be advantageous to
25 provide expression vectors encoding these molecules rather than the polypeptides themselves. Essentially, the most reasonable mechanism for delivering an effective amount of the candidate inhibitor substance to the proper intracellular site will be chosen. "Effective amount," for the purposes of the screening assay, is intended to mean an amount that will cause a detectable difference, and preferably a significant difference, in

the cytopathology of the cell as compared to a similar treatment of the cell without the candidate inhibitor substance. A similar protocol may be used to test the effect of a candidate substance on ICP4 activity.

Once the candidate inhibitor substance has been provided to a cell that expresses
5 the relevant peptide(s) (U_s3, ICP4 or both), the evaluation of cytopathology may be undertaken. Depending on the type of assay used to examine cytopathology, it is possible to automate this process and test hundreds of candidates at the same time. For example, 96-well trays may be employed in which several wells are reserved for controls while the remainder comprise test substances, usually with each substance being tested at several
10 different amounts.

In certain embodiments, the present invention concerns a method for identifying modulators of U_s3 function or activity. Such modulators may be inhibitors or stimulators of such a function or activity. It is contemplated that this screening technique will prove
15 useful in the general identification of any compound that will serve the purpose of inhibiting or stimulating U_s3-mediated kinase activity. In other embodiments a method for identifying modulators of BAD activity are also provided. Generally, the present invention provides methods for screening apoptosis modulators, that is, modulators of apoptosis. A "modulator" is a compound, substance, or agent that causes an alteration.
20 An "apoptosis modulator" is such a compound, substance, or agent that causes an alteration with respect to apoptosis; an apoptosis modulator can inhibit, retard, prevent, reduce, increase, promote, induce, or trigger the frequency, rate, or incidence of apoptosis. In specific embodiments of the invention, an apoptosis modulator affects U_s3 so as to prevent it from inhibiting apoptosis, while in other embodiments U_s3 is the
25 apoptosis modulator by being able to inhibit a cell from undergoing apoptosis.

The active compounds may include fragments or parts of naturally-occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive. However, prior to testing of such compounds in humans or animal

models, it will possibly be necessary to test a variety of candidates to determine which have potential.

Accordingly, in screening assays to identify pharmaceutical agents that modulate U_s3 kinase activity or BAD's pro-apoptotic activity, it is proposed that compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds.

10 In these embodiments, the present invention is directed to a method for determining the ability of a candidate substance to inhibit or stimulate a protein kinase assay, the method including generally the steps of:

- 15 (a) obtaining an enzyme composition comprising a protein kinase, preferably U_s3 protein kinase that is capable of phosphorylating threonine/serine residue;
- (b) admixing a candidate substance with the enzyme composition; and
- (c) determining the ability of the candidate substance to inhibit or stimulate threonine/serine phosphorylation.

20 In alternative embodiments, the present invention is directed to a method for determining the ability of a candidate substance to inhibit or stimulate BAD apoptotic activity, the method including generally:

- (a) obtaining an proteinaceous composition comprising a pro-apoptotic activity, preferably BAD;
- (b) admixing a candidate substance with the composition; and
- 25 (c) determining the ability of the candidate substance to inhibit or stimulate apoptosis of a cell.

To identify a candidate substance as being capable of modulating protein phosphorylation, one would first obtain an enzyme composition that is capable of phosphorylating threonine/serine residues on a protein of interest. Naturally, one would measure or determine the phosphorylation activity of the threonine/serine kinase composition in the absence of the added candidate substance. One would then add the candidate substance to the threonine/serine kinase composition and re-determine the ability of the threonine/serine kinase composition to phosphorylate threonine/serine residues on a test protein in the presence of the candidate substance. A candidate substance which reduces the phosphorylation activity of the threonine/serine kinase composition relative to the activity in its absence is indicative of a candidate substance with inhibitor capability. Likewise, a candidate substance which increases the phosphorylation activity of the threonine/serine kinase composition relative to the activity in its absence is indicative of a candidate substance with stimulatory capability. To identify a modulator of apoptosis, one would also compare the ability of a cell to undergo apoptosis in the presence and absence of the candidate substance. To perform the study, one may employ a cell that is prone to undergoing apoptosis or resistant to apoptosis. A cell may be rendered resistant to apoptosis by introducing all or part of a herpesvirus U_s3 polypeptide into a cell or using a cell transformed with such a polypeptide. Alternatively, a cell may be prone to undergoing apoptosis or induced to undergo apoptosis by introducing into the cell all or part of a BAD polypeptide or using a cell transformed with such a polypeptide. In other embodiments, a cell with a BAD polypeptide may be rendered resistant to apoptosis by introducing a compound that inhibits BAD activity. It is contemplated that the types of comparisons with respect to identifying kinase activity discussed above may be employed with respect to identifying modulators of apoptosis.

The candidate screening assay is quite simple to set up and perform, after obtaining a relatively purified preparation of the enzyme, either from native or recombinant sources, one will admix a candidate substance with the enzyme preparation, under conditions which would allow the enzyme to perform its threonine/serine phosphorylation function but for inclusion of a candidate substance. In this fashion, one can measure the ability of the candidate substance to reduce or increase the

threonine/serine phosphorylation activity relatively in the presence of the candidate substance. Similarly, the candidate screening assay may be performed after obtaining a cell that can be assayed for characteristics of apoptosis in the presence and absence of a candidate compound under conditions that would allow apoptosis to occur.

5 "Effective amounts" in certain circumstances are those amounts effective to reproducibly reduce or increase threonine/serine kinase activity, or to inhibit or induce the apoptosis of cells, in comparison to their normal levels. Compounds that achieve significant appropriate changes in activity will be used. If desired, a battery of compounds may be screened *in vitro* to identify agents for use in the present invention.

10 Significant decrease in threonine/serine phosphorylation, *e.g.*, as measured using immunoblotting techniques with anti-phosphorylation antibodies, are represented by a reduction in protein phosphorylation levels of at least about 30%-40%, and most preferably, by decreases of at least about 50%, with higher values of course being possible. Threonine/serine kinase assays that measure threonine/serine phosphorylation
15 are well known in the art and may be conducted *in vitro* or *in vivo*. Likewise increases in threonine/serine phosphorylation are represented by an increase in protein phosphorylation levels of at least about 30%-40%, and most preferably, by increases of at least about 50%, with higher values of course being possible.

20 Assays for apoptosis will measure certain cellular events, including nuclear condensation, DNA fragmentation, cytoplasmic membrane blebbing and, ultimately, irreversible cell death. The methodology for such measurements is well known to those of skill in the art. A significant alteration in apoptosis is represented by an increase or decrease of at least about 30%-40% as compared to normal, and most preferably, of at least about 50%, with more significant increases or decreases also being possible.
25 Therefore, if a candidate substance exhibited inhibition or induction of apoptosis in this type of study, it would likely be a suitable compound for use in the present invention.

Quantitative *in vitro* testing is not a requirement of the invention as it is generally envisioned that the candidate substance will often be selected on the basis of their known

properties or by structural and/or functional comparison to those agents already known to have an effect on threonine/serine kinases.

It will, of course, be understood that all the screening methods of the present invention are useful in themselves notwithstanding the fact that effective candidates may not be found. The invention provides methods for screening for such candidates, not
5 solely methods of finding them.

As used herein the term "candidate substance" refers to any molecule that may potentially modify apoptosis, including the activity of U_s3 or BAD. The candidate substance may inhibit or induce apoptosis activity or alter sensitivity to apoptosis
10 inducers or inhibitors. The candidate substance may be a protein or fragment thereof, a small molecule, or even a nucleic acid molecule. An example of pharmacological compounds will be compounds that are structurally related to BAD, or a substrate of a U_s3. Using lead compounds to help develop improved compounds is known as "rational drug design" and includes not only comparisons with known inhibitors and activators,
15 but predictions relating to the structure of target molecules. An "inhibitor" is a molecule which represses or prevents another molecule from engaging in a reaction. An "activator" is a molecule that increases the activity of an polypeptide or a protein that increases the production of a gene product in DNA transcription.

The goal of rational drug design is to produce structural analogs of biologically
20 active polypeptides or target compounds. By creating such analogs, it is possible to fashion drugs, which are more active or stable than the natural molecules, which have different susceptibility to alteration or which may affect the function of various other molecules. In one approach, one would generate a three-dimensional structure for a target molecule, or a fragment thereof. This could be accomplished by x-ray
25 crystallography, computer modeling or by a combination of both approaches.

It also is possible to use antibodies to ascertain the structure of a target compound activator or inhibitor. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies to a functional, pharmacologically

active antibody. As a mirror image of a mirror image, the binding site of anti-idiotypic would be expected to be an analog of the original antigen. The anti-idiotypic could then be used to identify and isolate peptides from banks of chemically- or biologically-produced peptides. Selected peptides would then serve as the pharmacore. Anti-
5 idiotypes may be generated using the methods described herein for producing antibodies, using an antibody as the antigen.

On the other hand, one may simply acquire, from various commercial sources, small molecule libraries that are believed to meet the basic criteria for useful drugs in an effort to "brute force" the identification of useful compounds. Screening of such
10 libraries, including combinatorially generated libraries (e.g., peptide libraries), is a rapid and efficient way to screen large number of related (and unrelated) compounds for activity. Combinatorial approaches also lend themselves to rapid evolution of potential drugs by the creation of second, third and fourth generation compounds modeled of active, but otherwise undesirable compounds.

15 Candidate compounds may include fragments or parts of naturally-occurring compounds, or may be found as active combinations of known compounds, which are otherwise inactive. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds. Thus, it is understood that the candidate substance identified by the present
20 invention may be peptide, polypeptide, polynucleotide, small molecule inhibitors or any other compounds that may be designed through rational drug design starting from known inhibitors or stimulators.

Other suitable modulators include antisense molecules, ribozymes, and antibodies (including single chain antibodies), each of which would be specific for the target
25 molecule. Such compounds are well known to those of skill in the art. For example, an antisense molecule that bound to a translational or transcriptional start site, or splice junctions, would be ideal candidate inhibitors.

In addition to the modulating compounds initially identified, the inventors also contemplate that other sterically similar compounds may be formulated to mimic the key

portions of the structure of the modulators. Such compounds, which may include peptidomimetics of peptide modulators, may be used in the same manner as the initial modulators.

An inhibitor according to the present invention may be one which exerts its inhibitory or activating effect upstream, downstream or directly on compounds in an apoptosis pathway. Regardless of the type of inhibitor or activator identified by the present screening methods, the effect of the inhibition or activator by such a compound results in alteration in the disposition of a cell to undergo apoptosis as compared to that cell in the absence of the added candidate substance.

10 A. *In vitro* Assays

A quick, inexpensive and easy assay to run is an *in vitro* assay. Such assays generally use isolated molecules, can be run quickly and in large numbers, thereby increasing the amount of information obtainable in a short period of time. A variety of vessels may be used to run the assays, including test tubes, plates, dishes and other surfaces such as dipsticks or beads.

One example of a cell free assay is a binding assay. While not directly addressing function, the ability of a modulator to bind to a target molecule such as U₃ or BAD polypeptide in a specific fashion is strong evidence of a related biological effect. For example, binding of a molecule to a target may, in and of itself, be inhibitory, due to steric, allosteric or charge-charge interactions. The target may be either free in solution, fixed to a support, expressed in or on the surface of a cell. Either the target or the compound may be labeled, thereby permitting determining of binding. Usually, the target will be the labeled species, decreasing the chance that the labeling will interfere with or enhance binding. Competitive binding formats can be performed in which one of the agents is labeled, and one may measure the amount of free label versus bound label to determine the effect on binding.

A technique for high throughput screening of compounds is described in WO 84/03564. Large numbers of small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. Bound polypeptide can be detected

by various methods.

B. *In cyto* Assays

The present invention also contemplates the screening of compounds for their ability to modulate apoptosis in cells. Various cell lines can be utilized for such screening assays, including cells specifically engineered for this purpose.

Depending on the assay, culture may be required. The cell is examined using any of a number of different physiologic assays. Alternatively, molecular analysis may be performed, for example, looking at protein expression, mRNA expression (including differential display of whole cell or polyA RNA) and others.

C. *In vivo* Assays

In vivo assays involve the use of various animal models, including transgenic animals that have been engineered to have specific defects, or carry markers that can be used to measure the ability of a candidate substance to reach and effect different cells within the organism. Due to their size, ease of handling, and information on their physiology and genetic make-up, mice are a preferred embodiment, especially for transgenics. However, other animals are suitable as well, including rats, rabbits, hamsters, guinea pigs, gerbils, woodchucks, cats, dogs, sheep, goats, pigs, cows, horses and monkeys (including chimps, gibbons and baboons). Assays for modulators may be conducted using an animal model derived from any of these species.

In such assays, one or more candidate substances are administered to an animal, and the ability of the candidate substance(s) to alter one or more characteristics, as compared to a similar animal not treated with the candidate substance(s), identifies a modulator. The characteristics may be any of those discussed above with regard to the function of a particular compound (e.g., enzyme, receptor, hormone) or cell (e.g., apoptosis, survival), or instead a broader indication such as behavior, anemia, immune response, recovery from viral infection, etc.

The present invention provides methods of screening for a candidate substance that is an apoptosis modulator. In these embodiments, the present invention is directed to a method for determining the ability of a candidate substance to induce or inhibit

apoptosis in a cell, generally including the steps of: administering a candidate substance to the animal; and determining the ability of the candidate substance to modulate apoptosis.

5 Treatment of these animals with test compounds will involve the administration of the compound, in an appropriate form, to the animal. Administration will be by any route that could be utilized for clinical or non-clinical purposes, including but not limited to oral, nasal, buccal, or even topical. Alternatively, administration may be by intratracheal instillation, bronchial instillation, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Specifically contemplated routes are systemic
10 intravenous injection, regional administration via blood or lymph supply, or directly to an affected site.

Determining the effectiveness of a compound *in vivo* may involve a variety of different criteria. Also, measuring toxicity and dose response can be performed in animals in a more meaningful fashion than in *in vitro* or *in cyto* assays.

15 **D. Methods for the Inhibition of Apoptosis**

In one embodiment of the present invention, there are provided methods for the inhibition of apoptosis in a cell. This is particularly useful where one seeks to immortalize a cell or, at a minimum, increase the longevity of a cell. This permits one to maintain that cell in culture for extended periods of time, perhaps indefinitely.
20 Immortalized cells are useful primarily as factories for production of viral vectors or proteins of interest, but it also may be important to immortalize cell simply so that they may be studied *in vitro* with greater ease. In addition, though many viruses provide promise as gene therapeutic vectors, these vectors may trigger apoptosis in the cells they infect. Blocking virally-induced apoptosis will prevent cell death caused by these
25 therapeutic vectors. As mentioned above, adenovirus, papilloma viruses, retrovirus, adeno-associated virus and HSV, for example, are candidate gene therapeutic vectors that could benefit from this application.

The general approach to inhibiting apoptosis, according to the present invention, will be to provide a cell with an U_s3 polypeptide, an ICP4 polypeptide or both, thereby permitting the inhibitory activity of U_s3, ICP4 or both to take effect. While it is conceivable that the protein may be delivered directly, a preferred embodiment involves
5 providing a nucleic acid encoding the polypeptide, *i.e.*, an U_s3 gene, an α 4 gene or both, to the cell. Following this provision, the polypeptide is synthesized by the host cell's transcriptional and translational machinery, as well as any that may be provided by the expression construct. Cis-acting regulatory elements necessary to support the expression of the U_s3 or α 4 gene will be provided, as described above, in the form of an expression
10 construct. It also is possible that, in the case of an HSV-infected cell, expression of the virally-encoded U_s3 or ICP4 could be stimulated or enhanced, or the expressed polypeptide stabilized, thereby achieving the same or similar effect.

In order to effect expression of constructs encoding U_s3 and/or ICP genes, the expression construct must be delivered into a cell. As described above in the discussion
15 of viral vectors, one mechanism for delivery is via viral infection, where the expression construct is encapsidated in a viral particle which will deliver either a replicating or non-replicating nucleic acid. The preferred embodiment is an HSV vector, although virtually any vector would suffice. Similarly, where viral vectors are used to delivery other therapeutic genes, inclusion in these vectors of an U_s3 and/or α 4 gene advantageously
20 will protect the cell from virally induced apoptosis.

Several non-viral methods for the transfer of expression constructs into cultured mammalian cells also are contemplated by the present invention. These include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa *et al.*, 1986;
25 Potter *et al.*, 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley *et al.*, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer *et al.*, 1987), gene bombardment using high velocity microprojectiles (Yang *et al.*, 1990), and receptor-mediated transfection (Wu

and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use, as discussed below.

In another embodiment of the invention, the expression construct may simply consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer *in vitro*, but it may be applied to *in vivo* use as well. Another embodiment of the invention for transferring a naked DNA expression construct into cells may involve particle bombardment. This method depends on the ability to accelerate DNA coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

In a further embodiment of the invention, the expression construct may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated are lipofectamine-DNA complexes.

Liposome-mediated nucleic acid delivery and expression of foreign DNA *in vitro* has been very successful. Wong *et al.* (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells. In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda

et al., 1989). In other embodiments, the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, the liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In other embodiments, the delivery vehicle may comprise a
5 ligand and a liposome. Where a bacterial promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacterial polymerase.

Other expression constructs which can be employed to deliver a nucleic acid encoding an U₃ and/or α 4 transgene into cells are receptor-mediated delivery vehicles. These take advantage of the selective uptake of macromolecules by receptor-mediated
10 endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993).

Receptor-mediated gene targeting vehicles generally consist of two components: a cell receptor-specific ligand and a DNA-binding agent. Several ligands have been used for receptor-mediated gene transfer. The most extensively characterized ligands are
15 asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner *et al.*, 1990). Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol *et al.*, 1993; Perales *et al.*, 1994). Mannose can be used to target the mannose receptor on liver cells. Also, antibodies to CD5 (CLL), CD22 (lymphoma), CD25 (T-cell leukemia) and MAA (melanoma) can similarly be used
20 as targeting moieties. In other embodiments, the delivery vehicle may comprise a ligand and a liposome.

Primary mammalian cell cultures may be prepared in various ways. In order for the cells to be kept viable while *in vitro* and in contact with the expression construct, it is necessary to ensure that the cells maintain contact with the correct ratio of oxygen and
25 carbon dioxide and nutrients but are protected from microbial contamination. Cell culture techniques are well documented and are disclosed herein by reference (Freshner, 1992).

One embodiment of the foregoing involves the use of gene transfer to immortalize cells for the production of proteins. The gene for the protein of interest may be

transferred as described above into appropriate host cells followed by culture of cells under the appropriate conditions. The gene for virtually any polypeptide may be employed in this manner. The generation of recombinant expression vectors, and the elements included therein, are discussed above. Alternatively, the protein to be produced
5 may be an endogenous protein normally synthesized by the cell in question.

Examples of useful mammalian host cell lines are Vero and HeLa cells and cell lines of Chinese hamster ovary, W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCK cells. In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and process the gene product in the manner desired. Such
10 modifications (*e.g.*, glycosylation) and processing (*e.g.*, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to insure the correct modification and processing of the foreign protein expressed.

15 A number of selection systems may be used including, but not limited to, HSV thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase genes, in *tk-*, *hgpri-* or *aprt-* cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for *dhfr*, that confers resistance to; *gpt*, that confers resistance to mycophenolic acid; *neo*, that confers resistance to the
20 aminoglycoside G418; and *hygro*, that confers resistance to hygromycin.

Animal cells can be propagated *in vitro* in two modes: as non-anchorage dependent cells growing in suspension throughout the bulk of the culture or as anchorage-dependent cells requiring attachment to a solid substrate for their propagation (*i.e.*, a monolayer type of cell growth).

25 Non-anchorage dependent or suspension cultures from continuous established cell lines are the most widely used means of large scale production of cells and cell products. However, suspension cultured cells have limitations, such as tumorigenic potential and lower protein production than adherent cells.

Large scale suspension culture of mammalian cells in stirred tanks is a common method for production of recombinant proteins. Two suspension culture reactor designs are in wide use - the stirred reactor and the airlift reactor. The stirred design has successfully been used on an 8000 liter capacity for the production of interferon (Phillips *et al.*, 1985; Mizrahi, 1983). Cells are grown in a stainless steel tank with a height-to-diameter ratio of 1:1 to 3:1. The culture is usually mixed with one or more agitators, based on bladed disks or marine propeller patterns. Agitator systems offering less shear forces than blades have been described. Agitation may be driven either directly or indirectly by magnetically coupled drives. Indirect drives reduce the risk of microbial contamination through seals on stirrer shafts.

The airlift reactor, also initially described for microbial fermentation and later adapted for mammalian culture, relies on a gas stream to both mix and oxygenate the culture. The gas stream enters a riser section of the reactor and drives circulation. Gas disengages at the culture surface, causing denser liquid free of gas bubbles to travel downward in the downcomer section of the reactor. The main advantage of this design is the simplicity and lack of need for mechanical mixing. Typically, the height-to-diameter ratio is 10:1. The airlift reactor scales up relatively easily, has good mass transfer of gases and generates relatively low shear forces.

E. Methods for the Induction of Apoptosis

In another embodiment of the present invention, there is contemplated the method of inducing apoptosis in HSV-infected cells, *i.e.*, blocking the apoptotic function of U_s3, ICP4 or both. In this way, it may be possible to curtail viral infection by bringing about a premature death of the infected cell. In addition, it may prove effective to use this sort of therapeutic intervention in combination with more traditional chemotherapies, such as the administration acyclovir.

The general form that this aspect of the invention will take is the provision, to a cell, of an agent that will inhibit U_s3 function, ICP4 function or indeed inhibit the function of both. A number of such agents are contemplated as outlined below.

First, one may employ an antisense nucleic acid that will hybridize either to the U_s3 gene or the U_s3 transcript, thereby preventing transcription or translation, respectively. Likewise, one may employ an antisense nucleic acid that will hybridize to an α 4 gene or an α 4 transcript. The considerations relevant to the design of antisense constructs have been presented above.

Second, one may utilize an U_s3-binding protein or peptide, for example, a peptidomimetic or an antibody that binds immunologically to an U_s3, the binding of either will block or reduce the activity of an U_s3. Again the same is true of ICP4 in that one may utilize an ICP4-binding protein or peptide, for example, a peptidomimetic or an antibody that binds immunologically to an ICP4, the binding of either resulting in a block or reduction of ICP4 activity. The methods of making and selecting peptide binding partners and antibodies are well known to those of skill in the art.

Third, one may provide to the cell an antagonist of U_s3 for example, the in the case of U_s3 phosphorylation target sequence, alone or coupled to another agent. Equally one may provide to the cell an antagonist of ICP4, for example, the transactivation target sequence, alone or coupled to another agent. And fourth, one may provide an agent that binds to the U_s3 or ICP4 target without the same functional result as would arise with U_s3 or ICP4 binding.

Moreover, one may provide all or part of a BAD polypeptide to a cell, which could induce apoptosis. Alternatively, in a cell infected with a herpesvirus or having a U_s3 polypeptide, an inhibitor of U_s3 may be provided to prevent its effect on BAD. Such an inhibitor may prevent U_s3 from post-translationally modifying BAD or may prevent the reduction of BAD protein levels in cells containing U_s3.

Provision of an U_s3 gene or encoding nucleic acid, an U_s3-binding protein, a U_s3 polypeptide or peptide, an U_s3 antagonist, an U_s3 modulator, or an α 4 gene, BAD peptide or polypeptide, BAD-encoding nucleic acid, a BAD modulator, an ICP4-binding protein, or an ICP4 antagonist, would be according to any appropriate pharmaceutical route. The formulation of such compositions and their delivery to tissues is discussed below. The method by which the nucleic acid, protein or chemical is transferred, along with the

preferred delivery route, will be selected based on the particular site to be treated. Those of skill in the art are capable of determining the most appropriate methods based on the relevant clinical considerations.

Many of the gene transfer techniques that generally are applied *in vitro* can be adapted for *ex vivo* or *in vivo* use. For example, selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). Naked DNA also has been used in clinical settings to effect gene therapy. These approaches may require surgical exposure of the tumor tissue or direct intratumoral injection. Nicolau *et al.* (1987) accomplished successful liposome-mediated gene transfer in rats after intravenous injection.

Dubensky *et al.* (1984) successfully injected polyomavirus DNA in the form of CaPO₄ precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of CaPO₄ precipitated plasmids results in expression of the transfected genes. Thus, it is envisioned that DNA encoding an antisense construct also may be transferred in a similar manner *in vivo*.

Where the embodiment involves the use of an antibody that recognizes an U_s3 or an ICP4 polypeptide, consideration must be given to the mechanism by which the antibody is introduced into the cell cytoplasm. This can be accomplished, for example, by providing an expression construct that encodes a single-chain antibody version of the antibody to be provided. Most of the discussion above relating to expression constructs for antisense versions of the respective genes will be relevant to this aspect of the invention. Alternatively, it is possible to present a bifunctional antibody, where one antigen binding arm of the antibody recognizes an U_s3 or ICP4 polypeptide and the other antigen binding arm recognizes a receptor on the surface of the cell to be targeted. Examples of suitable receptors would be an HSV glycoprotein such as gB, gC, gD, or gH. In addition, it may be possible to exploit the Fc-binding function associated with HSV gE, thereby obviating the need to sacrifice one arm of the antibody for purposes of cell targeting.

Advantageously, one may combine this approach with more conventional chemotherapeutic options. Acyclovir is an active agent against HSV-1 and HSV-2. The drug inhibits actively replicating herpes virus but is not active against latent virus. Acyclovir is available in three formulations. For topical use, a five percent ointment
5 produces therapeutic drug levels in mucocutaneous lesions. For systemic use, acyclovir may be administered orally or intravenously. The usual intravenous dosage in adults with normal renal function is 5 mg/kg infused at a constant rate over one hour and given every eight hours; this dosage produces peak plasma levels at about 10 g/ml. For HSV encephalitis, twice this dose is used. The usual adult oral dosage is 200 mg, five times
10 daily, which produces plasma levels that are less than 10% as high as those achieved with intravenous administration; even these levels are inhibitory to the virus, however. Acyclovir is given in an oral dosage of 800 mg five times daily for the treatment of herpes zoster, although oral administration generally is reserved for patients with severe symptoms. A three percent ophthalmic preparation produces inhibitory drug levels in the
15 aqueous humor and is effective for herpes keratitis.

In contemplating combinatorial aspects of the present invention, it will be possible to combine the U_s3 therapeutic compositions of the present invention with other apoptosis inducing or inhibiting compositions. For example the present inventors have shown that it is possible to affect apoptosis using compositions derived from ICP4
20 protein or polypeptide and the α 4 gene or gene constructs. Thus in light of the teachings presented herein, it will be possible for one of ordinary skill in the art to combine the U_s3 therapeutic compositions with those derived from ICP4 and α 4 to affect apoptosis as described herein below. Alternatively, a combination may be employed using a BAD peptide or polypeptide, or some other apoptosis modulator. In further embodiments, anti-
25 viral compounds may be employed such as famcyclovir, valacyclovir, or acyclovir.

To kill cells, inhibit cell growth, inhibit apoptosis, or induce apoptosis as defined above, using the methods and compositions of the present invention, one would generally contact a "target" cell with a U_s3 and/or an ICP4 expression construct alone or in combination with at least one other agent. These compositions would be provided in a

combined amount effective to inhibit or to kill or induce apoptosis of the cell. This process may involve contacting the cells with the expression construct and the agent(s) or factor(s) at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting
 5 the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the expression construct and the other includes the agent.

Alternatively, the gene therapy treatment may precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agent and expression construct are applied separately to the cell, one would generally
 10 ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one would contact the cell with both modalities within about 12-24 hours of each other and, more preferably, within about 6-12 hours of each other, with a delay time of only about
 15 12 hours being most preferred. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

It also is conceivable that more than one administration of either U₃ or the other agent will be desired. Various combinations may be employed, where U₃ is "A" and the
 20 other agent is "B", as exemplified below:

A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B B/B/B/A B/B/A/B
 A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B B/B/B/A
 A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B B/B/A/B

Other combinations are contemplated where ICP4 and α 4 may also be used, or a
 25 BAD peptide or polypeptide, or other apoptosis modulator. Again, to achieve apoptosis, both agents are delivered to a cell in a combined amount effective induce cell death. To inhibit apoptosis, multiple agents are delivered to a cell in a combined amount effective

to inhibit apoptosis for more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more days.

The skilled artisan is directed to "Remington's Pharmaceutical Sciences" 15th Edition, chapter 33, in particular pages 624-652. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

The inventors propose that the regional delivery of U_s3 expression constructs and/or ICP4 expression constructs to patients with HSV linked disease will be a very efficient method for delivering a therapeutically effective gene to counteract the clinical disease. Similarly, the chemotherapy may be directed to a particular, affected region of the subjects body. Alternatively, systemic delivery of expression construct and/or the agent may be appropriate in certain circumstances, for example, where extensive metastasis has occurred.

In addition to combining U_s3-targeted therapies with chemotherapies, it also is contemplated that combination with other gene therapies will be advantageous. For example, targeting of U_s3 and α 4 mutations at the same time may produce an improved apoptotic treatment.

It also should be pointed out that any of the foregoing therapies may prove useful by themselves in treating a U_s3 related disease. In this regard, reference to chemotherapeutics and non-U_s3 gene therapy in combination should also be read as a contemplation that these approaches may be employed separately.

F. Methods for the Inhibition of Virus-Induced Cell Death *In Vivo*

In another embodiment of the present invention, there are provided methods for the inhibition of cell death induced *in vivo* by any cause comprising the provision of U_s3 polypeptides or U_s3 genes, or ICP4 polypeptides and α 4 genes or combinations of the

two. Alternatively, other embodiments are contemplated in which inhibition of apoptosis that might otherwise be induced through BAD. Also contemplated in this aspect of the invention is the stimulation of viral U_S3 expression, and/or stimulation of viral ICP4 expression or stabilization of the virally-expressed U_S3 polypeptide and/or ICP4 polypeptide. Though inhibition of apoptosis generally is thought of as advantageous to the virus, it may be desirable to effect this result as part of a method of treating a viral infection. For example, if the host cell remains viable, the virus may continue to replicate; alternatively, if apoptosis were occurring, the virus might be inclined to “go latent” in the neural ganglia, where chemotherapeutic intervention is not helpful. Thus, by preventing early death of the cell, U_S3 and/or ICP4 may cause the virus to remain susceptible to treatment where it otherwise would escape.

The mechanisms for delivering proteins and nucleic acids to a cell are discussed elsewhere in this document and need not be repeated here. The use of standard chemotherapeutics or antiviral treatments has been presented in the preceding section, and is incorporated in this section.

V. PHARMACEUTICALS AND *IN VIVO* METHODS FOR THE TREATMENT OF DISEASE

Aqueous pharmaceutical compositions of the present invention will have an effective amount of an U_S3, BAD, and/or α 4 expression construct, an antisense U_S3 and/or α 4 expression construct, an expression construct that encodes a therapeutic gene along with U_S3 and/or α 4, a protein that inhibits U_S3 and/or α 4 function, such as an anti-U_S3 antibody or an anti-ICP4 antibody, respectively, or an U_S3 polypeptide and/or an ICP4 polypeptide. Alternatively, an effective amount of a BAD peptide or polypeptide, a BAD-encoding nucleic acid, a BAD antisense or ribozyme molecule, or an apoptosis modulator—inhibitors or inducers—may also be formulated in a pharmaceutical composition. Such compositions generally will be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. An “effective amount,” for the purposes of therapy, is defined at that amount that causes a clinically measurable

difference in the condition of the subject. This amount will vary depending on the substance, the condition of the patient, the type of treatment, the location of the lesion, *etc.*

The phrases "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or human, as appropriate. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in the therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-cancer agents, can also be incorporated into the compositions.

In addition to the compounds formulated for parenteral administration, such as those for intravenous or intramuscular injection, other pharmaceutically acceptable forms include, *e.g.*, tablets or other solids for oral administration; time release capsules; and any other form currently used, including cremes, lotions, mouthwashes, inhalants and the like.

The active compounds of the present invention will often be formulated for parenteral administration, *e.g.*, formulated for injection *via* the intravenous, intramuscular, subcutaneous, or even intraperitoneal routes. The preparation of an aqueous composition that contains glycosylceramide synthesis inhibitory compounds alone or in combination with a chemotherapeutic agent as active ingredients will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.

Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid

polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous
5 solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In many cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of
10 microorganisms, such as bacteria and fungi.

The active compounds may be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic,
15 tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

The carrier also can be a solvent or dispersion medium containing, for example,
20 water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by
25 various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

10 In certain cases, the therapeutic formulations of the invention could also be prepared in forms suitable for topical administration, such as in cremes and lotions. These forms may be used for treating skin-associated diseases, such as various sarcomas. In certain other cases, the formulation will be geared for administration to the central nervous system, *e.g.*, the brain.

15 Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, with even drug release capsules and the like being employable.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being

treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

A. Lipid Compositions

In certain embodiments, the present invention concerns a novel composition comprising one or more lipids associated with a polynucleotide or polypeptide of the claimed invention. A lipid is a substance that is characteristically insoluble in water and extractable with an organic solvent. Compounds than those specifically described herein are understood by one of skill in the art as lipids, and are encompassed by the compositions and methods of the present invention.

A lipid may be naturally occurring or synthetic (*i.e.*, designed or produced by man). However, a lipid is usually a biological substance. Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glucolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.

1. Lipid Types

A neutral fat may comprise a glycerol and a fatty acid. A typical glycerol is a three carbon alcohol. A fatty acid generally is a molecule comprising a carbon chain with an acidic moiety (*e.g.*, carboxylic acid) at an end of the chain. The carbon chain may of a fatty acid may be of any length, however, it is preferred that the length of the carbon chain be of from about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, to about 30 or more carbon atoms, and any range derivable therein.

However, a preferred range is from about 14 to about 24 carbon atoms in the chain portion of the fatty acid, with about 16 to about 18 carbon atoms being particularly preferred in certain embodiments. In certain embodiments the fatty acid carbon chain may comprise an odd number of carbon atoms, however, an even number of carbon

atoms in the chain may be preferred in certain embodiments. A fatty acid comprising only single bonds in its carbon chain is called saturated, while a fatty acid comprising at least one double bond in its chain is called unsaturated.

Specific fatty acids include, but are not limited to, linoleic acid, oleic acid, 5 palmitic acid, linolenic acid, stearic acid, lauric acid, myristic acid, arachidic acid, palmitoleic acid, arachidonic acid, ricinoleic acid, tuberculosteric acid, lactobacillic acid. An acidic group of one or more fatty acids is covalently bonded to one or more hydroxyl groups of a glycerol. Thus, a monoglyceride comprises a glycerol and one fatty acid, a diglyceride comprises a glycerol and two fatty acids, and a triglyceride comprises a 10 glycerol and three fatty acids.

A phospholipid generally comprises either glycerol or an sphingosine moiety, an ionic phosphate group to produce an amphipathic compound, and one or more fatty acids. Types of phospholipids include, for example, phosphoglycerides, wherein a phosphate group is linked to the first carbon of glycerol of a diglyceride, and sphingophospholipids 15 (e.g., sphingomyelin), wherein a phosphate group is esterified to a sphingosine amino alcohol. Another example of a sphingophospholipid is a sulfatide, which comprises an ionic sulfate group that makes the molecule amphipathic. A phospholipid may, of course, comprise further chemical groups, such as for example, an alcohol attached to the phosphate group. Examples of such alcohol groups include serine, ethanolamine, 20 choline, glycerol and inositol. Thus, specific phosphoglycerides include a phosphatidyl serine, a phosphatidyl ethanolamine, a phosphatidyl choline, a phosphatidyl glycerol or a phosphatidyl inositol. Other phospholipids include a phosphatidic acid or a diacetyl phosphate. In one aspect, a phosphatidylcholine comprises a dioleoylphosphatidylcholine (a.k.a. cardiolipin), an egg phosphatidylcholine, a dipalmitoyl phosphatidylcholine, a 25 monomyristoyl phosphatidylcholine, a monopalmitoyl phosphatidylcholine, a monostearoyl phosphatidylcholine, a monooleoyl phosphatidylcholine, a dibutoyl phosphatidylcholine, a divaleroyl phosphatidylcholine, a dicaproyl phosphatidylcholine, a diheptanoyl phosphatidylcholine, a dicapryloyl phosphatidylcholine or a distearoyl phosphatidylcholine.

A glycolipid is related to a sphingophospholipid, but comprises a carbohydrate group rather than a phosphate group attached to a primary hydroxyl group of the sphingosine. A type of glycolipid called a cerebroside comprises one sugar group (*e.g.*, a glucose or galactose) attached to the primary hydroxyl group. Another example of a glycolipid is a ganglioside (*e.g.*, a monosialoganglioside, a GM1), which comprises about 2, about 3, about 4, about 5, about 6, to about 7 or so sugar groups, that may be in a branched chain, attached to the primary hydroxyl group. In other embodiments, the glycolipid is a ceramide (*e.g.*, lactosylceramide).

A steroid is a four-membered ring system derivative of a phenanthrene. Steroids often possess regulatory functions in cells, tissues and organisms, and include, for example, hormones and related compounds in the progestagen (*e.g.*, progesterone), glucocorticoid (*e.g.*, cortisol), mineralocorticoid (*e.g.*, aldosterone), androgen (*e.g.*, testosterone) and estrogen (*e.g.*, estrone) families. Cholesterol is another example of a steroid, and generally serves structural rather than regulatory functions. Vitamin D is another example of a sterol, and is involved in calcium absorption from the intestine.

A terpene is a lipid comprising one or more five carbon isoprene groups. Terpenes have various biological functions, and include, for example, vitamin A, coenzyme Q and carotenoids (*e.g.*, lycopene and β -carotene).

2. Charged and Neutral Lipid Compositions

In certain embodiments, a lipid component of a composition is uncharged or primarily uncharged. In one embodiment, a lipid component of a composition comprises one or more neutral lipids. In another aspect, a lipid component of a composition may be substantially free of anionic and cationic lipids, such as certain phospholipids and cholesterol. In certain aspects, a lipid component of an uncharged or primarily uncharged lipid composition comprises about 95%, about 96%, about 97%, about 98%, about 99% or 100% lipids without a charge, substantially uncharged lipid(s), and/or a lipid mixture with equal numbers of positive and negative charges.

In other aspects, a lipid composition may be charged. For example, charged phospholipids may be used for preparing a lipid composition according to the present invention and can carry a net positive charge or a net negative charge. In a non-limiting example, diacetyl phosphate can be employed to confer a negative charge on the lipid composition, and stearylamine can be used to confer a positive charge on the lipid composition.

3. Making Lipids

Lipids can be obtained from natural sources, commercial sources or chemically synthesized, as would be known to one of ordinary skill in the art. For example, phospholipids can be from natural sources, such as egg or soybean phosphatidylcholine, brain phosphatidic acid, brain or plant phosphatidylinositol, heart cardiolipin and plant or bacterial phosphatidylethanolamine. In another example, lipids suitable for use according to the present invention can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be obtained from Sigma Chemical Co., dicetyl phosphate ("DCP") is obtained from K & K Laboratories (Plainview, NY); cholesterol ("Chol") is obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol ("DMPG") and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). In certain embodiments, stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20°C. Preferably, chloroform is used as the only solvent since it is more readily evaporated than methanol.

4. Lipid Composition Structures

A compound associated with a lipid may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid or otherwise associated with a lipid. A lipid or lipid-associated composition of the present invention is not limited to any particular structure. For example, they may also simply be interspersed in a solution, possibly forming aggregates which are not uniform in either size or shape. In another example, they may be present in a bilayer structure, as micelles, or with a

"collapsed" structure. In another non-limiting example, a lipofectamine(Gibco BRL) or Superfect (Qiagen) complex is also contemplated.

In certain embodiments, a lipid composition may comprise about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%,
5 about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about
10 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%,
15 about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any range derivable therein, of a particular lipid, lipid type or non-lipid component such as a drug, protein, sugar, nucleic acids or other material disclosed herein or as would be known to one of skill in the art. In a non-limiting example, a lipid
20 composition may comprise about 10% to about 20% neutral lipids, and about 33% to about 34% of a cerebroside, and about 1% cholesterol. In another non-limiting example, a liposome may comprise about 4% to about 12% terpenes, wherein about 1% of the micelle is specifically lycopene, leaving about 3% to about 11% of the liposome as comprising other terpenes; and about 10% to about 35% phosphatidyl choline, and about
25 1% of a drug. Thus, it is contemplated that lipid compositions of the present invention may comprise any of the lipids, lipid types or other components in any combination or percentage range.

a. Emulsions

A lipid may be comprised in an emulsion. A lipid emulsion is a substantially permanent heterogenous liquid mixture of two or more liquids that do not normally dissolve in each other, by mechanical agitation or by small amounts of additional substances known as emulsifiers. Methods for preparing lipid emulsions and adding additional components are well known in the art (e.g., Modern Pharmaceutics, 1990, incorporated herein by reference).

For example, one or more lipids are added to ethanol or chloroform or any other suitable organic solvent and agitated by hand or mechanical techniques. The solvent is then evaporated from the mixture leaving a dried glaze of lipid. The lipids are resuspended in aqueous media, such as phosphate buffered saline, resulting in an emulsion. To achieve a more homogeneous size distribution of the emulsified lipids, the mixture may be sonicated using conventional sonication techniques, further emulsified using microfluidization (using, for example, a Microfluidizer, Newton, Mass.), and/or extruded under high pressure (such as, for example, 600 psi) using an Extruder Device (Lipex Biomembranes, Vancouver, Canada).

b. Micelles

A lipid may be comprised in a micelle. A micelle is a cluster or aggregate of lipid compounds, generally in the form of a lipid monolayer, and may be prepared using any micelle producing protocol known to those of skill in the art (e.g., Canfield *et al.*, 1990; El-Gorab *et al.*, 1973; Colloidal Surfactant, 1963; and Catalysis in Micellar and Macromolecular Systems, 1975, each incorporated herein by reference). For example, one or more lipids are typically made into a suspension in an organic solvent, the solvent is evaporated, the lipid is resuspended in an aqueous medium, sonicated and then centrifuged.

5. Liposomes

In particular embodiments, a lipid comprises a liposome. A "liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by

the generation of enclosed lipid bilayers or aggregates. Liposomes may be characterized as having vesicular structures with a bilayer membrane, generally comprising a phospholipid, and an inner medium that generally comprises an aqueous composition.

A multilamellar liposome has multiple lipid layers separated by aqueous medium.

- 5 They form spontaneously when lipids comprising phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Lipophilic molecules or molecules with lipophilic regions may also dissolve in or associate with the lipid bilayer.

- 10 In specific aspects, a lipid and/or modified protein or polynucleotide encoding a modified protein may be, for example, encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the composition, entrapped in a liposome, complexed with a liposome, etc.

15 **a. Making Liposomes**

A liposome used according to the present invention can be made by different methods, as would be known to one of ordinary skill in the art.

- For example, a phospholipid (Avanti Polar Lipids, Alabaster, AL), such as for example the neutral phospholipid dioleoylphosphatidylcholine (DOPC), is dissolved in
20 tert-butanol. The lipid(s) is then mixed with the polynucleotide or polypeptide, and/or other component(s). Tween 20 is added to the lipid mixture such that Tween 20 is about 5% of the composition's weight. Excess tert-butanol is added to this mixture such that the volume of tert-butanol is at least 95%. The mixture is vortexed, frozen in a dry ice/acetone bath and lyophilized overnight. The lyophilized preparation is stored at -
25 20°C and can be used up to three months. When required the lyophilized liposomes are reconstituted in 0.9% saline. The average diameter of the particles obtained using Tween 20 for encapsulating the compound is about 0.7 to about 1.0 μm in diameter.

Alternatively, a liposome can be prepared by mixing lipids in a solvent in a container, e.g., a glass, pear-shaped flask. The container should have a volume ten-times greater than the volume of the expected suspension of liposomes. Using a rotary evaporator, the solvent is removed at approximately 40°C under negative pressure. The solvent normally is removed within about 5 min. to 2 hours, depending on the desired volume of the liposomes. The composition can be dried further in a desiccator under vacuum. The dried lipids generally are discarded after about 1 week because of a tendency to deteriorate with time.

Dried lipids can be hydrated at approximately 25-50 mM phospholipid in sterile, pyrogen-free water by shaking until all the lipid film is resuspended. The aqueous liposomes can be then separated into aliquots, each placed in a vial, lyophilized and sealed under vacuum.

In other alternative methods, liposomes can be prepared in accordance with other known laboratory procedures (e.g., see Bangham *et al.*, 1965; Gregoriadis, 1979; Deamer and Uster 1983, Szoka and Papahadjopoulos, 1978, each incorporated herein by reference in relevant part). These methods differ in their respective abilities to entrap aqueous material and their respective aqueous space-to-lipid ratios.

The dried lipids or lyophilized liposomes prepared as described above may be dehydrated and reconstituted in a solution of inhibitory peptide and diluted to an appropriate concentration with an suitable solvent, e.g., DPBS. The mixture is then vigorously shaken in a vortex mixer. Unencapsulated additional materials, such as agents including but not limited to hormones, drugs, nucleic acid constructs and the like, are removed by centrifugation at $29,000 \times g$ and the liposomal pellets washed. The washed liposomes are resuspended at an appropriate total phospholipid concentration, e.g., about 50-200 mM. The amount of additional material or active agent encapsulated can be determined in accordance with standard methods. After determination of the amount of additional material or active agent encapsulated in the liposome preparation, the liposomes may be diluted to appropriate concentrations and stored at 4°C until use. A

pharmaceutical composition comprising the liposomes will usually include a sterile, pharmaceutically acceptable carrier or diluent, such as water or saline solution.

The size of a liposome varies depending on the method of synthesis. Liposomes in the present invention can be a variety of sizes. In certain embodiments, the liposomes are small, e.g., less than about 100 nm, about 90 nm, about 80 nm, about 70 nm, about 60 nm, or less than about 50 nm in external diameter. In preparing such liposomes, any protocol described herein, or as would be known to one of ordinary skill in the art may be used. Additional non-limiting examples of preparing liposomes are described in U.S. Patents 4,728,578, 4,728,575, 4,737,323, 4,533,254, 4,162,282, 4,310,505, and 4,921,706; International Applications PCT/US85/01161 and PCT/US89/05040; U.K. Patent Application GB 2193095 A; Mayer *et al.*, 1986; Hope *et al.*, 1985; Mayhew *et al.*, 1987; Mayhew *et al.*, 1984; Cheng *et al.*, 1987; and Liposome Technology, 1984, each incorporated herein by reference).

A liposome suspended in an aqueous solution is generally in the shape of a spherical vesicle, having one or more concentric layers of lipid bilayer molecules. Each layer consists of a parallel array of molecules represented by the formula XY, wherein X is a hydrophilic moiety and Y is a hydrophobic moiety. In aqueous suspension, the concentric layers are arranged such that the hydrophilic moieties tend to remain in contact with an aqueous phase and the hydrophobic regions tend to self-associate. For example, when aqueous phases are present both within and without the liposome, the lipid molecules may form a bilayer, known as a lamella, of the arrangement XY-YX. Aggregates of lipids may form when the hydrophilic and hydrophobic parts of more than one lipid molecule become associated with each other. The size and shape of these aggregates will depend upon many different variables, such as the nature of the solvent and the presence of other compounds in the solution.

The production of lipid formulations often is accomplished by sonication or serial extrusion of liposomal mixtures after (I) reverse phase evaporation (II) dehydration-rehydration (III) detergent dialysis and (IV) thin film hydration. In one aspect, a contemplated method for preparing liposomes in certain embodiments is heating

sonicating, and sequential extrusion of the lipids through filters or membranes of decreasing pore size, thereby resulting in the formation of small, stable liposome structures. This preparation produces liposomal/therapeutic compound or liposomes only of appropriate and uniform size, which are structurally stable and produce maximal activity. Such techniques are well-known to those of skill in the art (see, for example Martin, 1990).

Once manufactured, lipid structures can be used to encapsulate compounds that are toxic (e.g., chemotherapeutics) or labile (e.g., nucleic acids) when in circulation. Liposomal encapsulation has resulted in a lower toxicity and a longer serum half-life for such compounds (Gabizon *et al.*, 1990).

Numerous disease treatments are using lipid based gene transfer strategies to enhance conventional or establish novel therapies, in particular therapies for treating hyperproliferative diseases. Advances in liposome formulations have improved the efficiency of gene transfer in vivo (Templeton *et al.*, 1997) and it is contemplated that liposomes are prepared by these methods. Alternate methods of preparing lipid-based formulations for nucleic acid delivery are described (W0 99/18933).

In another liposome formulation, an amphipathic vehicle called a solvent dilution microcarrier (SDMC) enables integration of particular molecules into the bi-layer of the lipid vehicle (U.S. Patent 5,879,703). The SDMCs can be used to deliver lipopolysaccharides, polypeptides, nucleic acids and the like. Of course, any other methods of liposome preparation can be used by the skilled artisan to obtain a desired liposome formulation in the present invention.

b. Liposome Targeting

Association of the compositions of the invention with a liposome may improve its biodistribution and other properties. For example, liposome-mediated nucleic acid delivery and expression of foreign DNA *in vitro* has been very successful (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987). The feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo,

HeLa and hepatoma cells has also been demonstrated (Wong *et al.*, 1980). Successful liposome-mediated gene transfer in rats after intravenous injection has also been accomplished (Nicolau *et al.*, 1987).

It is contemplated that a liposome composition may comprise additional materials
5 for delivery to a tissue. For example, in certain embodiments of the invention, the lipid or liposome may be associated with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda *et al.*, 1989). In another example, the lipid or liposome may be complexed or employed in conjunction with nuclear non-histone
10 chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, the lipid may be complexed or employed in conjunction with both HVJ and HMG-1.

Targeted delivery is achieved by the addition of ligands without compromising the ability of these liposomes deliver large amounts of any disclosed compound of the invention. It is contemplated that this will enable delivery to specific cells, tissues and
15 organs. The targeting specificity of the ligand-based delivery systems are based on the distribution of the ligand receptors on different cell types. The targeting ligand may either be non-covalently or covalently associated with the lipid complex, and can be conjugated to the liposomes by a variety of methods.

Exemplary methods for cross-linking ligands (some discussed above) to
20 liposomes are described in U.S. Patent 5,603,872 and U.S. Patent 5,401,511, each specifically incorporated herein by reference in its entirety). Various ligands can be covalently bound to liposomal surfaces through the cross-linking of amine residues. Liposomes, in particular, multilamellar vesicles (MLV) or unilamellar vesicles such as microemulsified liposomes (MEL) and large unilamellar liposomes (LUVET), each
25 containing phosphatidylethanolamine (PE), have been prepared by established procedures. The inclusion of PE in the liposome provides an active functional residue, a primary amine, on the liposomal surface for cross-linking purposes. Ligands such as epidermal growth factor (EGF) have been successfully linked with PE-liposomes. Ligands are bound covalently to discrete sites on the liposome surfaces. The number and

surface density of these sites will be dictated by the liposome formulation and the liposome type. The liposomal surfaces may also have sites for non-covalent association. To form covalent conjugates of ligands and liposomes, cross-linking reagents have been studied for effectiveness and biocompatibility. Cross-linking reagents include
5 glutaraldehyde (GAD), bifunctional oxirane (OXR), ethylene glycol diglycidyl ether (EGDE), and a water soluble carbodiimide, preferably 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). Through the complex chemistry of cross-linking, linkage of the amine residues of the recognizing substance and liposomes is established.

10 i. Targeting Ligands

The targeting ligand can be either anchored in the hydrophobic portion of the complex or attached to reactive terminal groups of the hydrophilic portion of the complex. The targeting ligand can be attached to the liposome via a linkage to a reactive group, *e.g.*, on the distal end of the hydrophilic polymer. Preferred reactive groups
15 include amino groups, carboxylic groups, hydrazide groups, and thiol groups. The coupling of the targeting ligand to the hydrophilic polymer can be performed by standard methods of organic chemistry that are known to those skilled in the art. In certain embodiments, the total concentration of the targeting ligand can be from about 0.01 to about 10% mol.

20 Targeting ligands are any ligand specific for a characteristic component of the targeted region. Preferred targeting ligands include proteins such as polyclonal or monoclonal antibodies, antibody fragments, or chimeric antibodies, enzymes, or hormones, or sugars such as mono-, oligo- and poly-saccharides (see, Heath *et al.*, 1986). For example, disialoganglioside GD2 is a tumor antigen that has been identified
25 neuroectodermal origin tumors, such as neuroblastoma, melanoma, small-cell lung carcinoma, glioma and certain sarcomas (Cheresh *et al.*, 1986; Schulz *et al.*, 1984). Liposomes containing anti-disialoganglioside GD2 monoclonal antibodies have been used to aid the targeting of the liposomes to cells expressing the tumor antigen (Montaldo *et al.*, 1999; Pagnan *et al.*, 1999). In another non-limiting example, breast and

gynecological cancer antigen specific antibodies are described in U.S. Patent 5,939,277, incorporated herein by reference. In a further non-limiting example, prostate cancer specific antibodies are disclosed in U.S. Patent 6,107,090, incorporated herein by reference. Thus, it is contemplated that the antibodies described herein or as would be
5 known to one of ordinary skill in the art may be used to target specific tissues and cell types in combination with the compositions and methods of the present invention. In certain embodiments of the invention, contemplated targeting ligands interact with integrins, proteoglycans, glycoproteins, receptors or transporters. Suitable ligands include any that are specific for cells of the target organ, or for structures of the target
10 organ exposed to the circulation as a result of local pathology, such as tumors.

In certain embodiments of the present invention, in order to enhance the transduction of cells, to increase transduction of target cells, or to limit transduction of undesired cells, antibody or cyclic peptide targeting moieties (ligands) are associated with the lipid complex. Such methods are known in the art. For example, liposomes have
15 been described further that specifically target cells of the mammalian central nervous system (U.S. Patent 5,786,214, incorporated herein by reference). The liposomes are composed essentially of N-glutarylphosphatidylethanolamine, cholesterol and oleic acid, wherein a monoclonal antibody specific for neuroglia is conjugated to the liposomes. It is contemplated that a monoclonal antibody or antibody fragment may be used to target
20 delivery to specific cells, tissues, or organs in the animal, such as for example, brain, heart, lung, liver, etc.

Still further, a compound may be delivered to a target cell via receptor-mediated delivery and/or targeting vehicles comprising a lipid or liposome. These take advantage of the selective uptake of macromolecules by receptor-mediated endocytosis that will be
25 occurring in a target cell. In view of the cell type-specific distribution of various receptors, this delivery method adds another degree of specificity to the present invention.

Thus, in certain aspects of the present invention, a ligand will be chosen to correspond to a receptor specifically expressed on the target cell population. A cell-specific delivery of compounds of the invention and/or targeting vehicle may comprise a

specific binding ligand in combination with a liposome. The compounds to be delivered are housed within a liposome and the specific binding ligand is functionally incorporated into a liposome membrane. The liposome will thus specifically bind to the receptor(s) of a target cell and deliver the contents to a cell. Such systems have been shown to be functional using systems in which, for example, epidermal growth factor (EGF) is used in the receptor-mediated delivery of a nucleic acid to cells that exhibit upregulation of the EGF receptor.

In certain embodiments, a receptor-mediated delivery and/or targeting vehicles comprise a cell receptor-specific ligand and a binding agent. Others comprise a cell receptor-specific ligand to which modified protein or a polynucleotide encoding a modified protein to be delivered has been operatively attached. For example, several ligands have been used for receptor-mediated gene transfer (Wu and Wu, 1987; Wagner *et al.*, 1990; Perales *et al.*, 1994; Myers, EPO 0273085), which establishes the operability of the technique. In another example, specific delivery in the context of another mammalian cell type has been described (Wu and Wu, 1993; incorporated herein by reference).

In still further embodiments, the specific binding ligand may comprise one or more lipids or glycoproteins that direct cell-specific binding. For example, lactosyl-ceramide, a galactose-terminal asialganglioside, have been incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes (Nicolau *et al.*, 1987). The asialoglycoprotein, asialofetuin, which contains terminal galactosyl residues, also has been demonstrated to target liposomes to the liver (Spanjer and Scherphof, 1983; Hara *et al.*, 1996). The sugars mannosyl, fucosyl or N-acetyl glucosamine, when coupled to the backbone of a polypeptide, bind the high affinity manose receptor (U.S. Patent 5,432,260, specifically incorporated herein by reference in its entirety). It is contemplated that the cell or tissue-specific transforming constructs of the present invention can be specifically delivered into a target cell or tissue in a similar manner.

In another example, lactosyl ceramide, and peptides that target the LDL receptor related proteins, such as apolipoprotein E3 ("Apo E") have been useful in targeting liposomes to the liver (Spanjer and Scherphof, 1983; WO 98/0748).

Folate and the folate receptor have also been described as useful for cellular targeting (U.S. Patent 5,871,727). In this example, the vitamin folate is coupled to the complex. The folate receptor has high affinity for its ligand and is overexpressed on the surface of several malignant cell lines, including lung, breast and brain tumors. Anti-folate such as methotrexate may also be used as targeting ligands. Transferrin mediated delivery systems target a wide range of replicating cells that express the transferrin receptor (Gilliland *et al.*, 1980).

c. Liposome/Nucleic Acid Combinations

It is contemplated that when the liposome composition comprises a cell or tissue specific nucleic acid, this technique may have applicability in the present invention. In certain embodiments, lipid-based non-viral formulations provide an alternative to viral gene therapies. Although many cell culture studies have documented lipid-based non-viral gene transfer, systemic gene delivery via lipid-based formulations has been limited. A major limitation of non-viral lipid-based gene delivery is the toxicity of the cationic lipids that comprise the non-viral delivery vehicle. The *in vivo* toxicity of liposomes partially explains the discrepancy between *in vitro* and *in vivo* gene transfer results. Another factor contributing to this contradictory data is the difference in liposome stability in the presence and absence of serum proteins. The interaction between liposomes and serum proteins has a dramatic impact on the stability characteristics of liposomes (Yang and Huang, 1997). Cationic liposomes attract and bind negatively charged serum proteins. Liposomes coated by serum proteins are either dissolved or taken up by macrophages leading to their removal from circulation. Current *in vivo* liposomal delivery methods use aerosolization, subcutaneous, intradermal, intratumoral, or intracranial injection to avoid the toxicity and stability problems associated with cationic lipids in the circulation. The interaction of liposomes and plasma proteins is largely responsible for the disparity between the efficiency of *in vitro* (Felgner *et al.*,

1987) and *in vivo* gene transfer (Zhu *et al.*, 1993; Philip *et al.*, 1993; Solodin *et al.*, 1995; Liu *et al.*, 1995; Thierry *et al.*, 1995; Tsukamoto *et al.*, 1995; Aksentijevich *et al.*, 1996).

An exemplary method for targeting viral particles to cells that lack a single cell-specific marker has been described (U.S. Patent 5,849,718). In this method, for example,
5 antibody A may have specificity for tumor, but also for normal heart and lung tissue, while antibody B has specificity for tumor but also normal liver cells. The use of antibody A or antibody B alone to deliver an anti-proliferative nucleic acid to the tumor would possibly result in unwanted damage to heart and lung or liver cells. However, antibody A and antibody B can be used together for improved cell targeting. Thus,
10 antibody A is coupled to a gene encoding an anti-proliferative nucleic acid and is delivered, via a receptor mediated uptake system, to tumor as well as heart and lung tissue. However, the gene is not transcribed in these cells as they lack a necessary transcription factor. Antibody B is coupled to a universally active gene encoding the transcription factor necessary for the transcription of the anti-proliferative nucleic acid
15 and is delivered to tumor and liver cells. Therefore, in heart and lung cells only the inactive anti-proliferative nucleic acid is delivered, where it is not transcribed, leading to no adverse effects. In liver cells, the gene encoding the transcription factor is delivered and transcribed, but has no effect because no an anti-proliferative nucleic acid gene is present. In tumor cells, however, both genes are delivered and the transcription factor can
20 activate transcription of the anti-proliferative nucleic acid, leading to tumor-specific toxic effects.

The addition of targeting ligands for gene delivery for the treatment of hyperproliferative diseases permits the delivery of genes whose gene products are more toxic than do non-targeted systems. Examples of the more toxic genes that can be
25 delivered includes pro-apoptotic genes such as Bax and Bak plus genes derived from viruses and other pathogens such as the adenoviral E4orf4 and the *E.coli* purine nucleoside phosphorylase, a so-called "suicide gene" which converts the prodrug 6-methylpurine deoxyriboside to toxic purine 6-methylpurine. Other examples of suicide

genes used with prodrug therapy are the *E. coli* cytosine deaminase gene and the HSV thymidine kinase gene.

It is also possible to utilize untargeted or targeted lipid complexes to generate recombinant or modified viruses *in vivo*. For example, two or more plasmids could be used to introduce retroviral sequences plus a therapeutic gene into a hyperproliferative cell. Retroviral proteins provided in *trans* from one of the plasmids would permit packaging of the second, therapeutic gene-carrying plasmid. Transduced cells, therefore, would become a site for production of non-replicative retroviruses carrying the therapeutic gene. These retroviruses would then be capable of infecting nearby cells.

10 The promoter for the therapeutic gene may or may not be inducible or tissue specific.

Similarly, the transferred nucleic acid may represent the DNA for a replication competent or conditionally replicating viral genome, such as an adenoviral genome that lacks all or part of the adenoviral E1a or E2b region or that has one or more tissue-specific or inducible promoters driving transcription from the E1a and/or E1b regions.

15 This replicating or conditional replicating nucleic acid may or may not contain an additional therapeutic gene such as a tumor suppressor gene or anti-oncogene.

d. Lipid Administration

The actual dosage amount of a lipid composition (e.g., a liposome-modified protein or polynucleotide encoding a modified protein) administered to a patient can be determined by physical and physiological factors such as body weight, severity of condition, idiopathy of the patient and on the route of administration. With these considerations in mind, the dosage of a lipid composition for a particular subject and/or course of treatment can readily be determined.

20

25 VI. EXAMPLES

The following examples are included to demonstrate preferred embodiments of the present invention. It should be appreciated by those of skill in the art that that techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered

to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar results without departing from the spirit and scope of the invention.

5

EXAMPLE 1:

Materials And Methods

Cells and Viruses. Vero and BHK cells were originally obtained from ATCC. HSV-1(F) is the prototype HSV-1 strain used in this laboratory (Ejercito *et al.*, 1967).
10 Recombinant R325 derived from HSV-1(F), includes approximately 800 bp comprising the carboxyl-terminal half of the $\alpha 4$ gene and grows only in a Vero cell line expressing the $\alpha 4$ gene (DeLuca *et al.*, 1985). Both the virus and the cell line were kind gifts of Neal DeLuca (University of Pittsburgh). The $U_s 3$ gene was deleted from the recombinant R7041 (Longnecker *et al.*, 1987) and then repaired to yield R7306.

15 **Plasmids and Cosmids.** The plasmid pRB5166 was constructed by cloning into the SalI/BamHI sites of the pACYC184 vector a HSV-1 DNA fragment that extends from the Sal I site at + 177 with respect to the $\alpha 4$ gene transcription start site and includes the entire BamHI P and BamHI S fragments. The cosmid cloning vector pRB78 was constructed as follows. The multiple cloning site of the Stratagene SupercosI (La Jolla
20 CA, cat#251301) was cleaved with EcoRI and replaced with an oligonucleotide(s) containing EcoRI/PacI/Sse8387I/SpeI/BamHI/NdeI/EcoRV/ PacI/EcoRI cloning sites. The PacI restriction site, absent in HSV-1, serves to liberates the cloned HSV-1(F) DNA fragments from the vector. HSV-1(F) viral DNA was prepared from virions as previously described. To construct cosmid pBC1004, which contains the HSV-1(F) sequence
25 n133052 through n17059, viral DNA was partially digested with Sau3A I, dephosphorylated and ligated into the BamHI site of the pRB78 cosmid vector previously linearized with Xba I. The DNA was then packaged using Stratagene Gigapack XLII (La Jolla, CA), following the manufacturer's instructions. *E. coli* L-1 Blue MR was then infected and ampicillin-resistant colonies were screened by restriction enzyme analysis.

Insert termini were sequenced to verify mapping. Cosmid pBC1008 was constructed by cloning the *Bgl*II F-H fragment (HSV-1(F) n106750 through n142759) into the *Bam*HI site of pRB78 vector. Cosmid pBC1009 was constructed as follows. An *Nsi*I/*Sca*I DNA fragment was isolated from a double digest of viral DNA. The fragment (HSV-1(F) n137538 through n18545) was ligated into the *Sse*8387I/*Eco*RV sites of pBR78. Cosmids PBC1008 and PBC1009 were mapped by restriction enzyme analysis and insert termini were sequenced (FIG. 1).

Electron photomicroscopy. Vero cells infected with HSV-1(F) or d120 were incubated for 20 hrs at 37°C. Cells were fixed in 2% glutaraldehyde in PBS for 60 min at 4°C, post-fixed with 1% osmium tetroxide, en bloc stained with uranyl acetate (5mg/ml), dehydrated in acetone, and embedded in Epon 812. Thin sections were examined either unstained or poststained with uranyl acetate and lead hydroxide. The cells were photographed at 6000 X in a Siemens 101 electron microscope.

Light photomicroscopy. Cells were labeled with biotinylated dUTP. At indicated times the cells were fixed in ice-cold methanol at -20°C and air-dried, then rinsed in phosphate buffered saline, reacted for 15 min at room temperature with 40 ml of a solution containing 1x terminal transferase buffer (Promega), 1 mM CoCl₂, 0.05 mg/ml bovine serum albumin (BSA), 0.5 nmoles biotin-16-dUTP (Boehringer Mannheim Biochemicals) and 3 units of terminal transferase (TdT, Promega), rinsed extensively in PBS, reacted for 30 min at room temperature with 40 ml of a solution containing Texas red-conjugated avidin in 4x SSC (1x SSC is 0.15 M NaCl, 0.015 M Na-citrate), 0.1 % Triton X-100, 5% (w/v) nonfat dry milk, extensively rinsed with PBS, mounted in 10% PBS in glycerol and examined under a Zeiss confocal fluorescence microscope. The images were captured under identical settings with the software provided by Zeiss and printed in a Tektronix 440 phaser printer. Cells were mock infected, 37°C, 20 hrs; infected with d120 virus, 37°C 20 hrs; infected with HSV-1(F), 37°C, 20 hrs; infected with d120 virus, 37°C 30 hrs; mock-infected, 39.5°C, 30 hrs.; infected with d120 virus, 39.5°C, 30 hrs.; and infected with HSV-1(F), 39.5° C, 30 hrs.

DNA Fragmentation Assay. Vero cells or E5 cells were infected with HSV-1(F), d120 mutant, or HSV-1 tsHA1 mutant and maintained at 37°C or 39.5°C in the absence or in the presence of phosphonoacetic acid. At 30 hrs after infection, 2×10^6 cells per sample were collected, washed in PBS, lysed in a solution containing 10 mM Tris-HCl, pH 8.0, 10 mM EDTA, and 0.5 % Triton X-100, and centrifuged at 12,000 rpm for 25 min in an Eppendorf microcentrifuge to pellet chromosomal DNA. Supernatant fluids were digested with 0.1 mg RNase A per ml at 37°C for 1 hr, for 2 hrs with 1 mg proteinase K per ml at 50°C in the presence of 1 % sodium dodecylsulphate (SDS), extracted with phenol and chloroform, and precipitated in cold ethanol and subjected to electrophoresis on horizontal 1.5 % agarose gels containing 5 mg of ethidium bromide per ml. DNA was visualized by UV light transillumination. Photographs were taken with the aid of a computer-assisted image processor (Eagle Eye II, Stratagene).

Construction of recombinant viruses by marker rescue. Recombinant viruses were constructed using a modification of the technique originally described by Post and Roizman (1981). Vero cells were transfected with plasmid or cosmid DNA using Lipofectamine (Gibco-BRL), according to the manufacturer's instructions. At 6 hr after transfection, the cells were exposed to 0.1 to 1 PFU of HSV-1(Kos)d120 per cell. Recombinant viruses were isolated from single plaques and grown in Vero cells. To obtain HSV-1 120KR, Vero cells were exposed to 10 PFU of HSV-1(KOS)d120 per cell. The infected cells were harvested at 48 hr post infection, frozen-thawed and sonicated, and then serially diluted and titered on Vero cells. Recombinant viruses were isolated from single plaques and grown in Vero cells.

EXAMPLE 2

An HSV-1 mutant deleted in ICP4 induces apoptosis.

In this series of studies, Vero cells infected with wild-type or the d120 mutant were examined for morphologic evidence of apoptosis. Vero cells were fixed and harvested at 20 to 24 hrs after infection with wild-type or d120, embedded, sectioned, and examined in a Siemens 101 electron microscope. The cells infected with wild-type virus

showed typical infected cell morphology, *i.e.*, marginated chromatin, separation of inner and outer nuclear membranes, and accumulation of virus particles in some but not all cells. Cells infected with the d120 deletion mutant exhibited extensive condensation of chromatin, obliteration of the nuclear membrane, and extensive vacuolization and blebbing of the cytoplasm. It was estimated that approximately 40 to 50% of the infected cells exhibited some or all of the morphologic changes described above.

In another series of studies, Vero cells were mock-infected or infected with 10 PFU of either the wild-type or the d120 mutant virus per cell. After 20 hrs of incubation at 37° C the cells were fixed, labeled with biotinylated dUTP in the presence of terminal transferase, and then reacted with fluorescent avidin. Mock-infected cells or cells infected with wild-type virus showed no sign of labeling with biotinylated dUTP by terminal transferase, whereas cells infected with d120 and maintained at the same temperature showed extensive fluorescence due to the reaction of fluorescent avidin to biotinylated dUTP incorporated at the DNA termini created by the cleavage of DNA.

In the third series of studies, replicate Vero cell cultures were infected with 10 PFU of either HSV-1(F) or d120 per cell and incubated at 37°C. The study also included a Vero cell culture infected with HSV-1(F), overlaid with medium containing 300 µg of phosphonoacetate per ml and incubated at 37°C, and a set of Vero cell cultures infected with 10 PFU of HSV-1 tsHA1 and incubated at either 37°C or 39.5°C. This concentration of phosphonoacetate completely inhibits viral DNA synthesis and blocks the expression of γ_2 genes dependent on viral synthesis for their expression. The cells were harvested at 30 hrs after infection, lysed, and centrifuged to pellet the chromosomal DNA. The supernatant fluids were processed as described above and subjected to electrophoresis in agarose gels to test for the presence of soluble, fragmented DNA.

The results were as follows. Cells infected with d120 deletion mutant yielded high amounts of fragmented DNA which were readily visible on agarose gels stained with ethidium bromide. These ladders were not seen in agarose gels containing electrophoretically separated extracts of wild-type infected cells or E5 cells infected with

d120. When Vero cells were incubated in medium containing phosphonoacetate, fragmented DNA was detected from cells infected with d120 mutant but not with the wild-type. Fragmented DNA was visible in extracts of mock-infected cells incubated at 39.5°C, but not in cells infected with HSV-1 \underline{ts} HA1 and incubated at the same temperature.

From this series of studies, it is concluded that (i) HSV-1 is capable of inducing the morphologic and biochemical changes characteristic of apoptosis and these changes are prominent in cells infected with a mutant lacking ICP4; (ii) wild-type virus does not induce apoptosis indicating that ICP4 or a protein expressed subsequently is able to protect cells from apoptosis; (iii) the protective, anti-apoptotic effect is a viral function which does not depend on the onset of viral DNA synthesis; (iv) DNA degradation typical of apoptosis was observed upon incubation at 39.5°C in mock-infected but not HSV-1 \underline{ts} HA1 infected cells, which suggests that prolonged incubation at the elevated temperature can induce apoptosis that is blocked by a viral function expressed early.

EXAMPLE 3

ICP4 expresses an anti-apoptotic function.

In a fourth series of studies, Vero or E5 cells were mock infected or infected with 10 PFU per cell with either HSV-1(F) or d120. The cells were incubated at 39.5°C for 30 hrs. The rationale of these studies was as follows. As noted in Example 1, HSV-1(F) carries a \underline{ts} lesion in the α 4 gene and at the nonpermissive temperature (39.5°C) expresses only α genes. The α 4 gene resident in the E5 cell line and the d120 mutant virus lacking the α 4 gene were derived from the HSV-1(KOS) strain which does not exhibit the \underline{ts} phenotype. In addition, the α 4 gene resident in the E5 cell line is induced after infection and is not expressed in uninfected cells. In the first series of studies, the cells were harvested, lysed, centrifuged to sediment chromosomal DNA and the supernatant fluids were processed as described in Example 1 and subjected to electrophoresis in agarose gels.

The results were as follows. Fragmented DNA was present in lanes containing electrophoretically separated extracts of mock-infected Vero cells, Vero cells infected with d120 mutant, and the mock infected E5 cells. Fragmented DNA was not detected in Vero cells infected with wild-type virus, or in E5 cells infected with either d120 mutant virus or HSV-1(F) virus.

In the second series of studies Vero cells were mock infected, or infected with either d120 or with wild-type virus. After 30 hrs of incubation at 39.5°C, the cells were fixed and labeled with biotinylated dUTP by terminal transferase, and reacted with fluorescent avidin. Fluorescence was detected in mock-infected or infected with d120 mutant, but not in cells infected with wild-type virus.

These studies permit the conclusion that HSV-1(F) $\alpha 4$ gene encodes a function which blocks apoptosis reflected in the degradation of DNA, and that this function is separable from the repressor and transactivator functions of ICP4 which are affected by the temperature sensitive lesion of the $\alpha 4$ gene of HSV-1(F).

A summary of the results is provided in Table 6. Induction of (+), or protection from (-) apoptosis is indicated upon conditions (infecting virus and incubation temperature) which induce apoptosis in Vero and E5 cell lines. "nt" indicates not tested.

TABLE 6

	VERO (37°C)	VERO (39°C)	E5 (37°C)	E5 (39.5°C)
MOCK	-	+	-	+
HSV-1(F)	-	-	-	-
HSV-1 d120	+	+	-	-
HSV-1 <u>ts</u> HA1	-	-	nt	-

EXAMPLE 4**HSV-1(KOS)d120 carries an additional mutation.**

The results described in this section emerged from studies designed to repair the deletion in both copies of the $\alpha 4$ gene of HSV-1(KOS)d120. The inventors isolated
5 recombinants in which this gene was repaired by two different procedures. In the first, the inventors cloned an HSV-1(F) DNA fragment that contains an $\alpha 4$ sequence plus enough flanking sequence to allow homologous recombination. In this series of studies Vero cells were transfected with plasmid DNA and infected with 0.1 to 1 PFU of HSV-1(KOS)d120 per cell. Under these conditions, plaques formed only in cultures of cells
10 transfected with the plasmid DNA. Recombinant virus was recovered from individual plaques, and designated 120FR (for HSV-1(F) repair).

The second procedure was based on the observation that a small amount of virus recombines with the resident $\alpha 4$ gene in the E5 cell line to yield rescued virus capable of replicating efficiently in the absence of exogenous source of ICP4. The observed
15 recombination frequency is 10^{-6} to 10^{-7} and therefore such rescued virus would be expected to be present in HSV-1(KOS)d120 stock. To isolate these recombinants, Vero cells were infected at a high multiplicity with HSV-1 d120. At 24 hr after infection cells were harvested, frozen-thawed and serial dilutions were used to infect Vero cells. The recombinant virus obtained in this fashion was designated 120KR (for HSV-1(KOS)
20 repair).

Analyses of DNA extracted from replicate Vero cell cultures infected with HSV-1(KOS)d120, 120FR or 120KR showed ladders typical of apoptotic cells. These ladders were absent in extracts of mock-infected cells or cells infected with HSV-1(F). The inventors conclude from these studies that HSV-1(KOS)d120 genome contain an
25 additional mutation other than in the $\alpha 4$ gene.

EXAMPLE 5**The U_S3 protein kinase is required to
block apoptosis induced by HSV-1 infection.**

In the following series of studies, the inventors defined the region that contains
5 the additional mutation in HSV-1(KOS)d120 by rescue of the HSV-1(KOS)d120 with
cosmids containing large HSV-1 DNA fragments. The three cosmids used in these
studies were cosmid pBC8008, which contains all of the HSV-1 terminal repeat sequence,
almost all of the U_S sequence, and part of the U_L sequence (FIG. 1) and cosmids
pBC8004 and pBC8009 which contain fragments spanning over the entire repeat
10 sequence but differ in the extent of coverage of the U_S region. Individual plaques purified
from each transfection were tested for their ability to protect infected cells from apoptosis
induced by infection. The results shown in Table 7 suggested that the second mutation in
HSV-1(KOS)d120 may map in the U_S domain containing the genes U_S1 through U_S3.

15 **TABLE 7**

Plasmid/Cosmid	Recombinant	Protection From Apoptosis
pRB5166	HSV-1 120FR	0/9
None	HSV-1 120KR	0/5
pBC1004	HSV-1 120AR	1/4
pBC1009	HSV-1 120BR	0/9
pBC1008	HSV-1 120CR	8/9

To map the function required to block apoptosis more precisely, the inventors
took advantage of the availability in this laboratory of several deletion mutants which
20 span the sequence thought to encode the gene required to block apoptosis in infected
cells. Recombinant virus R325 lacks the carboxyl terminal half of the α 22 gene, and the
3' domain of the U_S2 gene. Recombinant virus R7041, lacks most of the U_S3 gene
whereas in recombinant R7306 the U_S3 gene had been repaired. The results indicate that

apoptosis was induced in cells infected with R7041 (ΔU_3) but not in cells infected with the other mutants.

Two series of studies verified the conclusion that a functional U_3 gene is required for prevention of apoptosis and that the second mutation in the HSV-1(KOS)d120 resides in the U_3 gene. In the first series, the inventors carried out simple complementation tests to determine whether the second mutation in HSV-1(KOS)d120 was the same as that in the rescued virus or in R7041 (ΔU_3) recombinant. Specifically Vero cells were infected with artificial mixtures of 120FR and HSV-1(KOS)d120, 120FR and R7041, or 120FR and R7306 (U_3 repaired). The results indicate the following. As could be expected, 120FR did not complement HSV-1(KOS)d120, the parent virus from which it was derived. The second, mixture of 120FR and R7041 also did not complement each other suggesting that 120FR and its parent virus, HSV-1(KOS)d120 contained a nonfunctional U_3 . Verification of this hypothesis emerged from the observation that R7306 containing a repaired U_3 gene complemented 120FR and blocked apoptosis in cells infected with these two viruses.

The second series of studies served to verify the HSV-1(KOS)d120 and its derivatives lacked a functional U_3 gene. As described in this introduction, the production of U_L34 gene has been shown in earlier studies from this laboratory to be a substrate for the U_3 protein kinase. In wild-type infected cells, U_L34 has an apparent M_r of 30,000 whereas in cells infected with R7041 (ΔU_3), U_L34 has an apparent migrates of M_r 33,000. Inasmuch as the original studies were done in BHK cells, in this series of studies replicate cultures of BHK cells were infected 10 PFU of HSV-1(F), 120FR, R7041, and R7306 per cell. The results, shown in FIG. 2 indicate that the fully processed U_L34 protein was present in cells infected with HSV-1(F) but not cells infected with 120FR or R7041. As could be expected, the cells infected with HSV-1(KOS)d120 did not make detectable quantities of U_L34 protein inasmuch as they lack the $\alpha 4$ gene. In the absense of $\alpha 4$ gene expression there is no β or γ gene expression and therefore, no U_3 gene expression. Taken together, the inventors' results indicate the U_3 kinase is

functionally absent in HSV-1(KOS)d120 and 120FR. The inventors conclude that U_S3 is required for protection from apoptosis induced by HSV-1.

EXAMPLE 6

5 Materials and Methods

Cells and viruses. Rabbit skin cells were originally obtained by J. McLaren and grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 5% newborn calf serum.

Plasmids. An EcoRI/NotI fragment from pEBG-mBAD (Cell Signalling, Beverly, MA) containing the mouse BAD open reading fused to glutathione S transferase (GST) was cloned into the baculovirus transfer vector MTS-1. MTS-1 contains a CMV promoter inserted into the XhoI/EcoRI sites of pAcSG2 (Pharmingen, San Diego, Calif.). An EcoRI/BamHI fragment encoding GST was removed creating BAD-MTS-1 that contains the BAD open reading frame under the control of the CMV promoter.

Baculoviruses. A BAD expressing baculovirus was constructed by cotransfecting the BAD-MTS-1 transfer plasmid, with Baculogold DNA (Pharmingen, San Diego, Calif.) as per manufacturer's instructions. Efficient baculovirus gene expression in mammalian cells requires treatment with sodium butyrate, a histone deacetylase inhibitor (Meigner *et al.*, 1988). In all experiments in which rabbit skin cells were infected with baculoviruses, all infected or treated cultures were exposed to medium containing 5 mM sodium butyrate after 2 hrs of viral infection at 37°C.

Immunoblot assays. Cells were harvested by scrapping cells into their medium, pelleted by low speed centrifugation, rinsed twice with PBS A (0.14M NaCl, 3mM KCL, 10 mM Na₂HPO₄, 1.5 mM KH₂PO₄), lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS in PBS A), stored on wet ice for 10 min before centrifugation at 14,000 x g for 10 min. The protein concentration of the supernatant fluids was determined with the aid of the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, Calif.) according to directions provided by the manufacturer. Protein samples,

denatured in disruption buffer (50 mM tris pH 7.0, 2.75% sucrose, 5% β -ME, 2% SDS) were electrophoretically separated in a 12% denaturing polyacrylamide gel (100 μ g of protein per lane), electrically transferred to a nitrocellulose sheet, blocked, and reacted with a rabbit polyclonal antibody specific for either poly(ADP-ribose) polymerase (PARP, Santa Cruz Biotechnologies, Santa Cruz, CA), BAD, BAD-ser136P, BAD-ser155P (Cell Signalling Technology, Beverly, MA), or mouse monoclonal specific for BAD-ser112P. Protein bands were visualized with either alkaline phosphatase or through enhanced chemiluminescent detection (ECL) according to the instructions of the manufacturer (Amersham, Buckinghamshire, England).

10 *Measurement of DEVDase activity.* Cellular extracts were assayed for caspase-3 activity with a tetrapeptide (Asp-Glu-Val-Asp) conjugated to phenylnitraniline (DEVD-pNA). Rabbit skin cells grown in 25 cm² flask cultures were either mock infected or infected with recombinant baculoviruses as indicated. At 18 hrs after infection, the cells were scraped in their medium, rinsed twice with PBS A, resuspended in 150 μ l lysis
15 buffer (50 mM HEPES, pH 7.4, 0.1% CHAPS, 1mM DTT, 0.1 mM EDTA) and left on ice for 5 min. The lysates were then centrifuged at 14,000 x g for 10 min at 4° C and the supernatant was collected and tested for DEVDase activity as recommended by the manufacturer (BIOMOL). The released chromophore was measured in a spectrophotometer at 405 nm after 2 hrs.

20 *DNA fragmentation assay.* Infected or uninfected cells were collected, washed in PBS, lysed in a solution containing 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 0.5% Triton X-100, centrifuged at 14,000 rpm for 25 min in an Eppendorf microcentrifuge to pellet chromosomal DNA. The supernatant was digested with RNase A (0.1 mg/ml) at 37°C for 1 hr, and digested with proteinase K (1 mg/ml) at 50°C for 2 hrs in the presence
25 of 1% sodium dodecyl sulfate, precipitated in cold ethanol, and subjected to electrophoresis in 1.5% agarose gels containing 0.5 mg of ethidium bromide per ml. Oligonucleosomal DNA fragments were visualized by UV light transillumination. Photographs were taken with the aid of Eagle Eye II (Stratagene).

EXAMPLE 7

Induction of apoptosis by a baculovirus expressing the BAD protein.

To facilitate the studies on the role of the U₃ protein kinase in blocking apoptosis, it became critical to express the BAD protein to all cells in a dose dependent manner. BAD was delivered to cells by exposing cells to a recombinant baculovirus designated Bac-BAD, which expresses the BAD open reading frame driven by the hCMV immediate early promoter as described in Example 6. Rabbit skin cells were either mock infected, or exposed to 5 PFU of Bac-WT or Bac-BAD per cell. The cells were harvested at 18 hrs after addition of Bac-BAD, solubilized, electrophoretically separated in a denaturing polyacrylamide gel, transferred to a nitrocellulose sheet and reacted with the anti-BAD antibody. The BAD protein was detected in cells infected with Bac-BAD but not in mock or Bac-WT infected cells. None of the experiments described in this study were able to detect endogenous BAD. In addition, a potential BAD cleavage product of M_r 15,000 was also detected.

To address whether baculovirus mediated overexpression of BAD is sufficient to induce apoptosis, rabbit skin cells were mock-infected or exposed to 10 or 20 PFU of Bac-WT or Bac-U₃, or to 0.5, 2.5 or 5.0 PFU of Bac-BAD per cell. Cells were harvested at 18 hrs after infection, lysed and tested for DEVDase activity. The results, normalized with respect to the level of caspase activity in mock-infected cells are shown in FIG. 3 and were as follows: Cells infected with either 10 or 20 PFU of Bac-WT per cell exhibited less than a two-fold increase in DEVDase activity. In cells infected with either 10 or 20 PFU of Bac-U₃ per cell, the DEVDase activity was identical to that of mock infected cells. The DEVDase activity of cells infected with 0.5, 2.5 or 5.0 PFU of Bac-BAD per cell exhibited a 2.5-, 6- or 8-fold increase in DEVDase activity, respectively, relative to that of mock-infected cells. These results indicated that while Bac-WT and Bac-U₃ did not induce significant amounts of caspase activity, Bac-BAD induced significant caspase activity in a dose dependent manner.

EXAMPLE 8

U₅3 protein kinase blocks DEVDase activity induced by BAD expression

The objective of this series of experiments was to test whether the U₅3 protein kinase is sufficient to prevent BAD- induced apoptosis. Rabbit skin cells were either mock infected, or infected with 20 PFU of Bac-WT or Bac-U₅3 per cell 6.5 hrs prior to exposure of the cells to 5.0 PFU of Bad-BAD per cell. The cells were harvested at 18 hrs after Bac-BAD infection and tested for DEVDase activity. As shown in FIG. 4, rabbit skin cells either mock infected or infected with Bac-WT prior prior to exposure to Bac-BAD, exhibited a 8- and 9-fold increase in DEVDase activity, respectively, relative to that of mock-infected cells. In contrast, cells infected with Bac-U₅3 prior to Bac-BAD addition exhibited significantly less DEVDase activity (less than 2 fold increase). These results indicate that U₅3 is sufficient to prevent BAD-induced caspase activation.

EXAMPLE 9

U₅3 protein kinase blocks the cleavage of poly(ADP-ribose) polymerase (PARP)-induced by BAD expression

To further verify that Bac-BAD induced caspase activity and that Bac-U₅3 blocked Bac-BAD-induced caspase activity, the status of PARP, a substrate of caspase 3, was examined. Active caspase 3 cleaves the M_r 110,000 PARP to yield a truncated polypeptide with an M_r of 85,000. To address whether U₅3 could prevent BAD induced PARP cleavage, rabbit skin cells were either mock infected, or exposed to 20 PFU of Bac-WT or Bac-U₅3 per cell 6.5 hrs prior to exposure to 5 PFU of Bac-Bad per cell. The cells were harvested at 18 hrs after addition of Bac-Bad, solubilized, electrophoretically separated in a denaturing polyacrylamide gel, transferred to a nitrocellulose sheet and reacted with the anti PARP antibody. The results were as follows: The M_r 85,000 PARP cleavage product was not detected in mock, Bac-WT, or Bac-U₅3 infected cells that had not been treated with Bac-Bad. The M_r 85,000 PARP cleavage product was readily detected in mock- or in Bac-WT-infected cells that had been exposed to Bac-Bad, but not in Bac-U₅3 infected cells that had been exposed to Bac-Bad. Thus, the U₅3 protein kinase prevented the cleavage of PARP by caspases induced by BAD.

EXAMPLE 10

Us3 protein kinase blocks DNA fragmentation induced by BAD expression

The objective of this series of experiments was to further verify that U_s3 blocks
5 BAD induced apoptosis by testing whether U_s3 prevents the fragmentation of cellular
DNA induced by BAD. Rabbit skin cells were either mock infected, or infected with 20
PFU of Bac-WT or Bac-U_s3 per cell 6.5 hrs prior to exposure to 5 PFU Bac-Bad per cell.
The cells were harvested 18 hrs after exposure to Bac-Bad and processed as described in
Example 6. Cellular DNA was fragmented in cells mock-infected or infected with Bac-
10 WT prior to exposure to Bac-Bad, but not in mock-infected cells or cells infected with
Bac-WT or Bac-U_s3. In contrast, DNA fragmentation was not observed in extracts of
Bac-Bad treated cells that had been previously exposed to Bac-U_s3. U_s3 protein kinase is
sufficient to block BAD induced apoptosis.

15

EXAMPLE 11

Bac-U_s3 mediates posttranslational modification of BAD

BAD phosphorylated at serines 112 and 136 is sequestered by the 14-3-3 proteins.
In turn this step blocks the translocation of BAD to the mitochondria and its pro-
apoptotic activity (Harada *et al.*, 1999; Pastorino *et al.*, 1998; Zha *et al.*, 1996; Hsu *et al.*,
20 1997). In addition, phosphorylation of BAD at serine 155 appears to be necessary in order
to release the protein from its association with Bcl-2 family member Bcl-X_L (30-32). It
was of interest to determine whether U_s3 prevents BAD-induced apoptosis by
posttranslational modification of BAD. To resolve this question, rabbit skin cells were
mock infected or infected with 20 PFU of Bac-WT or Bac-U_s3 per cell 6.5 hrs prior to the
25 exposure of the cells to Bac-Bad (5 PFU/cell). The cells were harvested 18 hrs after
exposure to Bac-BAD, solubilized, electrophoretically separated in denaturing
polyacrylamide gels, transferred to a nitrocellulose sheet and reacted with antibody
specific for total BAD protein or to either BAD-ser136P, BAD-155P, or BAD-ser112P.
The results were as follows:

(i) The total amount of BAD protein detected by anti-BAD antibody in lysates of cells infected with Bac-U₅3 prior to exposure to Bac-BAD migrated more slowly and was significantly reduced in amount relative to those detected in lysates of cells exposed to BAC-WT or mock-infected prior to exposure to Bac-BAD. In this series of experiments we detected BAD only in cells exposed to Bac-BAD. It is of note that Bac-U₅3 did not affect the accumulation of an irrelevant viral protein expressed by a recombinant baculovirus. These results indicate that U₅3 mediates both a posttranslational processing of BAD and a reduction in the amount of total BAD protein.

(ii) The levels of BAD phosphorylated at ser136, ser155, and ser112 present in cells mock infected were similar to those present in cells infected with Bac-WT or Bac-U₅3. Inasmuch as the total amount of BAD was significantly reduced in cells exposed to Bac-U₅3, this observation suggests that in cells treated with Bac-U₅3 the total amount of Bad protein decreased, the amount of BAD protein phosphorylated at specific serines remained the same as in cells exposed to Bac-Bad in the absence of Bac-U₅3. The results suggest therefore that U₅3 down regulated primarily, if not exclusively, active, pro-apoptotic, nonphosphorylated BAD and concomitantly mediated posttranslational modification of all phosphorylated forms of the protein.

(iii) BAD cleavage products were present in cells that had been mock infected or Bac-WT infected prior to Bac-BAD addition, but were absent in cells infected with Bac-U₅3 prior to Bac-Bad addition. Recently it has been reported that caspase mediated cleavage of BAD results in a M_r 15,000 truncated product that stimulates BAD's apoptotic activity (35). That Bac-U₅3 prevents the cleavage of BAD and is consistent with the evidence that U₅3 protein kinase prevents BAD from inducing apoptosis.

These results indicate that U₅3: (i) mediated a posttranslational modification of full length Bad, (ii) mediated a decrease in the total amount of BAD, and (iii) prevented the accumulation of a M_r15,000 cleavage product of BAD, all of which could serve to block the pro-apoptotic activity of BAD.

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of embodiments, it will be apparent to those of skill in the art that variations may be applied
5 to the compositions and methods, and in the steps or in the sequence of steps of the methods, described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and
10 modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

VI. REFERENCES

The following references, to the extent that they provide exemplary procedural details or other information supplementary to that set forth herein, are incorporated by reference:

5

Pending Application No. 07/931,811

U. S. Patent 4,162,282

U. S. Patent 4,196,265

U. S. Patent 4,310,505

10 U. S. Patent 4,533,254

U. S. Patent 4,554,101

U. S. Patent 4,659,774

U. S. Patent 4,676,980

U. S. Patent 4,682,195

15 U. S. Patent 4,683,202

U. S. Patent 4,684,611

U. S. Patent 4,728,575

U. S. Patent 4,728,578

U. S. Patent 4,737,323

20 U. S. Patent 4,797,368

U. S. Patent 4,816,571

U. S. Patent 4,879,236

U. S. Patent 4,921,706

U. S. Patent 4,952,500

25 U. S. Patent 4,959,463

U. S. Patent 5,028,592

U. S. Patent 5,139,941

U. S. Patent 5,141,813

U. S. Patent 5,214,136

30 U. S. Patent 5,223,618

- U. S. Patent 5,264,566
- U. S. Patent 5,302,523
- U. S. Patent 5,322,783
- U. S. Patent 5,354,855
- 5 U. S. Patent 5,359,046
- U. S. Patent 5,378,825
- U. S. Patent 5,384,253
- U. S. Patent 5,401,511
- U. S. Patent 5,428,148
- 10 U. S. Patent 5,432,260
- U. S. Patent 5,446,137
- U. S. Patent 5,464,765
- U. S. Patent 5,466,786
- U. S. Patent 5,470,967
- 15 U. S. Patent 5,538,877
- U. S. Patent 5,538,880
- U. S. Patent 5,539,082
- U. S. Patent 5,550,318
- U. S. Patent 5,554,744
- 20 U. S. Patent 5,563,055
- U. S. Patent 5,563,055
- U. S. Patent 5,574,146
- U. S. Patent 5,580,859
- U. S. Patent 5,589,221
- 25 U. S. Patent 5,589,466
- U. S. Patent 5,591,616
- U. S. Patent 5,602,240
- U. S. Patent 5,602,244
- U. S. Patent 5,603,872
- 30 U. S. Patent 5,610,042

- U. S. Patent 5,610,289
- U. S. Patent 5,614,617
- U. S. Patent 5,623,070
- U. S. Patent 5,645,897
- 5 U. S. Patent 5,652,099
- U. S. Patent 5,656,610
- U. S. Patent 5,670,663
- U. S. Patent 5,672,697
- U. S. Patent 5,681,947
- 10 U. S. Patent 5,693,762
- U. S. Patent 5,700,922
- U. S. Patent 5,702,932
- U. S. Patent 5,705,629
- U. S. Patent 5,708,154
- 15 U. S. Patent 5,714,331
- U. S. Patent 5,714,331
- U. S. Patent 5,714,606
- U. S. Patent 5,719,262
- U. S. Patent 5,719,262
- 20 U. S. Patent 5,736,336
- U. S. Patent 5,736,524
- U. S. Patent 5,763,167
- U. S. Patent 5,766,855
- U. S. Patent 5,766,855
- 25 U. S. Patent 5,773,571
- U. S. Patent 5,777,092
- U. S. Patent 5,780,448
- U. S. Patent 5,786,214
- U. S. Patent 5,786,461
- 30 U. S. Patent 5,789,215

- U. S. Patent 5,792,847
U. S. Patent 5,849,718
U. S. Patent 5,858,988
U. S. Patent 5,861,155
5 U. S. Patent 5,871,727
U. S. Patent 5,871,986
U. S. Patent 5,872,232
U. S. Patent 5,879,703
U. S. Patent 5,886,165
10 U. S. Patent 5,891,625
U. S. Patent 5,891,625
U. S. Patent 5,908,845
U. S. Patent 5,939,277
U. S. Patent 5,945,100
15 U. S. Patent 5,965,703
U. S. Patent 5,981,274
U. S. Patent 5,994,136
U. S. Patent 5,994,624
U. S. Patent 6,013,516
20 U. S. Patent 6,020,192
U. S. Patent 6,054,297
U. S. Patent 6,099,842
U. S. Patent 6,107,090
UK Patent Application GB 2193095
25 EP 01219
EP 03089
EP 266032
EP 0273085
PCT/US85/01161
30 PCT/US89/05040

- WO 91/00360
WO 92/20702
WO 92/200373
WO 93/08829
5 WO 94/09699
WO 95/06128
WO 98/0748
WO 99/18933
- Aksentijevich *et al.*, *Hum. Gene Ther.*, 7(9):1111-22, 1996.
- 10 Asano *et al.*, *J. Gen. Virol.* 80:51-56, 1999.
Asano *et al.*, *Neurosci. Lett.* 294:105-8, 2000.
Auber *et al.*, *J. Virology*, 73:2803-2813, 1999.
Aubert *et al.*, *J. Virology*, 73:10359-70, 1999.
Ausubel, In: *Current protocols in molecular biology*, NY, John Wiley and Sons, 1996.
- 15 Baichwal and Sugden, In: *Gene Transfer*, Kucherlapati, (ed.), NY, Plenum Press,
117-148, 1986.
- Bangham, *et al.*, *J. Mol. Biol.*, 13:238-252, 1965.
Batterson *et al.*, *J. Virology*, 45:397-407, 1983.
Batterson *et al.*, *J. Virology*, 46:371-377, 1983.
- 20 Bedzyk *et al.*, *J. Biol. Chem.*, 265:18615-20, 1990.
Benvenisty *et al.*, *Proc. Natl. Acad. Sci. USA*, 83:9551-9555, 1986.
Berzal-Herranz, *et al.*, *Genes and Devel.*, 6:129-134, 1992.
Bittner *et al.*, *Methods in Enzymol.*, 153:516-544, 1987.
Blomer *et al.*, *J. Virology*, 71(9):6641-6649, 1997.
- 25 Brutlag *et al.*, *CABIOS*, 6:237-245, 1990.
Campbell *et al.*, *J. Mol. Biol.*, 180:1-19, 1984.
Canfield *et al.*, *Methods in Enzymology*, 189, 418-422, 1990.
Cech *et al.*, *Cell*, 27:487-496, 1981.
Chaudhary *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:9491-9494, 1990.
- 30 Chen *et al.*, *Mol. Cell Biol.*, 7:2745-2752, 1987.

- Cheng, *et al.*, *Invest. Radiol.*, 22:47-55, 1987.
- Cheresh *et al.*, *Cancer Res.*, 46:5112-5118, 1986.
- Chittenden *et al.*, *EMBO J.*, 14:5589-5596, 1995.
- Chou *et al.*, *Adv. Enzymol. Relat. Areas Mol. Biol.*, 47:45-148, 1978a.
- 5 Chou *et al.*, *Ann. Rev. Biochem.* 47:251-276, 1978b.
- Chou *et al.*, *Biochemistry*, 13(2):222-245, 1974a.
- Chou *et al.*, *Biochemistry*, 13(2):211-222, 1974b.
- Chou *et al.*, *Biophys. J.*, 26:367-384, 1979.
- Chou *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:3266-3270, 1992.
- 10 Chowrira, *et al.*, *Biochem.*, 32:1088-1095, 1993.
- Chowrira, *et al.*, *J. Biol. Chem.*, 269:25856-25864, 1994.
- Clem *et al.*, In: *Apoptosis II: The Molecular Basis of Apoptosis in Disease*, Tomei and Cope (eds.), Cold Spring Harbor Laboratory Press, 89-110, 1994.
- Condorelli *et al.*, *Mol. Cell Biol.*, 21:3025-36, 2001.
- 15 Condreay *et al.*, *Proc. Natl. Acad. Sci. USA*, 96:127-132, 1999.
- Conley *et al.*, *J. Virology*, 37:191-206, 1981.
- Cotten *et al.*, *Proc. Natl. Acad. Sci. USA*, 89(13):6094-6098, 1992.
- Coupar *et al.*, *Gene*, 68:1-10, 1988.
- Curiel *et al.*, *Nat. Immun.*, 13(2-3):141-164, 1994.
- 20 Datta *et al.*, *Mol. Cell.*, 6:41-51, 2000.
- Deamer *et al.*, In: *Liposomes*, Ostro (ed.), Marcel Dekker, Inc., NY, 27-52, 1983.
- De Jager, *et al.*, *Semin. Nucl. Med.*, 23(2):165-79, 1993.
- del Peso *et al.*, *Science*, 278:687-689, 1997.
- DeLuca *et al.*, *J. Virology*, 56:558-570, 1985.
- 25 Dixon *et al.*, *J. Virology*, 36:189-203, 1980.
- Doolittle, *et al.*, *Methods Mol. Biol.*, 109:215-237, 1999.
- Dubensky *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:7529-7533, 1984.
- Egholm *et al.*, *Nature*, 365:566, 1993
- Ejercito *et al.*, *J. Gen. Virol.*, 2:357-364, 1968.
- 30 el Gorab, *et al.*, *Biochim. Biophys. Acta*, 306(1):58-66, 1973.

- Faber *et al.*, *Nucleic Acids Res.*, 14:6067-6083, 1986.
- Fechheimer *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:8463-8467, 1987.
- Felgner *et al.*, *Proc Natl Acad Sci USA*, 84(21):7413-7417, 1987.
- Fendler *et al.*, In: *Catalysis in Micellar and Macromolecular Systems*, Academic Press,
5 NY, 1975.
- Ferkol *et al.*, *FASEB J.*, 7:1081-1091, 1993.
- Fetrow *et al.*, *Biotechnology*, 11:479-483, 1993.
- Forster and Symons, *Cell*, 49:211-220, 1987.
- Fraley *et al.*, *Proc. Natl. Acad. Sci. USA*, 76:3348-3352, 1979.
- 10 Franke *et al.*, *Cell*, 91:231-241, 1997.
- Freshner, In: *Animal Cell Culture: A Practical Approach*, Second Edition, Oxford/NY,
IRL Press, Oxford University Press, 1992.
- Friedmann, *Science*, 244:1275-1281, 1989.
- Froehler *et al.*, *Nucl. Acids Res.*, 14:5399-5407, 1986.
- 15 Gabizon *et al.*, *Cancer Res.*, 50(19):6371-8, 1990.
- Galvan *et al.*, *J. Virology*, 73:3219-3226, 1999.
- Galvan *et al.*, *J. Virology*, 74:1931-1938, 2000.
- Galvan *et al.*, *Proc. Natl. Acad. Sci. USA*, 95:3931-3936, 1998.
- Gerlach *et al.*, *Nature (London)*, 328:802-805, 1987.
- 20 Ghosh *et al.*, In: *Liver diseases, targeted diagnosis and therapy using specific receptors
and ligands*, NY, Marcel Dekker, 87-104, 1991.
- Gilliland *et al.*, *Cancer Res.*, 40(10):3564-9, 1980.
- Glorioso *et al.*, *Ann. Rev. Microbiol.*, 49:675-710, 1995.
- Gopal, *Mol. Cell. Biol.*, 5:1188-1190, 1985.
- 25 Gorczyca *et al.*, *Cancer Res.*, 53:1945-1951, 1993.
- Graham *et al.*, *J. Virology*, 52:456-467, 1973.
- Gregoriadis, *et al.*, *Biochem. Biophys. Res. Commun.*, 89(4):1287-1293, 1979.
- Grunhaus, *et al.*, *Seminar in Virology*, 3:237-252, 1992.
- Gulbis, *et al.*, *Hum. Pathol.*, 24(12):1271-1285, 1993.
- 30 Hara *et al.*, *Biochim. Biophys. Acta*, 1278:51-58, 1996.

- Harada *et al.*, *Mol. Cell.*, 3:413-422, 1999.
- Harland *et al.*, *J. Cell. Biol.*, 101:1094-1099, 1985.
- Harlow and Lane, In: *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988.
- 5 Haseloff *et al.* *Nature*, 334(6183):585-591, 1988.
- Hata *et al.*, *Microbes. Infect.*, 1:601-607, 1999.
- Heath, *et al.*, *Chem. Phys. Lipids*, 40:347, 1986.
- Henderson *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:8479-8483, 1993.
- Herz *et al.*, *Cell*, 33:145-151, 1983.
- 10 Holland *et al.*, *J. Virology*, 101:10-18, 1980.
- Honess *et al.*, *J. Virology*, 14:8-19, 1974.
- Honess *et al.*, *J. Virology*, 16:1308-1326, 1975.
- Hope *et al.*, *Biochimica. et Biophysica. Acta*, 812: 55-65, 1985.
- Horwich *et al.* *J. Virology*, 64:642-650, 1990.
- 15 Hsu *et al.*, *Mol. Endocrinol.*, 12:1858-1867, 1997.
- Jameson *et al.*, *Comput. Appl. Biosci.*, 4(1):181-186, 1988.
- Jerome *et al.*, *J. Virology*, 73:8950-8957, 1999.
- Johnson *et al.*, In: *Biotechnology and Pharmacy*, Pezzuto *et al* (eds.), Chapman and Hall, NY, 1993.
- 20 Joyce, *Nature*, 338:217-244, 1989.
- Kaeppler *et al.*, *Plant Cell Reports*, 9:415-418, 1990.
- Kaneda *et al.*, *Science*, 243:375-378, 1989.
- Kato *et al.*, *J. Biol. Chem.*, 266:3361-3364, 1991.
- Kelleher *et al.*, *Biotechniques*, 17(6):1110-1117, 1994.
- 25 Kim and Cech, *Proc. Natl. Acad. Sci. USA*, 84:8788-8792, 1987.
- Klein *et al.*, *Nature*, 327:70-73, 1987.
- Kornberg and Baker, In: *DNA Replication*, 2nd Ed., Freeman, San Francisco, 1992.
- Koyama *et al.*, *J. Virology*, 71:2567-2571, 1997.
- Kristie *et al.*, *Proc. Natl. Acad. Sci. USA*, 83:3218-3222, 1986a.
- 30 Kristie *et al.*, *Proc. Natl. Acad. Sci. USA*, 83:4700-4704, 1986b.

- Kuddus *et al.*, *J. Virology*, 69:5568-5575, 1995.
- Kyte *et al.*, *J. Mol. Biol.*, 157(1):105-132, 1982.
- Laughlin *et al.*, *J. Virology*, 60:515-524, 1986.
- Leader *et al.*, *Biochim. Biophys. Acta*, 1091:426-431, 1991.
- 5 Lebkowski, *et al.*, *Mol. Cell. Biol.*, 8:3988-3996, 1988.
- Lemaster *et al.*, *J. Virology*, 35:798-811, 1980.
- Leopardi *et al.*, *J. Virology*, 71(2):1133-9, 1997.
- Leopardi *et al.*, *J. Virology*, 69:3042-3048, 1995.
- Leopardi *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:9583-9587, 1996.
- 10 Leopardi *et al.*, *Proc. Natl. Acad. Sci. USA*, 94:7891-7896, 1997.
- Leopardi *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:9583-9587.
- Lieber and Strauss, *Mol. Cell. Biol.*, 15: 540-551, 1995.
- Liu *et al.*, *Biochim. Biophys. Acta*, 1240(2):277-284, 1995.
- Longnecker *et al.*, *Science*, 236:573-576, 1987.
- 15 Mann *et al.*, *Cell*, 33:153-159, 1983.
- Martin *et al.*, *Nature*, 345(6277):739-743, 1990.
- Mayer *et al.*, *Biochimica. et Biophysica. Acta*, 858:161-168, 1986.
- Mayhew *et al.*, *Biochimica. et Biophysica. Acta*, 775:169-174, 1984.
- Mayhew *et al.*, *Methods Enzymol.*, 149:64-77, 1987.
- 20 McCarthy *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:3979-3983, 1994.
- McLaughlin *et al.*, *J. J. Virology*, 62:1963-1973, 1988.
- Meignier *et al.*, *J. Virology*, 162:251-254, 1988.
- Michael *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:9808-9812, 1989.
- Michael *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:2286-2290, 1993.
- 25 Michael *et al.*, *Science*, 239:1531-1534, 1988.
- Michel and Westhof, *J. Mol. Biol.*, 216:585-610, 1990.
- Miller *et al.*, *Am. J. Clin. Oncol.*, 15(3):216-21, 1992.
- Millstein and Cuello, *Nature*, 305:537-539, 1983.
- Mizrahi, *Process Biochem.*, 9-12, 1983.
- 30 Montaldo, *et al.*, *Int. J. Cancer*, 81:262-267, 1999.

- Muller, J. J. *Virology*, 61:858-865, 1987.
- Munger et al., *J. Virology*, 75:5491-5497, 2001.
- Muzyczka, *Curr. Top. Microbiol. Immunol.*, 158:97-129, 1992.
- Nabel et al., *Science*, 244(4910):1342-4, 1989.
- 5 Naldini et al., *Proc. Natl. Acad. Sci. USA*, 93(21):11382-11388, 1996.
- Nicolas et al., In: *Vectors: A survey of molecular cloning vectors and their uses*, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513, 1988.
- Nicolau et al., *Biochem. Biophys. Acta*, 721:185-190, 1982.
- Nicolau et al., *Methods Enzymol.*, 149:157-176, 1987.
- 10 Oltvai et al., *Cell*, 74:609-619, 1993.
- Omirulleh et al., *Plant Mol. Biol.*, 21:415-28, 1993.
- Oz et al., *J. Vasc. Surg.*, 11(5):718-725, 1990.
- Pagnan et al., *Int. J. Cancer*, 81:268-74, 1999.
- Palukaitis et al., *J. Virology*, 99:145-151, 1979.
- 15 Pan et al., *Genes Dev.*, 8:1285-1299, 1994.
- Paskind et al., *J. Virology*, 67:242-248, 1975.
- Pastorino et al., *J. Biol. Chem.*, 274:19411-19416, 1998.
- Perales et al., *Proc. Natl. Acad. Sci. USA*, 91:4086-4090, 1994.
- Perriman. et al., *Gene*, 113:157-163, 1992.
- 20 Perrotta and Been, *Biochemistry*, 31:16, 1992.
- Philip et al., *J. Biol. Chem.*, 268:16087-90, 1993.
- Phillips et al., In: *Large Scale Mammalian Cell Culture*, Feder and Tolbert (eds.), Academic Press, Orlando, FL, 1985.
- Post et al., *Cell*, 24:555-565, 1981.
- 25 Post et al., *Cell*, 25:227-232, 1981.
- Potrykus et al., *Mol. Gen. Genet.*, 199:183-188, 1985.
- Potter et al., *Proc. Natl. Acad. Sci. USA*, 81:7161-7165, 1984.
- Prody, et al., *Science*, 231, 1577-1580, 1986.
- Purves et al., *Biochim. Biophys. Acta*, 889:208-215, 1986.
- 30 Purves et al., *J. Virology*, 61:2896-2901, 1987.

- Purves *et al.*, *J. Virology*, 4295-4303, 1992.
- Purves *et al.*, *J. Virology*, 61:2896-2901, 1987.
- Purves *et al.*, *J. Virology*, 65:5757-5764, 1991.
- Rao *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:7742-7746, 1992.
- 5 Ray *et al.*, *Cell*, 69:597-604, 1992.
- Reinhold-Hurek and Shub, *Nature*, 357:173-176, 1992.
- Ridgeway *et al.*, In: *Vectors: A survey of molecular cloning vectors and their uses*,
Stoneham: Butterworth, 467-492, 1988.
- Rippe *et al.*, *Mol. Cell Biol.*, 10:689-695, 1990.
- 10 Roizman *et al.*, In *Fields' Virology*, 3rd Edition, Fields, *et al.* (eds.), Raven Press, NY,
2231-2295, 1996.
- Roux *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:9079-9083, 1989.
- Salomoni *et al.*, *Blood*, 96:676-684, 2000.
- Sambrook *et al.*, In: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor
15 Laboratory Press, Cold Spring Harbor, NY, 1(7):19-17.29, 1989.
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 3rd Ed., Cold Spring Harbor
Press, Cold Spring Harbor, NY, 2001.
- Sarre, *Byosistems*, 22:311-325, 1989.
- Sarver, *et al.*, *Science*, 247:1222-1225, 1990.
- 20 Sattler *et al.*, *Science* 275:983-986, 1997.
- Scanlon *et al.*, *Proc. Nat'l Acad. Sci. USA*, 88:10591-10595, 1991.
- Scheid *et al.*, *Proc. Natl. Acad. Sci. USA*, 95:7439-7444, 1998.
- Schulz *et al.*, *Cancer Res.*, 44:5914-5920, 1984.
- Sheldrick *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 34:667-678, 1974.
- 25 Shen *et al.*, *Curr. Opin. Genet. Dev.*, 5:105-111, 1995.
- Shepard *et al.*, *J. Virology*, 65:787-795, 1991.
- Shinoda *et al.*, In: *Colloidal Surfactant*, Academic Press, 1:1-96, 1963.
- Sieg *et al.*, *J. Virology*, 8747-8751, 1996.
- Sioud *et al.*, *J. Mol. Biol.*, 223:831-835, 1992.
- 30 Solodin *et al.*, *Biochemistry*, 34(41):13537-44, 1995.

- Spanjer *et al.*, *Biochim. Biophys. Acta*, 734(1):40-47, 1983.
- Symons, *Nucl. Acids Res.*, 9:6527-6537, 1981.
- Symons, *Ann. Rev. Biochem.*, 61:641-671, 1992.
- Szoka, *et al.*, *Proc. Natl. Acad. Sci. USA*, 75:4194-4198, 1978.
- 5 Tan *et al.*, *J. Biol. Chem.*, 274:34859-67, 1999.
- Tan *et al.*, *J. Biol. Chem.*, 275:25865-25869, 2000.
- Termin, *In: Gene Transfer*, Kucherlapati (ed.), NY, Plenum Press, 149-188, 1986.
- Templeton *et al.*, *Nat. Biotechnol.*, 15(7):647-52, 1997.
- Thierry *et al.*, *Proc. Natl. Acad. Sci. USA*, 92(21):9742-6, 1995.
- 10 Thompson *et al.*, *Nat. Med.*, 1:277-278, 1995.
- Tratschin *et al.*, *Mol. Cell. Biol.*, 4:2072-2081, 1984.
- Traunecker *et al.*, *EMBO*, 10:3655-3659, 1991.
- Tsukamoto *et al.*, *Nat. Genet.*, 9:243-248, 1995.
- Tur-Kaspa *et al.*, *Mol. Cell. Biol.*, 6:716-718, 1986.
- 15 Wadsworth, *et al.*, *J. Virology*, 15:1487-1497, 1975.
- Wagner *et al.*, *Science*, 260:1510-1513, 1990.
- Wang *et al.*, *Science*, 284:339-343, 1999.
- Weinberger *et al.*, *Science*, 228:740-742, 1985.
- White *et al.*, *In: The Molecular Basis of Apoptosis in Disease*, Tomei and Cope (eds.),
- 20 Cold Spring Harbor Laboratory Press, 111-141, 1994.
- White, *Genes and Dev.*, 7:2277-2284, 1993.
- Wilson *et al.*, *Science*, 244:1344-1346, 1989.
- Wolf *et al.*, *Comput. Appl. Biosci.*, 4(1):187-191, 1988.
- Wong *et al.*, *Gene*, 10:87-94, 1980.
- 25 Wu *et al.*, *Adv. Drug Delivery Rev.*, 12:159-167, 1993.
- Wu *et al.*, *Biochemistry*, 27:887-892, 1988.
- Wu *et al.*, *J. Biol. Chem.*, 262:4429-4432, 1987.
- Wyllie *et al.*, *Int. Rev. Cytol.*, 68:251-306, 1980.
- Yang *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:9568-9572, 1990.
- 30 Yang *et al.*, *Gene Therapy*, 4 (9):950-960, 1997.

- Yin *et al.*, *Nature*, 369:321-323, 1994.
- Zelenin *et al.*, *FEBS Lett.*, 280:94-96, 1991.
- Zha *et al.*, *Cell*, 87:619-628, 1996.
- Zhou *et al.*, *J. Biol. Chem.*, 275:25046-25051, 2000.
- 5 Zhou *et al.*, *J. Virology*, 74:11782-11791, 2000.
- Zhu *et al.*, *Chin. J. Biotechnol.*, 9(4):257-261, 1993.
- Zhu *et al.*, *J. Virology*, 69:7960-7970, 1995.
- Zufferey *et al.*, *Nat. Biotechnol.*, 15(9):871-875, 1997.

WHAT IS CLAIMED IS:

1. A method for inducing apoptosis in a cell infected with herpes simplex virus (HSV) comprising administering to the cell a composition comprising an agent
5 that inhibits phosphorylation of BAD by HSV Ug3.
2. The method of claim 1, wherein the agent comprises a peptide comprising a sequence of between 4 to 100 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4, wherein the peptide comprises an amino acid that is a substrate for
10 phosphorylation.
3. The method of claim 2, wherein the amino acid is ser136, ser155, or ser112, or a combination thereof.
- 15 4. The method of claim 2, wherein the peptide comprises a sequence of at least 15 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
5. The method of claim 4, wherein the peptide comprises a sequence of at least 20 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
20
6. The method of claim 5, wherein the peptide comprises a sequence of at least 25 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
7. The method of claim 6, wherein the peptide comprises a sequence of at least 40
25 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
8. The method of claim 2, wherein the peptide comprises more than one amino acid that is a substrate for phosphorylation.

9. The method of claim 2, wherein the composition further comprises a second peptide comprising a sequence of between 4 to 100 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4, wherein the second peptide comprises an amino acid that is a substrate for phosphorylation.
- 5
10. The method of claim 9, wherein the amino acid that is a substrate for phosphorylation by HSV U_s3.
11. The method of claim 1, wherein the agent is a peptide mimetic of a peptide comprising between 4 and 100 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4, including an amino acid that is a substrate for phosphorylation.
- 10
12. The method of claim 1, wherein the agent is a peptide mimetic of a peptide comprising between 4 and 100 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4, including an amino acid analogue of a phosphorylated amino acid, wherein the amino acid analogue corresponds to one or more of ser112, ser136, or ser 152.
- 15
13. The method of claim 1, wherein the composition further comprises a lipid.
- 20
14. The method of claim 1, wherein the agent is a polypeptide that binds to an amino acid residue of BAD that is a substrate for phosphorylation, wherein the polypeptide inhibits phosphorylation of the amino acid residue, but does not inhibit the pro-apoptotic activity of BAD.
- 25
15. The method of claim 14, wherein BAD has an amino acid sequence comprising SEQ ID NO:2 or SEQ ID NO:4.
16. The method of claim 14, wherein the amino acid residue that is a substrate for phosphorylation is ser136, ser155, or ser112.
- 30

17. The method of claim 14, wherein the polypeptide is an antibody.
18. The method of claim 17, wherein the antibody is a single chain antibody.
- 5 19. The method of claim 17, wherein the antibody is a humanized antibody.
20. The method of claim 1, further comprising administering to the cell a BAD polypeptide, wherein the BAD polypeptide comprises at least 100 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4.
- 10 21. The method of claim 20, wherein the polypeptide is administered to the cell by contacting the cell with an expression construct comprising a nucleic acid sequence encoding the BAD polypeptide.
- 15 22. The method of claim 21, wherein the expression construct is a viral vector.
23. The method of claim 22, wherein the viral vector is an adenovirus, adeno-associated virus, herpesvirus, lentivirus, or retrovirus.
- 20 24. The method of claim 1, further comprising administering to the cell an antiviral agent.
- 25 25. The method of claim 24, wherein the antiviral agent is famcyclovir, valacyclovir, or acyclovir.
26. The method of claim 24, wherein the antiviral agent is administered to the patient after the composition is administered.

27. The method of claim 24, wherein the antiviral agent and the composition are administered at the same time to the patient.
28. The method of claim 1, wherein the cell is in a human.
- 5
29. A method for treating a patient infected with herpes simplex virus comprising administering to the patient an effective amount of a composition comprising a peptide comprising a sequence comprising between 4 to 100 continuous amino acids of SEQ ID NO:2 or SEQ ID NO:4, wherein the peptide comprises ser112, ser 135, or ser155, or a combination thereof.
- 10
30. A method for treating a patient infected with herpes simplex virus comprising administering to the patient an effective amount of a composition comprising at least two peptides, each peptide comprising a different sequence comprising between 4 to 100 continuous amino acids of SEQ ID NO:2 or SEQ ID NO:4, wherein the peptides comprise one, two, or three of ser112, ser135, and ser155.
- 15
31. The method of claim 30, wherein the peptides each comprise a sequence of at least 15 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
- 20
32. The method of claim 30, wherein the peptides each comprise a sequence of at least 20 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
33. The method of claim 30, wherein the peptides each comprise a sequence of at least 25 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.
- 25
34. The method of claim 30, wherein the peptides each comprise a sequence of at least 40 contiguous amino acids from SEQ ID NO:2 or SEQ ID NO:4.

35. The method of claim 30, wherein at least one peptide comprises more than one amino acid that is a substrate for phosphorylation.
36. The method of claim 35, wherein the amino acid is a substrate for phosphorylation by a HSV U_s3.
37. The method of claim 30, further comprising administering to the patient an antiviral agent.
38. The method of claim 37, wherein the antiviral agent is famcyclovir, valacyclovir, or acyclovir.
39. The method of claim 37, wherein the antiviral agent is administered to the patient after the composition is administered.
40. The method of claim 37, wherein the antiviral agent and the composition are administered at the same time to the patient.
41. The method of claim 30, wherein the composition further comprises a lipid.
42. The method of claim 29, further comprising administering to the patient an agent that inhibits the activity of a herpesvirus U_s3 protein.
43. A method for blocking BAD-induced apoptosis of a cell comprising providing to a cell suspected of undergoing BAD-induced apoptosis a U_s3 polypeptide.
44. The method of claim 43, wherein the U_s3 polypeptide is from a herpes simplex virus (HSV) type 1, HSV-2, varicella zoster virus, bovine herpesvirus 1, equine herpesvirus 1, equine herpesvirus 4, galid herpesvirus 1, galid herpesvirus 2, galid herpesvirus 3, cercopithecine herpesvirus 7, cercopithecine herpesvirus 9, simian

herpesvirus B, infectious laryngotracheitis virus, canine herpesvirus, or suid virus
1.

- 5 45. The method of claim 43, wherein providing comprises introducing into the cell a nucleic acid comprising a nucleic acid sequence encoding a U_s3 protein.
46. The method of claim 45, wherein the nucleic acid is an expression construct.
- 10 47. The method of claim 46, wherein the nucleic sequence is under the transcriptional control of a promoter active in eukaryotic cells.
48. The method of claim 47, wherein the promoter is a tetracycline controlled promoter.
- 15 49. The method of claim 46, wherein said expression vector further comprises a selectable marker.
50. A method of identifying an inhibitor of apoptosis comprising:
- 20 a) contacting a BAD peptide or polypeptide with a candidate compound; and
b) assaying the compound for the ability to inhibit the apoptotic activity of the BAD peptide or polypeptide,
- wherein the inhibition of the apoptotic activity of the BAD peptide or polypeptide identifies the compound as an inhibitor of apoptotic activity.
- 25 51. The method of claim 50, further comprising:
- c) assaying the ability of the BAD peptide or polypeptide to promote apoptosis after contacting the BAD peptide or polypeptide with the
30 candidate compound.

52. The method of claim 50, wherein the BAD peptide or polypeptide comprises at 10 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4.
- 5 53. The method of claim 50, wherein the BAD peptide or polypeptide is a BAD polypeptide.
54. The method of claim 53, wherein the BAD polypeptide comprises SEQ ID NO:2 or SEQ ID NO:4.
- 10 55. The method of claim 51, wherein the BAD peptide or polypeptide is in a cell.
56. The method of claim 50, wherein the BAD peptide or polypeptide comprises ser112, ser 135, or ser155.
- 15 57. The method of claim 50, wherein a BAD peptide is obtained and contacted with a candidate compound.
58. The method of claim 50, wherein the compound inhibits the activity of the BAD peptide or polypeptide by binding to the BAD peptide or polypeptide.
- 20 59. The method of claim 58, wherein the compound inhibits the activity of the BAD peptide or polypeptide by reducing its activity.
- 25 60. The method of claim 55, wherein the compound reduces the activity of the BAD peptide or polypeptide activity by reducing the amount of the BAD peptide or polypeptide in the cell.
61. The method of claim 50, wherein the candidate compound is a peptide.
- 30

62. The method of claim 50, wherein the candidate compound is a polypeptide.
63. The method of claim 62, wherein the polypeptide is an antibody.
- 5 64. The method of claim 50, wherein the candidate compound is a small molecule.
65. The method of claim 50, wherein the candidate compound is a peptide mimetic.
66. The method of claim 50, further comprising:
- 10 c) comparing the BAD peptide or polypeptide activity after being contacted with the candidate compound to a second BAD peptide or polypeptide not contacted with the candidate compound.
- 15 67. The method of claim 51, further comprising:
- d) incubating the BAD peptide or polypeptide with a U₃ polypeptide prior to step c).
- 20 68. The method of claim 50, wherein the BAD peptide or polypeptide is in a cell.
69. The method of claim 68, wherein assaying for inhibition of activity of the BAD peptide or polypeptide comprises assaying for an amount of the BAD peptide or polypeptide.
- 25 70. The method of claim 50, wherein assaying for inhibition of activity of the BAD peptide or polypeptide comprises assaying the BAD peptide or polypeptide for phosphorylation.

71. The method of claim 70, wherein the BAD peptide or polypeptide is assayed for phosphorylation at ser112, ser 135, or ser155.

72. A method of screening for a promoter of apoptosis comprising:

- a) incubating a BAD peptide or polypeptide with a U₃ polypeptide and a candidate compound;
- b) assaying the compound for an ability to relieve inhibition of apoptosis by the U₃ polypeptide on the BAD peptide or polypeptide,

wherein the relief of inhibition of apoptosis by the compound identifies it as a promoter of apoptosis.

73. The method of claim 72, further comprising:

- c) comparing the inhibition of apoptosis by U₃ on the BAD peptide or polypeptide in the absence of the candidate compound.

74. The method of claim 72, wherein the U₃ polypeptide comprises SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20.

75. An apoptosis modulator identified by a process comprising:

- a) contacting a BAD peptide or polypeptide with a candidate compound;
- b) assaying the compound for an ability to modulate the BAD peptide or polypeptide, wherein the compound modulates the BAD peptide or polypeptide.

76. The apoptosis modulator of claim 75, wherein the process further comprises:
- c) incubating the BAD peptide or polypeptide with a U_s3 polypeptide; and
 - d) comparing the BAD peptide or polypeptide after being contacted with the candidate compound to a second BAD peptide or polypeptide not contacted with the candidate compound.
77. The apoptosis modulator of claim 75, wherein the apoptosis modulator inhibits apoptosis.
78. A method for blocking apoptosis of a cell comprising providing to the cell a herpesvirus U_s3 polypeptide.
79. The method of claim 78, wherein the U_s3 polypeptide is from a herpes simplex virus (HSV) type 1, HSV-2, varicella zoster virus, bovine herpesvirus 1, equine herpesvirus 1, equine herpesvirus 4, galid herpesvirus 1, galid herpesvirus 2, galid herpesvirus 3, cercopithecine herpesvirus 7, cercopithecine herpesvirus 9, simian herpesvirus B, infectious laryngotracheitis virus, canine herpesvirus, or suid virus 1.
80. The method of claim 78, wherein providing comprising introducing into the cell nucleic acid comprising a nucleic acid sequence encoding the U_s3 polypeptide.
81. The method of claim 80, wherein the nucleic acid is an expression vector.
82. The method of claim 81, wherein the expression vector is a viral vector.
83. The method of claim 76, wherein the U_s3 polypeptide comprises an amino acid sequence of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ

ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or
SEQ ID NO:20.

1/4




FIG. 1

2/4




FIG.2

3/4




FIG.3

4/4




FIG.4

SEQUENCE LISTING

<110> MUNGER, JOSHUA
ROIZMAN, BERNARD

<120> METHODS AND COMPOSITION CONCERNING HERPESVIRUS US3 AND
BAD-INVOLVED APOPTOSIS

<130> ARCD:380US

<140> UNKNOWN

<141> 2002-07-31

<150> 60/308,929

<151> 2001-07-31

<160> 25

<170> PatentIn Ver. 2.1

<210> 1

<211> 945

<212> DNA

<213> Human BAD

<220>

<221> CDS

<222> (52)..(555)

<400> 1

```

gggcctaggg cgccgggtca ggggcctcga gatcgggctt gggcccagag c atg ttc 57
                                         Met Phe
                                         1

cag atc cca gag ttt gag ccg agt gag cag gaa gac tcc agc tct gca 105
Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu Asp Ser Ser Ser Ala
      5              10              15

gag agg ggc ctg ggc ccc agc ccc gca ggg gac ggg ccc tca ggc tcc 153
Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly Asp Gly Pro Ser Gly Ser
      20              25              30

ggc aag cat cat cgc cag gcc cca ggc ctc ctg tgg gac gcc agt cac 201
Gly Lys His His Arg Gln Ala Pro Gly Leu Leu Trp Asp Ala Ser His
      35              40              45              50

cag cag gag cag cca acc agc agc agc cat cat gga ggc gct ggg gct 249
Gln Gln Glu Gln Pro Thr Ser Ser Ser His His Gly Gly Ala Gly Ala
      55              60              65

gtg gag atc cgg agt cgc cac agc tcc tac ccc gcg ggg acg gag gac 297
Val Glu Ile Arg Ser Arg His Ser Ser Tyr Pro Ala Gly Thr Glu Asp
      70              75              80

```

gac gaa ggg atg ggg gag gag ccc agc ccc ttt cgg ggc cgc tcg cgc 345
 Asp Glu Gly Met Gly Glu Glu Pro Ser Pro Phe Arg Gly Arg Ser Arg
 85 90 95

tcg gcg ccc ccc aac ctc tgg gca gca cag cgc tat ggc cgc gag ctc 393
 Ser Ala Pro Pro Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu Leu
 100 105 110

cgg agg atg agt gac gag ttt gtg gac tcc ttt aag aag gga ctt cct 441
 Arg Arg Met Ser Asp Glu Phe Val Asp Ser Phe Lys Lys Gly Leu Pro
 115 120 125 130

cgc ccg aag agc gcg ggc aca gca acg cag atg cgg caa agc tcc agc 489
 Arg Pro Lys Ser Ala Gly Thr Ala Thr Gln Met Arg Gln Ser Ser Ser
 135 140 145

tgg acg cga gtc ttc cag tcc tgg tgg gat cgg aac ttg ggc agg gga 537
 Trp Thr Arg Val Phe Gln Ser Trp Trp Asp Arg Asn Leu Gly Arg Gly
 150 155 160

agc tcc gcc ccc tcc cag tgaccttcgg tccacatccc gaaatccacc 585
 Ser Ser Ala Pro Ser Gln
 165

cgttcccatt gccctgggca gccattttga atatgggagg aagtaagttc cctcaggcct 645

atgcaaaaag aggatccgtg ctgtatcctt tggagggagg gttgaccag attcccttcc 705

ggtgtgtgtg aagccacgga aggttgggtcc catcggaagt tttgggtttt ccgcccacag 765

ccgcccgaag tggctccgtg gccccgccct caggttcgg gggttcccc aggcgctgc 825

gctaagtagc gagccagggt taaccgttgt gtcaccggga cccgagcccc cgcgatgccc 885

tgggggcccgt gatcagtacc aaatgttaat aaagcccgcg tgtgtgccaa aaaaaaaaaa 945

<210> 2

<211> 168

<212> PRT

<213> Human BAD

<400> 2

Met Phe Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu Asp Ser Ser
 1 5 10 15

Ser Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly Asp Gly Pro Ser
 20 25 30

Gly Ser Gly Lys His His Arg Gln Ala Pro Gly Leu Leu Trp Asp Ala
 35 40 45

Ser His Gln Gln Glu Gln Pro Thr Ser Ser Ser His His Gly Gly Ala
 50 55 60

25184298.1

Gly Ala Val Glu Ile Arg Ser Arg His Ser Ser Tyr Pro Ala Gly Thr
 65 70 75 80
 Glu Asp Asp Glu Gly Met Gly Glu Glu Pro Ser Pro Phe Arg Gly Arg
 85 90 95
 Ser Arg Ser Ala Pro Pro Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg
 100 105 110
 Glu Leu Arg Arg Met Ser Asp Glu Phe Val Asp Ser Phe Lys Lys Gly
 115 120 125
 Leu Pro Arg Pro Lys Ser Ala Gly Thr Ala Thr Gln Met Arg Gln Ser
 130 135 140
 Ser Ser Trp Thr Arg Val Phe Gln Ser Trp Trp Asp Arg Asn Leu Gly
 145 150 155 160
 Arg Gly Ser Ser Ala Pro Ser Gln
 165

<210> 3

<211> 1454

<212> DNA

<213> Mus musculus

<400> 3

ggcacgagcg gaccccgccc cctagcttgt gtctgcaggc cccgcgtccg gcccggggca 60
 gcgtacgcac acctatcctg gcagcagagg cccctggagc cccacggctc gccttctctg 120
 gcgccccgct ccttcttccg caccggggcg gccatcctgc cgtaaaggag ctccccgaaat 180
 ggcgcggggg gttgtcccca agacggggcag tgcaaggccc tccacgatcg ggaagaagga 240
 gctggtcttc ccatcccggt cactcgggtc aggggggagca ataaccatcg caacgaccat 300
 tgcattccgac ggccgagctt cagtgaacgg ctctataagt aatcactaag ctgtttacag 360
 agttttcacc agctccccag ggaggtgtca ttaaccccat ttacaggag ggaattcggg 420
 ccagaaggcg ctggaggact tatcagccga agcaggcctc caggatccaa atgggaaccc 480
 caaagcagcc ctgctggct cctgcacacg ccctaggctt gaggaagtcc gatcccgaa 540
 tccggagcct ggggagcgac gcgggaggaa ggcggtggag accagcagcc cagagtatgt 600
 tccagatccc agagtttgag ccgagtgagc aggaagacgc tagtgctaca gataggggccc 660
 tgggccctag cctcactgag gaccagccag gtccctacct ggccccaggt ctctggggga 720
 gcaacattca tcagcaggga cgggcagcca ccaacagtca tcatggaggc gcaggggcta 780
 tggagactcg gagtcgccac agttcgtacc cagcggggac cgaggaggat gaagggatgg 840
 aggaggagct tagccctttt cgaggacgct cgcgttcggc tcccccaat ctctgggcag 900
 cgcagcgcta cggccgtgag ctccgaagga tgagcgatga gtttgagggt tccttcaagg 960
 gacttctctg cccaaagagc gcaggcactg caacacagat gcgacaaagc gccggctgga 1020
 cgcgcattat ccagtccttg tgggatcgaa acttgggcaa aggaggctcc acccctctcc 1080
 agtgatcttc tgctccacat cccggaactc taccgctcc cgtcgccgc catattgggt 1140
 gtgggcggaa gcttttcgag gccttaggaa aaaaaagag gatcgctgtg tcccttaaag 1200
 agggagaaga gctgacgtac agcttgagtc ccttccggtg cgtgcaatag ccacggaggg 1260
 gtggctctctg tttggagttt caaagttttc cagcaccacc accccctaag cctccggaag 1320
 tggctgtttt cctctctctg ttctggactg cctcgggtg cctgtgctaa gttgggggtc 1380
 tgggtgctgt cctgtcataa ctggggaccc gaggtcgcga gaaacgtgct ttataataaa 1440

25184298.1

gcctgcgcgt gtgc

1454

<210> 4

<211> 204

<212> PRT

<213> Mus musculus

<400> 4

Met Gly Thr Pro Lys Gln Pro Ser Leu Ala Pro Ala His Ala Leu Gly
 1 5 10 15

Leu Arg Lys Ser Asp Pro Gly Ile Arg Ser Leu Gly Ser Asp Ala Gly
 20 25 30

Gly Arg Arg Trp Arg Pro Ala Ala Gln Ser Met Phe Gln Ile Pro Glu
 35 40 45

Phe Glu Pro Ser Glu Gln Glu Asp Ala Ser Ala Thr Asp Arg Gly Leu
 50 55 60

Gly Pro Ser Leu Thr Glu Asp Gln Pro Gly Pro Tyr Leu Ala Pro Gly
 65 70 75 80

Leu Leu Gly Ser Asn Ile His Gln Gln Gly Arg Ala Ala Thr Asn Ser
 85 90 95

His His Gly Gly Ala Gly Ala Met Glu Thr Arg Ser Arg His Ser Ser
 100 105 110

Tyr Pro Ala Gly Thr Glu Glu Asp Glu Gly Met Glu Glu Glu Leu Ser
 115 120 125

Pro Phe Arg Gly Arg Ser Arg Ser Ala Pro Pro Asn Leu Trp Ala Ala
 130 135 140

Gln Arg Tyr Gly Arg Glu Leu Arg Arg Met Ser Asp Glu Phe Glu Gly
 145 150 155 160

Ser Phe Lys Gly Leu Pro Arg Pro Lys Ser Ala Gly Thr Ala Thr Gln
 165 170 175

Met Arg Gln Ser Ala Gly Trp Thr Arg Ile Ile Gln Ser Trp Trp Asp
 180 185 190

Arg Asn Leu Gly Lys Gly Gly Ser Thr Pro Ser Gln
 195 200

<210> 5

<211> 605

<212> DNA

<213> Herpes Simplex Virus

25184298.1

<400> 5

gatatccact gacctttgga tgggtgctaca agctagtacc agttgagcca gataaggtag 60
aagaggccaa taaaggagag aacaccagct tgttacaccc tgtgagcctg catgggatgg 120
atgacccgga gagagaagtg ttagagtgga ggtttgacag ccgcctagca ttcatcacg 180
tggcccagag gctgcatccg gactacttca agaactgctg acatcgagct tgctacaagg 240
gactttccgc tggggacttt ccagggaggc gtggcctggg cgggactggg gagtggcgag 300
ccctcagatc ctgcatataa gcagctgctt tttgcctgta ctgggtctct ctgggttagac 360
cagatttgag cctgggagct ctctggctaa ctagggaacc cactgcttaa gcctcaataa 420
agcttgccct gagtgcttca acgatcgtgt gcccgctctgt tgtgtgactc tggtaactag 480
agatccctca gaccctttta gtcagtgtgg aaaatctcta gcagtggcgc ccgaacaggg 540
acttgaaagc gaaagggaaa ccagaggagc tctctcgacg caggactcgg cttgctgaag 600
cgcgc 605.

<210> 6

<211> 481

<212> PRT

<213> Herpes Simplex Virus

<400> 6

Met Ala Cys Arg Lys Phe Cys Arg Val Tyr Gly Gly Gln Gly Arg Arg
1 5 10 15
Lys Glu Glu Ala Val Pro Pro Glu Thr Lys Pro Ser Arg Val Phe Pro
20 25 30
His Gly Pro Phe Tyr Thr Pro Ala Glu Asp Ala Cys Leu Asp Ser Pro
35 40 45
Pro Pro Glu Thr Pro Lys Pro Ser His Thr Thr Pro Pro Ser Glu Ala
50 55 60
Glu Arg Leu Cys His Leu Gln Glu Ile Leu Ala Gln Met Tyr Gly Asn
65 70 75 80
Gln Asp Tyr Pro Ile Glu Asp Asp Pro Ser Ala Asp Ala Ala Asp Asp
85 90 95
Val Asp Glu Asp Ala Pro Asp Asp Val Ala Tyr Pro Glu Glu Tyr Ala
100 105 110
Glu Glu Leu Phe Leu Pro Gly Asp Ala Thr Gly Pro Leu Ile Gly Ala
115 120 125
Asn Asp His Ile Pro Pro Pro Cys Gly Ala Ser Pro Pro Gly Ile Arg
130 135 140
Arg Arg Ser Arg Asp Glu Ile Gly Ala Thr Gly Phe Thr Ala Glu Glu
145 150 155 160
Leu Asp Ala Met Asp Arg Glu Ala Ala Arg Ala Ile Ser Arg Gly Gly
165 170 175
Lys Pro Pro Ser Thr Met Ala Lys Leu Val Thr Gly Met Gly Phe Thr

25184298.1

180	185	190
Ile His Gly Ala Leu Thr Pro Gly Ser Glu Gly Cys Val Phe Asp Ser		
195	200	205
Ser His Pro Asp Tyr Pro Gln Arg Val Ile Val Lys Ala Gly Trp Tyr		
210	215	220
Thr Ser Thr Ser His Glu Ala Arg Leu Leu Arg Arg Leu Asp His Pro		
225	230	235
Ala Ile Leu Pro Leu Leu Asp Leu His Val Val Ser Gly Val Thr Cys		
245	250	255
Leu Val Leu Pro Lys Tyr Gln Ala Asp Leu Tyr Thr Tyr Leu Ser Arg		
260	265	270
Arg Leu Asn Pro Leu Gly Arg Pro Gln Ile Ala Ala Val Ser Arg Gln		
275	280	285
Leu Leu Ser Ala Val Asp Tyr Ile His Arg Gln Gly Ile Ile His Arg		
290	295	300
Asp Ile Lys Thr Glu Asn Ile Phe Ile Asn Thr Pro Glu Asp Ile Cys		
305	310	315
Leu Gly Asp Phe Gly Ala Ala Cys Phe Val Gln Gly Ser Arg Ser Ser		
325	330	335
Pro Phe Pro Tyr Gly Ile Ala Gly Thr Ile Asp Thr Asn Ala Pro Glu		
340	345	350
Val Leu Ala Gly Asp Pro Tyr Thr Thr Thr Val Asp Ile Trp Ser Ala		
355	360	365
Gly Leu Val Ile Phe Glu Thr Ala Val His Asn Ala Ser Leu Phe Ser		
370	375	380
Ala Pro Arg Gly Pro Lys Arg Gly Pro Cys Asp Ser Gln Ile Thr Arg		
385	390	395
Ile Ile Arg Gln Ala Gln Val His Val Asp Glu Phe Ser Pro His Pro		
405	410	415
Glu Ser Arg Leu Thr Ser Arg Tyr Arg Ser Arg Ala Ala Gly Asn Asn		
420	425	430
Arg Pro Pro Tyr Thr Arg Pro Ala Trp Thr Arg Tyr Tyr Lys Met Asp		
435	440	445
Ile Asp Val Glu Tyr Leu Val Cys Lys Ala Leu Thr Phe Asp Gly Ala		
450	455	460
Leu Arg Pro Ser Ala Ala Glu Leu Leu Cys Leu Pro Leu Phe Gln Gln		

25184298.1

465

470

475

480

Lys

<210> 7

<211> 481

<212> PRT

<213> Herpes Simplex Virus

<400> 7

Met Ala Cys Arg Lys Phe Cys Gly Val Tyr Arg Arg Pro Asp Lys Arg
 1 5 10 15

Gln Glu Ala Ser Val Pro Pro Glu Thr Asn Thr Ala Pro Ala Phe Pro
 20 25 30

Ala Ser Thr Phe Tyr Thr Pro Ala Glu Asp Ala Tyr Leu Ala Pro Gly
 35 40 45

Pro Pro Glu Thr Ile His Pro Ser Arg Pro Pro Ser Pro Gly Glu Ala
 50 55 60

Ala Arg Leu Cys Gln Leu Gln Glu Ile Leu Ala Gln Met His Ser Asp
 65 70 75 80

Glu Asp Tyr Pro Ile Val Asp Ala Ala Gly Ala Glu Glu Glu Asp Glu
 85 90 95

Ala Asp Asp Asp Ala Pro Asp Asp Val Ala Tyr Pro Glu Asp Tyr Ala
 100 105 110

Glu Gly Arg Phe Leu Ser Met Val Ser Ala Ala Pro Leu Pro Gly Ala
 115 120 125

Ser Gly His Pro Pro Val Pro Gly Arg Ala Ala Pro Pro Asp Val Arg
 130 135 140

Thr Cys Asp Thr Gly Lys Val Gly Ala Thr Gly Phe Thr Pro Glu Glu
 145 150 155 160

Leu Asp Thr Met Asp Arg Glu Ala Leu Arg Ala Ile Ser Arg Gly Cys
 165 170 175

Lys Pro Pro Ser Thr Leu Ala Lys Leu Val Thr Gly Leu Gly Phe Ala
 180 185 190

Ile His Gly Ala Leu Ile Pro Gly Ser Glu Gly Cys Val Phe Asp Ser
 195 200 205

Ser His Pro Asn Tyr Pro His Arg Val Ile Val Lys Ala Gly Trp Tyr
 210 215 220

Ala Ser Thr Ser His Glu Ala Arg Leu Leu Arg Arg Leu Asn His Pro
 225 230 235 240
 Ala Ile Leu Pro Leu Leu Asp Leu His Val Val Ser Gly Val Thr Cys
 245 250 255
 Leu Val Leu Pro Lys Tyr His Cys Asp Leu Tyr Thr Tyr Leu Ser Lys
 260 265 270
 Arg Pro Ser Pro Leu Gly His Leu Gln Ile Thr Ala Val Ser Arg Gln
 275 280 285
 Leu Leu Ser Ala Ile Asp Tyr Val His Cys Lys Gly Ile Ile His Arg
 290 295 300
 Asp Ile Lys Thr Glu Asn Ile Phe Ile Asn Thr Pro Glu Asn Ile Cys
 305 310 315 320
 Leu Gly Asp Phe Gly Ala Ala Cys Phe Val Arg Gly Cys Arg Ser Ser
 325 330 335
 Pro Phe His Tyr Gly Ile Ala Gly Thr Ile Asp Thr Asn Ala Pro Glu
 340 345 350
 Val Leu Ala Gly Asp Pro Tyr Thr Gln Val Ile Asp Ile Trp Ser Ala
 355 360 365
 Gly Leu Val Ile Phe Glu Thr Ala Val His Thr Ala Ser Leu Phe Ser
 370 375 380
 Ala Pro Arg Asp Pro Glu Arg Arg Pro Cys Asp Asn Gln Ile Ala Arg
 385 390 395 400
 Ile Ile Arg Gln Ala Gln Val His Val Asp Glu Phe Pro Thr His Ala
 405 410 415
 Glu Ser Arg Leu Thr Ala His Tyr Arg Ser Arg Ala Ala Gly Asn Asn
 420 425 430
 Arg Pro Ala Trp Thr Arg Pro Ala Trp Thr Arg Tyr Tyr Lys Ile His
 435 440 445
 Thr Asp Val Glu Tyr Leu Ile Cys Lys Ala Leu Thr Phe Asp Ala Ala
 450 455 460
 Leu Arg Pro Ser Ala Ala Glu Leu Leu Arg Leu Pro Leu Phe His Pro
 465 470 475 480

Lys

<210> 8
 <211> 393
 25184298.1

<212> PRT

<213> Herpes Simplex Virus

<400> 8

```

Met Asn Asp Val Asp Ala Thr Asp Thr Phe Val Gly Gln Gly Lys Phe
 1           5           10           15

Arg Gly Ala Ile Ser Thr Ser Pro Ser His Ile Met Gln Thr Cys Gly
          20           25           30

Phe Ile Gln Gln Met Phe Pro Val Glu Met Ser Pro Gly Ile Glu Ser
          35           40           45

Glu Asp Asp Pro Asn Tyr Asp Val Asn Met Asp Ile Gln Ser Phe Asn
 50           55           60

Ile Phe Asp Gly Val His Glu Thr Glu Ala Glu Ala Ser Val Ala Leu
 65           70           75           80

Cys Ala Glu Ala Arg Val Gly Ile Asn Lys Ala Gly Phe Val Ile Leu
          85           90           95

Lys Thr Phe Thr Pro Gly Ala Glu Gly Phe Ala Phe Ala Cys Met Asp
          100          105          110

Ser Lys Thr Cys Glu His Val Val Ile Lys Ala Gly Gln Arg Gln Gly
          115          120          125

Thr Ala Thr Glu Ala Thr Val Leu Arg Ala Leu Thr His Pro Ser Val
          130          135          140

Val Gln Leu Lys Gly Thr Phe Thr Tyr Asn Lys Met Thr Cys Leu Ile
          145          150          155          160

Leu Pro Arg Tyr Arg Thr Asp Leu Tyr Cys Tyr Leu Ala Ala Lys Arg
          165          170          175

Asn Leu Pro Ile Cys Asp Ile Leu Ala Ile Gln Arg Ser Val Leu Arg
          180          185          190

Ala Leu Gln Tyr Leu His Asn Asn Ser Ile Ile His Arg Asp Ile Lys
          195          200          205

Ser Glu Asn Ile Phe Ile Asn His Pro Gly Asp Val Cys Val Gly Asp
          210          215          220

Phe Gly Ala Ala Cys Phe Pro Val Asp Ile Asn Ala Asn Arg Tyr Tyr
          225          230          235          240

Gly Trp Ala Gly Thr Ile Ala Thr Asn Ser Pro Glu Leu Leu Ala Arg
          245          250          255

Asp Pro Tyr Gly Pro Ala Val Asp Ile Trp Ser Ala Gly Ile Val Leu
          260          265          270

```

25184298.1

Phe Glu Met Ala Thr Gly Gln Asn Ser Leu Phe Glu Arg Asp Gly Leu
 275 280 285
 Asp Gly Asn Cys Asp Ser Glu Arg Gln Ile Lys Leu Ile Ile Arg Arg
 290 295 300
 Ser Gly Thr His Pro Asn Glu Phe Pro Ile Asn Pro Thr Ser Asn Leu
 305 310 315 320
 Arg Arg Gln Tyr Ile Gly Leu Ala Lys Arg Ser Ser Arg Lys Pro Gly
 325 330 335
 Ser Arg Pro Leu Trp Thr Asn Leu Tyr Glu Leu Pro Ile Asp Leu Glu
 340 345 350
 Tyr Leu Ile Cys Lys Met Leu Ser Phe Asp Ala Arg His Arg Pro Ser
 355 360 365
 Ala Glu Val Leu Leu Asn His Ser Val Phe Gln Thr Leu Pro Asp Pro
 370 375 380
 Tyr Pro Asn Pro Met Glu Val Gly Asp
 385 390

<210> 9
 <211> 468
 <212> PRT
 <213> Bovine herpesvirus 1

<400> 9
 Met Glu Arg Ala Ala Glu Arg Leu Ala Arg Gln Arg Ala Arg Gly Leu
 1 5 10 15
 Trp Arg Ser Arg Phe Ala Cys Cys Val Ala Ala Glu Pro Ser Gly Glu
 20 25 30
 Pro Ala Arg Pro Glu Arg Ser Arg Ser Arg Cys Gly Ser Ala Arg Cys
 35 40 45
 Ala Ala Ala Gly Ser Ala Asp Leu Tyr Leu Ala Val Asn Asn Glu Gly
 50 55 60
 Pro Glu Val Ala Pro Pro Ala Arg Thr Gly Pro Pro Asp Ala Asp Gly
 65 70 75 80
 Ile Glu Gly Gly Ala Ala Val Gly Asn Glu Gln Gly Gly Val Ala Ala
 85 90 95
 Gly Asn Glu Arg Arg Ala Ala Ile Gly Asp Lys Lys Lys Ser Ala Ser
 100 105 110
 Gly Gly Glu Asn Glu Ser Glu Ser Glu Ser Glu Ser Glu Ser
 25184298.1

115	120	125
Gly Ser Glu Ser Gly Ala Asp Asp Gly Asp Trp Asp Asp Asp Asp Asp		
130	135	140
Ala Gly Pro Ala Gly Gly Val Thr Arg Glu Glu Ala Glu Gly Ala Ala		
145	150	155
Arg Ala Leu Asn Phe Arg Ile Ile Arg Arg Leu Thr Pro Gly Ser Glu		
165	170	175
Gly Arg Val Phe Glu Ala Thr Gly Pro Ala Pro Ala Gln Glu His Val		
180	185	190
Val Leu Lys Ile Gly Ala Ser Ala Ser Thr Leu Ala Glu Ala Met Leu		
195	200	205
Leu Arg Thr Leu Asp His Ala Asn Val Val Lys Leu Lys Ala Val Leu		
210	215	220
Phe His Gly Glu Leu Val Cys Val Val Leu Ala Arg Tyr Arg Glu Asp		
225	230	235
Leu His Thr His Leu Trp Arg Ile Asn Arg Pro Leu Ala Leu Pro Ala		
245	250	255
Ala Leu Ala Val Thr Arg Ala Val Leu Arg Gly Leu Ala Tyr Leu His		
260	265	270
Ser Arg Arg Ile Ala His Arg Asp Val Lys Thr Glu Asn Val Phe Leu		
275	280	285
Asn Gly Pro Gly Asp Val Cys Leu Gly Asp Phe Gly Ala Ala His Gly		
290	295	300
Pro Val Thr Glu Pro Arg Tyr Tyr Gly Leu Ala Gly Thr Leu Glu Thr		
305	310	315
Asn Ser Pro Glu Leu Leu Ala Arg Ala Arg Tyr Asp Cys Arg Thr Asp		
325	330	335
Val Trp Ser Ala Gly Val Val Ala Tyr Glu Met Leu Ala Tyr Pro Arg		
340	345	350
Ala Leu Phe Asp Ser Pro Ala Gly Pro Gln Gly Glu Asp Ala Glu Ala		
355	360	365
Ser Gly Pro Pro Thr Ile Leu Gly Asp Arg Asp Cys Ala Arg Gln Leu		
370	375	380
Leu Arg Val Ile Arg Arg Leu Ala Val His Ala Glu Glu Phe Pro Pro		
385	390	395
Ser Pro Thr Asp Arg Leu Thr Arg Asn Phe Lys Arg His Ala Ser Thr		
25184298.1		

405 410 415
 Arg Arg Glu Pro His Ser Pro Tyr Arg Cys Leu Ala Val Leu Arg Leu
 420 425 430
 Pro Cys Asp Ala Asp Arg Leu Leu His Gln Met Leu Thr Phe Asp Phe
 435 440 445
 Arg Ala Arg Pro Thr Ala Ala Glu Leu Leu Glu His Pro Val Phe Gly
 450 455 460
 Ala Ala Ser Gly
 465

 <210> 10
 <211> 382
 <212> PRT
 <213> Equine herpesvirus 1

 <400> 10
 Met Glu Asn Lys Gln Cys Asp His Leu Thr Asp Trp Phe Ser Thr Thr
 1 5 10 15
 Ser Asp Ala Ser Glu Ser Met Asp Thr Thr Pro Pro Leu Pro Pro Pro
 20 25 30
 Thr Pro Ser Val Asp Pro Ser Tyr Ser Gly Ala Ala Ala Asp Glu Asp
 35 40 45
 Leu Tyr Ser Asp Ile Ser Glu Gly Asp Leu Glu Tyr Ser Asp Cys Asp
 50 55 60
 Ser Ala Ser Glu Ser Asp Glu Asp Asp Asp Asp Cys Leu Ile Pro Ser
 65 70 75 80
 Lys Glu Lys Ala Arg Glu Val Ala Ala Ser Phe Gly Tyr Thr Val Ile
 85 90 95
 Lys Thr Leu Thr Pro Gly Ser Glu Gly Arg Val Met Val Ala Thr Lys
 100 105 110
 Asp Gly Gln Pro Glu Pro Val Val Leu Lys Ile Gly Gln Lys Gly Thr
 115 120 125
 Thr Leu Ile Glu Ala Met Met Leu Arg Asn Val Asn His Pro Ser Val
 130 135 140
 Ile Gln Met Lys Asp Thr Leu Val Ser Gly Ala Ile Thr Cys Met Val
 145 150 155 160
 Leu Pro His Tyr Ser Ser Asp Leu Tyr Thr Phe Leu Thr Lys Glu Ser
 165 170 175

Arg Arg Ile Pro Ile Asp Gln Ala Leu Ile Ile Glu Lys Gln Ile Leu
 180 185 190
 Glu Gly Leu Arg Tyr Leu His Ala Gln Arg Ile Ile His Arg Asp Val
 195 200 205
 Lys Thr Glu Asn Ile Phe Ile Asn Ser Val Asp Gln Val Cys Ile Ala
 210 215 220
 Asp Phe Gly Ala Ala Gln Phe Pro Val Val Glu Pro Ala Asp Leu Gly
 225 230 235 240
 Leu Ala Gly Thr Val Glu Thr Asn Ala Pro Glu Val Leu Ala Arg Ala
 245 250 255
 Lys Tyr Asn Ser Lys Ala Asp Ile Trp Ser Ala Gly Ile Val Leu Phe
 260 265 270
 Glu Met Leu Ala Tyr Pro Ser Thr Leu Phe Glu Asp Pro Pro Ser Thr
 275 280 285
 Pro Glu Glu Tyr Val Lys Ser Cys His Ser Gln Leu Leu Lys Ile Ile
 290 295 300
 Ser Thr Leu Lys Ile Asn Pro Glu Glu Phe Pro Arg Asp Pro Gly Ser
 305 310 315 320
 Arg Leu Val Arg Gly Tyr Ile Glu Tyr Ser Arg Leu Glu Arg Lys Pro
 325 330 335
 Tyr Thr Arg Tyr Pro Cys Phe Gln Arg Val Asn Leu His Ile Asp Gly
 340 345 350
 Glu Phe Leu Val His Lys Met Leu Ala Phe Asn Ala Ala Met Arg Pro
 355 360 365
 Ser Ala Glu Glu Leu Leu Ser Tyr Pro Met Phe Ala Gln Leu
 370 375 380

<210> 11

<211> 384

<212> PRT

<213> Equine herpesvirus 4

<400> 11

Met Glu Asn Lys Gln Tyr Asp His Leu Leu Ser Asp Trp Leu Ser Gly
 1 5 10 15

Asn Ile Ser Glu Ala Ser Glu Ser Met Asp Thr Thr Pro Pro Leu Gln
 20 25 30

Leu Ser Val His Pro Gln Asn Pro Ser Cys Gly Gly Ala Ala Ala Asn
 35 40 45

25184298.1

Glu Asp Leu Tyr Ser Asp Ile Ser Asp Gly Asp Leu Glu Cys Ser Asp
 50 55 60
 Cys Asp Ser Ala Ser Glu Ser Asp Glu Asp Asp Asp Gly Leu Met
 65 70 75 80
 Pro Pro Lys Glu Lys Ala Lys Glu Val Ala Ala Ser Phe Gly Phe Lys
 85 90 95
 Val Ile Lys Thr Leu Thr Pro Gly Ser Glu Gly Arg Val Met Val Ala
 100 105 110
 Thr Lys Glu Gly Gln Pro Asp Gln Val Val Leu Lys Ile Gly Gln Lys
 115 120 125
 Gly Thr Thr Leu Ile Glu Ala Met Met Leu Arg Asn Val Asn His Pro
 130 135 140
 Cys Val Ile Lys Met Lys Asp Thr Leu Val Ser Gly Gly Ile Thr Cys
 145 150 155 160
 Met Val Leu Pro His Tyr Asn Ser Asp Leu Tyr Thr Phe Leu Thr Arg
 165 170 175
 Arg Ser Thr Arg Ile Pro Ile Asp Gln Ala Leu Ile Ile Glu Arg Gln
 180 185 190
 Ile Leu Glu Gly Leu Arg Tyr Leu His Ala Gln Arg Ile Ile His Arg
 195 200 205
 Asp Val Lys Thr Glu Asn Ile Phe Ile Asn Ser Val Asp Gln Val Cys
 210 215 220
 Ile Ala Asp Phe Gly Ala Ala Gln Phe Pro Val Val Asp Pro Met Asp
 225 230 235 240
 Leu Gly Leu Ala Gly Thr Val Glu Thr Asn Ala Pro Glu Val Leu Ala
 245 250 255
 Arg Ala Lys Tyr Asn Ser Lys Val Asp Ile Trp Ser Ala Gly Ile Val
 260 265 270
 Leu Phe Glu Met Leu Ala Tyr Pro Ser Thr Leu Phe Glu Asp Pro Pro
 275 280 285
 Ser Thr Pro Gln Glu Tyr Val Lys Ser Cys His Ser Gln Leu Leu Arg
 290 295 300
 Ile Ile Ser Lys Leu Lys Ile Asn Pro Glu Glu Phe Pro Arg Glu Pro
 305 310 315 320
 Glu Ser Arg Leu Val Arg Gly Tyr Ile Glu Tyr Ala Ser Leu Glu Arg
 325 330 335

Lys Pro His Thr Arg Tyr Pro Cys Phe Gln Arg Val Asn Leu His Ile
 340 345 350

Asp Gly Glu Phe Leu Ile His Lys Met Leu Ala Phe Asn Ala Ala Met
 355 360 365

Arg Pro Ser Ala Glu Glu Leu Leu Ser Tyr Pro Met Phe Met Asn Leu
 370 375 380

<210> 12
 <211> 402
 <212> PRT
 <213> Gallid herpesvirus 1

<400> 12
 Met Ser Ser Ser Pro Glu Ala Glu Thr Met Glu Cys Gly Ile Ser Ser
 1 5 10 15

Ser Lys Val His Asp Ser Lys Thr Asn Thr Thr Tyr Gly Ile Ile His
 20 25 30

Asn Ser Ile Asn Gly Thr Asp Thr Thr Leu Phe Asp Thr Phe Pro Asp
 35 40 45

Ser Thr Asp Asn Ala Glu Val Thr Gly Asp Val Asp Asp Val Lys Thr
 50 55 60

Glu Ser Ser Pro Glu Ser Gln Ser Glu Asp Leu Ser Pro Phe Gly Asn
 65 70 75 80

Asp Gly Asn Glu Ser Pro Glu Thr Val Thr Asp Ile Asp Ala Val Ser
 85 90 95

Ala Val Arg Met Gln Tyr Asn Ile Val Ser Ser Leu Ser Pro Gly Ser
 100 105 110

Glu Gly Tyr Ile Tyr Val Cys Thr Lys Arg Gly Asp Asn Thr Lys Arg
 115 120 125

Lys Val Ile Val Lys Ala Val Thr Gly Asp Lys Thr Leu Gly Ser Glu
 130 135 140

Ile Asp Ile Leu Lys Lys Met Ser His Arg Ser Ile Ile Arg Leu Val
 145 150 155 160

His Ala Tyr Arg Trp Lys Ser Thr Val Cys Met Val Met Pro Lys Tyr
 165 170 175

Lys Cys Asp Leu Phe Thr Tyr Ile Asp Ile Met Gly Pro Leu Pro Leu
 25184298.1

His Met

Met Ser Ser Ser Pro Glu Ala Glu Thr Met Glu Cys Gly Ile Ser Ser
1 5 10 15

Ser Lys Val His Asp Ser Lys Thr Asn Thr Thr Tyr Gly Ile Ile His
 20 25 30
 Asn Ser Ile Asn Gly Thr Asp Thr Thr Leu Phe Asp Thr Phe Pro Asp
 35 40 45
 Ser Thr Asp Asn Ala Glu Val Thr Gly Asp Val Asp Asp Val Lys Thr
 50 55 60
 Glu Ser Ser Pro Glu Ser Gln Ser Glu Asp Leu Ser Pro Phe Gly Asn
 65 70 75 80
 Asp Gly Asn Glu Ser Pro Glu Thr Val Thr Asp Ile Asp Ala Val Ser
 85 90 95
 Ala Val Arg Met Gln Tyr Asn Ile Val Ser Ser Leu Ser Pro Gly Ser
 100 105 110
 Glu Gly Tyr Ile Tyr Val Cys Thr Lys Arg Gly Asp Asn Thr Lys Arg
 115 120 125
 Lys Val Ile Val Lys Ala Val Thr Gly Gly Lys Thr Leu Gly Ser Glu
 130 135 140
 Ile Asp Ile Leu Lys Lys Met Ser His Arg Ser Ile Ile Arg Leu Val
 145 150 155 160
 His Ala Tyr Arg Trp Lys Ser Thr Val Cys Met Val Met Pro Lys Tyr
 165 170 175
 Lys Cys Asp Leu Phe Thr Tyr Ile Asp Ile Met Gly Pro Leu Pro Leu
 180 185 190
 Asn Gln Ile Ile Thr Ile Glu Arg Gly Leu Leu Gly Ala Leu Ala Tyr
 195 200 205
 Ile His Glu Lys Gly Ile Ile His Arg Asp Val Lys Thr Glu Asn Ile
 210 215 220
 Phe Leu Asp Lys Pro Glu Asn Val Val Leu Gly Asp Phe Gly Ala Ala
 225 230 235 240
 Cys Lys Leu Asp Glu His Thr Asp Lys Pro Lys Cys Tyr Gly Trp Ser
 245 250 255
 Gly Thr Leu Glu Thr Asn Ser Pro Glu Leu Leu Ala Leu Asp Pro Tyr
 260 265 270
 Cys Thr Lys Thr Asp Ile Trp Ser Ala Gly Leu Val Leu Phe Glu Met
 275 280 285
 Ser Val Lys Asn Ile Thr Phe Phe Gly Lys Gln Val Asn Gly Ser Gly
 290 295 300

Ser Gln Leu Arg Ser Ile Ile Arg Cys Leu Gln Val His Pro Leu Glu
305 310 315 320

Phe Pro Gln Asn Asn Ser Thr Asn Leu Cys Lys His Phe Lys Gln Tyr
325 330 335

Ala Ile Gln Leu Arg His Pro Tyr Ala Ile Pro Gln Ile Ile Arg Lys
340 345 350

Ser Gly Met Thr Met Asp Leu Glu Tyr Ala Ile Ala Lys Met Leu Thr
355 360 365

Phe Asp Gln Glu Phe Arg Pro Ser Ala Gln Asp Ile Leu Met Leu Pro
370 375 380

Leu Phe Thr Lys Glu Pro Ala Asp Ala Leu Tyr Thr Ile Thr Ala Ala
385 390 395 400

His Met

<210> 14

<211> 391

<212> PRT

<213> Gallid herpesvirus 3

<400> 14

Met Glu Thr Asn Glu Leu Ser Ser Lys Val Ser Asp Tyr Asn Ala Asn
1 5 10 15

Arg Pro Tyr Glu Thr Ile Arg Ser Asp Thr Ser Asp Thr Asp Pro Ser
20 25 30

Val Ser Cys Gly Thr Leu Ser Asp Lys Asp Gly Asp Asp Glu Glu Ser
35 40 45

Ile Asp Leu Ser Lys Val Pro Asn Ala Thr Asn Val Gly Ala Gly Glu
50 55 60

Asp Cys Thr Ser Pro Asn Asp Gly Arg Thr Glu Leu Cys Arg Thr Thr
65 70 75 80

Ser Val Thr Gly Pro Ala Ser Val Val Arg Met Gln Tyr Asn Ile Ile
85 90 95

Ser Pro Leu Pro Pro Ser Ser Glu Gly Arg Val Phe Val Cys Thr Arg
100 105 110

Trp Asp Asp Val Ser Asn Lys Lys Val Ile Val Lys Val Val Thr Gly
115 120 125

Gly Arg Asp Pro Gly Arg Glu Ile Glu Ile Val Lys Thr Leu Ser His
130 135 140

25184298.1

Cys Ala Ile Ile Gln Leu Ile His Ala Tyr Ser Trp Lys Ser Thr Val
 145 150 155 160
 Cys Met Val Met Arg Lys Tyr Lys Cys Asp Leu Phe Thr Tyr Val Asp
 165 170 175
 Arg Lys Glu Ser Ile Pro Leu Lys Asp Val Ile Val Ile Glu Arg Arg
 180 185 190
 Leu Leu Glu Ala Leu Val Tyr Leu His Gly Lys Gly Val Ile His Arg
 195 200 205
 Asp Val Lys Thr Glu Asn Ile Phe Leu Asp Tyr Pro Gly Asn Ala Val
 210 215 220
 Leu Gly Asp Phe Gly Ala Ala Cys Lys Leu Asp Met His Asp Asn Ser
 225 230 235 240
 Pro Lys Cys Tyr Gly Trp Ala Gly Thr Met Glu Thr Asn Ser Pro Glu
 245 250 255
 Leu Leu Ala Leu Asp Pro Tyr Cys Ala Lys Thr Asp Ile Trp Ser Ala
 260 265 270
 Gly Leu Val Leu Phe Glu Met Ser Ala Lys Lys Arg Thr Leu Phe Gly
 275 280 285
 Lys Gln Val Lys Thr Ser Ser Ser Gln Leu Arg Ala Leu Ile Arg Cys
 290 295 300
 Leu Gln Ile His Ala Leu Glu Phe Pro Gln Asp Glu Ser Thr Thr Leu
 305 310 315 320
 Cys Lys Gln Phe Lys Gln Tyr Ala Ile Pro Leu Arg Pro Pro Phe Ser
 325 330 335
 Ile Pro Glu Val Val Arg Arg Asn Ile Pro Ser Met Asp Val Glu Tyr
 340 345 350
 Thr Ile Ala Lys Met Leu Thr Phe Asp Gln Glu Phe Arg Pro Ser Ala
 355 360 365
 Gln Asp Ile Leu Ala Phe Pro Leu Phe Val Lys Glu Ala Pro Gln Asn
 370 375 380
 Leu Gln Ala Leu Phe Val Pro
 385 390

<210> 15

<211> 345

<212> PRT

<213> Cercopithecine herpesvirus 7

25184298.1

<400> 15

Met Asn Tyr Asp Asp Asp Cys Leu Tyr Glu Asp Lys His Met Asp Thr
 1 5 10 15

Asp Ile Tyr Asp Met Leu Ala Asp Glu Asp Thr Ser Asp Val Asp Asn
 20 25 30

Thr Leu Ala Val Cys Ala Thr Ala Arg Ala Gly Ile Glu Lys Ala Gly
 35 40 45

Phe Ser Val Leu Glu Thr Phe Thr Pro Gly Ala Glu Gly Phe Thr Phe
 50 55 60

Ala Cys Ile Glu Asn Lys Thr Arg Glu Asn Val Val Ile Lys Ala Gly
 65 70 75 80

Gln Arg Gly Gly Thr Val Thr Glu Ala His Ile Leu Arg Asn Ile Asn
 85 90 95

His Pro Val Ile Ile Arg Leu Met Gly Thr Phe Thr Tyr Asn Ser Phe
 100 105 110

Thr Cys Leu Val Leu Pro Arg Tyr Lys Thr Asp Leu Tyr Cys Tyr Leu
 115 120 125

Ser Asp Arg Arg Arg Ile Ala Ile Cys Asp Met Leu Ser Ile Glu Arg
 130 135 140

Ser Val Leu Arg Ala Ile Gln Tyr Leu His Glu Asn Arg Ile Ile His
 145 150 155 160

Arg Asp Val Lys Ala Glu Asn Ile Phe Ile Asn His Pro Gly Asp Val
 165 170 175

Cys Leu Gly Asp Phe Gly Ala Ala Cys Tyr Pro Val Asp Ile Thr Gln
 180 185 190

Asn Lys Tyr Tyr Gly Trp Ala Gly Thr Ile Ala Thr Asn Ala Pro Glu
 195 200 205

Leu Leu Ala Arg Asp Pro Tyr Gly Pro Ala Val Asp Ile Trp Ser Ala
 210 215 220

Gly Ile Val Leu Phe Glu Met Ala Thr Cys His Asp Ser Leu Phe Glu
 225 230 235 240

Lys Asp Gly Leu Asp Gly Asp Cys Asp Ser Asp Arg Gln Ile Lys Leu
 245 250 255

Ile Ile Arg Arg Thr Gly Val His Pro Ser Glu Phe Pro Ile Asp Ala
 260 265 270

Gln Ala Thr Leu Asp Glu Ile Tyr Arg Thr Cys Gln Lys Thr Ser Arg
 25184298.1

275 280 285
 Lys Pro Gly Thr Arg Pro Thr Trp Thr Asn Leu Tyr Glu Leu Pro Leu
 290 295 300
 Glu Leu Glu Tyr Leu Ile Cys Lys Met Leu Ala Phe Asp Ala His Lys
 305 310 315 320
 Arg Pro Ser Ala Lys Ala Leu Leu Asp Phe Ala Ala Phe Tyr Asp Ile
 325 330 335
 Pro Asp Pro Tyr Pro Asn Pro Thr Asn
 340 345
 <210> 16
 <211> 345
 <212> PRT
 <213> Cercopithecine herpesvirus 9
 <400> 16
 Met Asn Tyr Asp Asp Asp Cys Leu Tyr Glu Asp Lys His Met Asp Thr
 1 5 10 15
 Asp Ile Tyr Asp Met Leu Ala Asp Glu Asp Thr Ser Asp Val Asp Asn
 20 25 30
 Thr Leu Ala Val Cys Ala Thr Ala Arg Ala Gly Ile Glu Lys Ala Gly
 35 40 45
 Phe Ser Val Leu Glu Thr Phe Thr Pro Gly Ala Glu Gly Phe Thr Phe
 50 55 60
 Ala Cys Ile Glu Asn Lys Thr Arg Glu Asn Val Val Ile Lys Ala Gly
 65 70 75 80
 Gln Arg Gly Gly Thr Val Thr Glu Ala His Ile Leu Arg Asn Ile Asn
 85 90 95
 His Pro Val Ile Ile Arg Leu Met Gly Thr Phe Thr Tyr Asn Ser Phe
 100 105 110
 Thr Cys Leu Val Leu Pro Arg Tyr Lys Thr Asp Leu Tyr Cys Tyr Leu
 115 120 125
 Ser Asp Arg Arg Arg Ile Ala Ile Cys Asp Met Leu Ser Ile Glu Arg
 130 135 140
 Ser Val Leu Arg Ala Ile Gln Tyr Leu His Glu Asn Arg Ile Ile His
 145 150 155 160
 Arg Asp Val Lys Ala Glu Asn Ile Phe Ile Asn His Pro Gly Asp Val
 165 170 175

Cys Leu Gly Asp Phe Gly Ala Ala Cys Tyr Pro Val Asp Ile Thr Gln
 180 185 190
 Asn Lys Tyr Tyr Gly Trp Ala Gly Thr Ile Ala Thr Asn Ala Pro Glu
 195 200 205
 Leu Leu Ala Arg Asp Pro Tyr Gly Pro Ala Val Asp Ile Trp Ser Ala
 210 215 220
 Gly Ile Val Leu Phe Glu Met Ala Thr Cys His Asp Ser Leu Phe Glu
 225 230 235 240
 Lys Asp Gly Leu Asp Gly Asp Cys Asp Ser Asp Arg Gln Ile Lys Leu
 245 250 255
 Ile Ile Arg Arg Thr Gly Val His Pro Ser Glu Phe Pro Ile Asp Ala
 260 265 270
 Gln Ala Thr Leu Asp Glu Ile Tyr Arg Thr Cys Gln Lys Thr Ser Arg
 275 280 285
 Lys Pro Gly Thr Arg Pro Thr Trp Thr Asn Leu Tyr Glu Leu Pro Leu
 290 295 300
 Glu Leu Glu Tyr Leu Ile Cys Lys Met Leu Ala Phe Asp Ala His Lys
 305 310 315 320
 Arg Pro Ser Ala Lys Ala Leu Leu Asp Phe Ala Ala Phe Tyr Asp Ile
 325 330 335
 Pro Asp Pro Tyr Pro Asn Pro Thr Asn
 340 345

<210> 17

<211> 147

<212> PRT

<213> Simian Herpes B

<400> 17

Val Asp Pro Ala His Tyr Gly Ile Ala Gly Thr Val Asp Thr Asn Ala
 1 5 10 15
 Pro Glu Val Leu Ala Gly Asp Pro Tyr Thr Pro Ser Val Asp Ile Trp
 20 25 30
 Ser Ala Gly Leu Val Ile Phe Glu Ala Ala Val His Thr Ala Ser Leu
 35 40 45
 Phe Ser Val Ser Arg Thr Asp Glu Gln Arg Pro Tyr Asp Ala Gln Ile
 50 55 60
 Leu Arg Ile Ile Gln Gln Ala Gln Val His Val Asp Glu Phe Pro Gln
 65 70 75 80

25184298.1

Arg Ala Gly Ser Arg Leu Val Ser Gln Tyr Arg His Arg Ala Ala Arg
 85 90 95

Asn Arg Arg Pro Pro His Thr Arg Pro Ala Trp Thr Arg Tyr Tyr Lys
 100 105 110

Leu Asp Leu Asp Val Glu Tyr Leu Val Cys Arg Ala Leu Thr Phe Asp
 115 120 125

Gly Ala Arg Arg Pro Ser Ala Ala Glu Leu Leu Arg Leu Pro Leu Phe
 130 135 140

Gln Ser Ser
 145

<210> 18
 <211> 402
 <212> PRT
 <213> Infectious Laryngotracheitis Virus

<400> 18
 Met Ser Ser Thr Pro Glu Ala Glu Thr Met Glu Cys Gly Ile Ser Ser
 1 5 10 15

Ser Lys Val His Asp Ser Lys Thr Asn Thr Thr Tyr Gly Ile Ile His
 20 25 30

Asn Ser Ile Asn Gly Thr Asp Thr Thr Leu Phe Asp Thr Phe Pro Asp
 35 40 45

Ser Thr Asp Asn Ala Glu Val Thr Gly Asp Val Asp Asp Val Lys Thr
 50 55 60

Glu Ser Ser Pro Glu Ser Gln Ser Glu Asp Leu Ser Pro Phe Gly Asn
 65 70 75 80

Asp Gly Asn Glu Ser Pro Glu Thr Val Thr Asp Ile Asp Ala Val Ser
 85 90 95

Ala Val Arg Met Gln Tyr Asn Ile Val Ser Ser Leu Pro Pro Gly Ser
 100 105 110

Glu Gly Tyr Ile Tyr Val Cys Thr Lys Arg Gly Asp Asn Thr Lys Arg
 115 120 125

Lys Val Ile Val Lys Ala Val Thr Gly Gly Lys Thr Leu Gly Ser Glu
 130 135 140

Ile Asp Ile Leu Lys Lys Met Ser His Arg Ser Ile Ile Arg Leu Val
 145 150 155 160

His Ala Tyr Arg Trp Lys Ser Thr Val Cys Met Val Met Pro Lys Tyr
 25184298.1

165 170 175
 Lys Cys Asp Leu Phe Thr Tyr Ile Asp Ile Met Gly Pro Leu Pro Leu
 180 185 190
 Asn Gln Ile Ile Thr Ile Glu Arg Gly Leu Leu Gly Ala Leu Ala Tyr
 195 200 205
 Ile His Glu Lys Gly Ile Ile His Arg Asp Val Lys Thr Glu Asn Ile
 210 215 220
 Phe Leu Asp Lys Pro Glu Asn Val Val Leu Gly Asp Phe Gly Ala Ala
 225 230 235 240
 Cys Lys Leu Asp Glu His Thr Asp Lys Pro Lys Cys Tyr Gly Trp Ser
 245 250 255
 Gly Thr Leu Glu Thr Asn Ser Pro Glu Leu Leu Ala Leu Asp Pro Tyr
 260 265 270
 Cys Thr Lys Thr Asp Ile Trp Ser Ala Gly Leu Val Leu Phe Glu Met
 275 280 285
 Ser Val Lys Asn Ile Thr Phe Phe Gly Lys Gln Val Asn Gly Ser Gly
 290 295 300
 Ser Gln Leu Arg Ser Ile Ile Arg Cys Leu Gln Val His Pro Leu Glu
 305 310 315 320
 Phe Pro Gln Asn Asn Ser Thr Asn Leu Cys Lys His Phe Lys Gln Tyr
 325 330 335
 Ala Ile Gln Leu Arg His Pro Tyr Ala Ile Pro Gln Ile Ile Arg Lys
 340 345 350
 Ser Gly Met Thr Met Asp Leu Glu Tyr Ala Ile Ala Lys Met Leu Thr
 355 360 365
 Phe Asp Gln Glu Phe Arg Pro Ser Ala Gln Asp Ile Leu Met Leu Pro
 370 375 380
 Leu Phe Thr Lys Glu Pro Ala Asp Ala Leu Tyr Thr Ile Thr Ala Ala
 385 390 395 400
 His Met

<210> 19

<211> 340

<212> PRT

<213> Canine Herpes Simplex Virus

<400> 19

25184298.1

Met Ala Lys Cys Thr Thr Glu Lys Phe Cys Cys Ile Ser Val Asn Arg
 1 5 10 15
 Glu Ser Ser Val Asp Pro Glu Asp Phe Tyr Lys Pro Val Pro Leu Thr
 20 25 30
 Ser Asp Leu Ile Glu Glu Asp Asn Leu His Gln Asp Lys Ile Met Asp
 35 40 45
 Glu Asp Leu Tyr Ser Asp Phe Ser Asp Asp Asp Phe Met Asp Tyr Thr
 50 55 60
 Lys Asn Pro Thr Glu Ser Glu Asn Glu Arg Glu Ser Asp Glu Glu Val
 65 70 75 80
 Glu Glu Ser Tyr Glu Ser Asp Glu Asp Lys Lys Ser Leu Ser Pro Thr
 85 90 95
 Lys Ser Glu Gly Ile Glu Ala Ala Glu Ala Leu Lys Phe Ser Val Val
 100 105 110
 Lys Ser Leu Thr Pro Gly Ser Glu Gly Arg Val Phe Ile Ala Leu Lys
 115 120 125
 Lys Asp Lys Asp Thr Ser Tyr Lys Val Ile Leu Lys Ile Gly Gln Arg
 130 135 140
 Gly Asn Thr Leu Val Glu Ser Leu Ile Leu Arg Asn Ile Ser His Gln
 145 150 155 160
 Ser Ile Ile Lys Leu Gln Asp Thr Leu Phe Tyr Lys Glu Leu Thr Cys
 165 170 175
 Leu Val Leu Pro Tyr Tyr Lys Tyr Asp Leu Tyr Asn Phe Leu Met Asp
 180 185 190
 His Gly Lys Ser Leu Ser Phe Glu Ser Val Ile Lys Ile Glu Lys Gln
 195 200 205
 Ile Leu Thr Gly Leu Gln Tyr Ile His Gly Lys Lys Ile Ile His Arg
 210 215 220
 Asp Ile Lys Thr Glu Asn Ile Phe Leu Asp Asn Asp Ser Asn Val Cys
 225 230 235 240
 Ile Gly Asp Phe Gly Ala Ser Gln Phe Pro Val Ser Ser Pro Asp Tyr
 245 250 255
 Leu Gly Ile Ala Gly Thr Ile Glu Thr Asn Ala Pro Glu Val Leu Ser
 260 265 270
 Lys Asp Ala Tyr Asn Cys Lys Ala Asp Ile Trp Ser Ala Gly Ile Ile
 275 280 285

Leu Phe Glu Met Leu Ala Tyr Pro Asn Val Leu Phe Glu Glu Glu Glu
 290 295 300
 Arg Asp Ser Ser Asp Leu Ile Asn Asn Cys Asn Leu His Leu Ile Lys
 305 310 315 320
 Ile Ile Ser Thr Leu Lys Ile Asn Pro Asn Glu Phe Pro Ser Asp Leu
 325 330 335
 Glu Ser Asn Leu
 340

<210> 20
 <211> 334
 <212> PRT
 <213> SUID HSV 20 (Straind KA)

<400> 20
 Met Ala Asp Ala Gly Ile Pro Asp Glu Ile Leu Tyr Ser Asp Ile Ser
 1 5 10 15
 Asp Asp Glu Ile Ile Ile Asp Gly Asp Gly Asp Ser Ser Gly Asp Glu
 20 25 30
 Asp Asp Asp Asp Gly Gly Leu Thr Arg Gln Ala Ala Ala Arg Ile Val
 35 40 45
 Thr Asp Leu Gly Phe Glu Val Leu Gln Pro Leu Gln Ser Gly Ser Glu
 50 55 60
 Gly Arg Val Phe Val Ala Arg Arg Pro Gly Glu Ala Asp Thr Val Val
 65 70 75 80
 Leu Lys Val Gly Gln Lys Pro Ser Thr Leu Met Glu Gly Met Leu Leu
 85 90 95
 Gln Arg Leu Ser His Asp Asn Val Met Arg Met Lys Gln Met Leu Ala
 100 105 110
 Arg Gly Pro Ala Thr Cys Leu Val Leu Pro His Phe Arg Cys Asp Leu
 115 120 125
 Tyr Ser Tyr Leu Thr Met Arg Asp Gly Pro Leu Asp Met Arg Asp Ala
 130 135 140
 Gly Cys Val Ile Arg Ala Val Leu Arg Gly Leu Ala Tyr Leu His Gly
 145 150 155 160
 Met Arg Ile Met His Arg Asp Val Lys Ala Glu Asn Ile Phe Leu Glu
 165 170 175
 Asp Val Asp Thr Val Cys Leu Gly Asp Leu Gly Ala Ala Arg Cys Asn
 180 185 190

25184298.1

Val Ala Ala Pro Asn Phe Tyr Gly Leu Ala Gly Thr Ile Glu Thr Asn
 195 200 205

Ala Pro Glu Val Leu Ala Arg Asp Arg Tyr Asp Thr Lys Val Asp Val
 210 215 220

Trp Gly Ala Gly Val Val Leu Phe Glu Thr Leu Ala Tyr Pro Lys Thr
 225 230 235 240

Ile Thr Gly Gly Asp Glu Pro Ala Ile Asn Gly Glu Met His Leu Ile
 245 250 255

Asp Leu Ile Arg Ala Leu Gly Val His Pro Glu Glu Phe Pro Pro Asp
 260 265 270

Thr Arg Leu Arg Ser Glu Phe Val Arg Tyr Ala Gly Thr His Arg Gln
 275 280 285

Pro Tyr Thr Gln Tyr Ala Arg Val Ala Arg Leu Gly Leu Pro Glu Thr
 290 295 300

Gly Ala Phe Leu Ile Tyr Lys Met Leu Thr Phe Asp Pro Val Arg Arg
 305 310 315 320

Pro Ser Ala Asp Glu Ile Leu Asn Phe Gly Met Trp Thr Val
 325 330

<210> 21

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:. Herpes Simplex
Virus

<400> 21

Arg Arg Arg Arg Thr Arg Arg Ser Arg Glu
 1 5 10

<210> 22

<211> 6

<212> PRT

<213> Herpes Virus

<400> 22

Arg Arg Arg Arg Ser Arg
 1 5

<210> 23

25184298.1

<211> 6
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Kinase
substrate

<400> 23

Arg Arg Arg Arg Thr Arg
1 5

<210> 24

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (4)

<223> Xaa = Anything

<220>

<223> Description of Artificial Sequence: Kinase
substrate

<400> 24

Arg Arg Arg Xaa Thr Tyr
1 5

<210> 25

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (4)

<223> Xaa = anything

<220>

<223> Description of Artificial Sequence: Kinase
substrate

<400> 25

Arg Arg Arg Xaa Ser Tyr
1 5